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3. Abstract 
High-throughput Bioanalytical Sample Preparation (HTBSP) is a method used in 
Research, Pre-Clinical and Clinical drug development to speed-up bioanalysis. 
Bioanalysis is the quantitative determination of drugs and their metabolites in biological 
fluids. This technique is used very early in the drug development process to provide 
support to drug discovery programs on the metabolic fate and pharmacokinetics of 
chemicals in living cells and in animals. Its use continues through the preclinical and 
clinical drug development phases, into post-marketing support and may sometimes extend 
into clinical therapeutic drug monitoring1. 
Developing high-capacity sample preparation systems and strategies are of key 
importance in providing breakthrough in the time required to develop a drug by increasing 
the number/time of analyzed samples. This objective must be achieved without loosing 
quality within the obtained data and it is of paramount importance in 
Pharmacokinetic/dynamic studies.  
The aim of this PhD project in Pharmaceutical, Biopharmaceutical and Toxicological 
Analysis at University of Milan developed in Merck Serono laboratories, is to automate 
the manual sample preparation processes for LC/MS analysis using high-throughput 
techniques, and to insert the developed processes in the frame of a Pharmaceutical 
Bioanalytical process managed by a LIMS system. 
The main techniques examined are: Automatic Liquid Handling, Sample Dilution, 
Protein Precipitation Technique (PPT), Liquid-Liquid Extraction (LLE), Solid Phase 
Extraction (SPE) and other innovative sample preparation techniques such as Dried Blood 
Spot (DBS) Technique and Hybrid PPT-SPE. 
The use of liquid handling technology, for example, to automate the protein 
precipitation procedures for collection microplates and filterplates, is an important step to 
improve the throughput of these universal sample preparation methods. All liquid handling 
steps can potentially be performed by a workstation: sample transfer, addition of internal 
standards and  
                                                     
 
1 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. 5, 1, 
(2003), 1. 
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precipitant solutions, transfer of supernatants to a clean microplates and preparation for 
injections via dilution or reconstitution in a mobile phase compatible solvents2. 
Additionally, automation can be utilized prior to the precipitation procedure in order to 
prepare the calibration standards and the quality control samples in a microplate format. 
It is important, to apply laboratory automation, choosing the right projects and 
technology, developing a strategy and plan, finding the resources, managing the project 
and implementing, validating and preparing for long-term operation. 
Therefore one of the first strategies developed during my project has been the 
implementation in the sample preparation process of a Hamilton Starlet Robot. This 
device should have then been interfaced with a LIMS system to further reduce manual 
routine operations like serial dilutions, tube-to-plate transfers and data management and 
storage. 
Initially, I focused my attention on the technologies for LC/MS, LIMS, whose 
knowledge was a mandatory background to properly establish a liquid handling platform 
based on 96 well plate format for different LC/MS sample preparation techniques. 
This strategy aimed to generate the following advantages: 
• 96 samples purified at the same time; 
• flexibility, i.e., enabling the scouting for the best approach by using different 
chemical strategies, such as PPT, LLE, SPE or others; 
• purified samples available in less time than manual operations;  
• precipitation and filtration in the same well; 
• no laborious pipetting and/or centrifugation required and minimal manual liquid 
handling; 
• use of LIMS interface to automatically generate and transfer the sample/plate 
maps to the liquid handling station. 
It is also important to validate, in a GLP environment, the systems, materials and 
processes that are necessary to be applied to conduct one pre-clinical study. This means 
                                                     
 
2 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. 5, 7, 
(2003), 255. 
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that all the process parameters will be evaluated, optimized and validated for long-term 
process usage in a regulated environment and eventually transferred to other studies.  
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4. Pharmacokinetics and Bioanalytics 
Pharmacokinetics, sometimes abbreviated as PK, (from Ancient Greek pharmakon 
"drug" and kinetikos "to do with motion") is a branch of pharmacology dedicated to the 
determination of the fate of substances administered externally to a living organism. In 
practice, this discipline is applied mainly to drug substances, though in principle it 
concerns itself with all manner of compounds ingested or otherwise delivered externally to 
an organism, such as nutrients, metabolites, hormones, toxins, etc. 
Pharmacokinetics is often studied in conjunction with Pharmacodynamics. 
Pharmacodynamics explores what a drug does to the body, whereas Pharmacokinetics 
explores what the body does to the drug. Pharmacokinetics includes the study of the 
mechanisms of absorption and distribution of an administered drug, the rate at which a 
drug action begins and the duration of the effect, the chemical changes of the substance in 
the body (e.g. by enzymes) and the effects and routes of excretion of the metabolites of the 
drug3. 
As described before, Pharmacokinetics is divided into several areas which include the 
extent and rate of Absorption, Distribution, Metabolism and Excretion. This is commonly 
referred as to the ADME scheme. However recent understanding about the drug-body 
interactions brought about the inclusion of new term Liberation.  
Now Pharmacokinetics can be better described as LADME. 
Description in  
Figure 1: 
• Liberation is the process of release of drug from the formulation. 
• Absorption is the process of a substance entering the body. 
• Distribution is the dispersion or dissemination of substances throughout the 
fluids and tissues of the body. 
• Metabolism is the irreversible transformation of parent compounds into 
daughter metabolites. 
                                                     
 
3 Pharmacokinetics (2006). In Mosby's Dictionary of Medicine, Nursing, & Health Professions. Philadelphia, PA: Elsevier 
Health Sciences. Retrieved December 11, 2008. 
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• Excretion is the elimination of the substances from the body. In rare cases, some 
drugs irreversibly accumulate in a tissue in the body. 
 
Figure 1: LADME scheme. 
Pharmacokinetics describes how the body affects a specific drug after administration. 
Pharmacokinetic properties of drugs may be affected by elements such as the site of 
administration and the concentration in which the drug is administrated. These may affect 
the absorption rate4. 
Pharmacokinetic analysis is performed by noncompartmental (model independent) or 
compartmental methods. Noncompartmental methods estimate the exposure to a drug by 
estimating the area under the curve of a concentration-time graph. Compartmental 
methods estimate the concentration-time graph using kinetic models. Compartment-free 
methods are often more versatile in that they do not assume any specific compartmental 
model and procedure accurate results also acceptable for bioequivalence studies. 
                                                     
 
4 Kathleen Knights; Bronwen Bryant (2002). Pharmacology for Health Professionals. Amsterdam: Elsevier. ISBN 0-7295-
3664-5. 
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4.1. Noncompartmental analysis 
Noncompartmental PK analysis is highly dependent on estimation of total drug 
exposure. Total drug exposure is most often estimated by Area Under the Curve methods, 
with the trapezoidal rule (numerical differential equations) the most common area 
estimation method. Due to the dependence on the length of 'x' in the trapezoidal rule, the 
area estimation is highly dependent on the blood/plasma sampling schedule. That is, the 
closer your time points are, the closer the trapezoids are to the actual shape of the 
concentration-time curve. 
4.2. Compartmental analysis 
Compartmental PK analysis uses kinetic models to describe and predict the 
concentration-time curve. PK compartmental models are often similar to kinetic models 
used in other scientific disciplines such as chemical kinetics and thermodynamics. The 
advantage of compartmental over some no compartmental analyses is the ability to predict 
the concentration at any time. The disadvantage is the difficulty in developing and 
validating the proper model. Compartment-free modeling based on curve stripping does 
not suffer this limitation. The simplest PK compartmental model is the one-compartmental 
PK model with IV bolus administration and first-order elimination. The most complex PK 
models (called PBPK models) rely on the use of physiological information to ease 
development and validation. 
4.3. PBPK model 
Physiologically-based pharmacokinetic (PBPK) modeling is a mathematical modeling 
technique for predicting the absorption, distribution, metabolism and excretion (ADME) 
of a compound in humans and other animal species. PBPK modeling is used in 
pharmaceutical research and development, and in health risk assessment. 
PBPK models strive to be mechanistic by mathematically transcribing anatomical, 
physiological, physical, and chemical descriptions of the phenomena involved in the 
complex ADME processes. Some degree of residual simplification and empiricism is still 
present in those models, but they have an extended domain of applicability compared to 
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that of classical, empirical function based, pharmacokinetic models. Given that property, 
PBPK models may have purely predictive uses, but other uses, such as statistical 
inference, have been made possible by the development of Bayesian statistical tools able 
to deal with complex models5. That is true for both toxicity risk assessment and 
therapeutic drug development. 
PBPK models try to rely a priori on the anatomical and physiological structure of the 
body. These are usually also multi-compartment models, but the compartments correspond 
to predefined organs or tissues, for which the interconnections correspond to blood or 
lymph flows (more rarely to diffusions). A system of differential equations can still be 
written, but its parameters represent blood flows, pulmonary ventilation rate, organ 
volumes etc., for which information is available in scientific publications. Indeed the 
description of the body is simplified and a balance needs to be struck between complexity 
and simplicity. Besides the advantage of allowing the recruitment of a priori information 
about parameter values, these models also facilitate inter-species transpositions or 
extrapolation from one mode of administration to another (e.g., inhalation to oral).  
It is interesting to note that the first pharmacokinetic model described in the scientific 
literature was in fact a PBPK model. It led, however, to computations intractable at that 
time. The focus shifted then to simpler models, for which analytical solutions could be 
obtained (such solutions were sums of exponential terms, which led to further 
simplifications). The availability of computers and numerical integration algorithms 
marked a renewed interest in physiological models in the early 1970s. 
PBPK models are compartmental models like many others, but they have a few 
advantages over so-called "classical" pharmacokinetic models, which are less grounded in 
physiology.  
An example of a 7-compartment PBTK model, suitable to describe the fate of many 
solvents in the mammalian body, is given in Figure 2. 
                                                     
 
5 Gelman A., Bois F., Jiang J. (1996) Physiological pharmacokinetic analysis using population modeling and informative 
prior distributions Journal of the American Statistical Association, 91:1400-1412. 
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Figure 2: Example of a 7-compartment PBTK model. 
PBPK models can first be used to abstract and eventually reconcile disparate data (from 
physico-chemical or biochemical experiments, in vitro or in vivo pharmacological or 
toxicological experiments, etc.). They give also access to internal body concentrations of 
chemicals or their metabolites, and in particular at the site of their effects, be it therapeutic 
or toxic. Finally they also help interpolation and extrapolation of knowledge between: 
• Doses: e.g., from the high concentrations typically used in laboratory 
experiments to those found in the environment. 
• Exposure duration: e.g., from continuous to discontinuous, or single to multiple 
exposures. 
• Routes of administration: e.g., from inhalation exposures to ingestion. 
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• Species: e.g., transpositions from rodents to human, prior to giving a drug for 
the first time to subjects of a clinical trial, or when experiments on humans are 
deemed unethical, such as when the compound is toxic without therapeutic 
benefit. 
• Individuals: e.g., from males to females, from adults to children, from non-
pregnant women to pregnant. 
Some of these extrapolations are "parametric": only changes in input or parameter 
values are needed to achieve the extrapolation (this is usually the case for dose and time 
extrapolations). Others are "nonparametric" in the sense that a change in the model 
structure itself is needed (e.g., when extrapolating to a pregnant female, equations for the 
fetus should be added). 
4.4. Bioanalytical methods 
Bioanalytical methods are necessary to construct a concentration-time profile. Chemical 
techniques are employed to measure the concentration of drugs in biological matrix, most 
often plasma or urine. Proper Bioanalytical methods should be selective and sensitive. 
Pharmacokinetics is often studied using mass spectrometry because of the complex 
nature of the matrix and the need for high sensitivity to observe low dose and long time 
point data. 
In order to measure the characteristics of individual molecules, a mass spectrometer 
converts them to ions so they can be moved about and manipulated by external electric 
and magnetic fields to be measured.  
The three essential functions of a mass spectrometer, and the associated components, 
are: 
• A small sample of compound is ionized, usually to cations by loss of an electron 
(the ion source). 
• The ions are sorted and separated according to their mass and charge (the mass 
analyzer). 
• The separated ions are then detected and tallied, and the results are displayed on 
a chart (the detector). 
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The most common instrumentation used in this application is LC-MS with a triple 
quadrupole mass spectrometer since multiple fragmentations can be induced a followed 
using MS/MS technique. Tandem mass spectrometry is in fact employed for adding 
specificity. The samples represent different time points as a pharmaceutical is 
administered and then metabolized or cleared from the body. Blank or t=0 samples taken 
before administration are important in determining background and insuring data integrity 
with such complex sample matrices. Standard curves and internal standards are used for 
quantitation of usually a single pharmaceutical in the samples. Much attention is paid to 
the linearity of the standard curve; however it is not uncommon to use curve fitting with 
more complex functions such as quadratics since the response of most mass spectrometers 
is less than linear across large concentration ranges6,7,8. 
There is currently considerable interest in the use of very high sensitivity mass 
spectrometry for micro dosing studies, which are seen as a promising alternative to animal 
experimentation9. 
4.4.1. HPLC-MS Technique 
The HPLC technique is one of the most used techniques in environmental analytical 
chemistry, to separate mixtures of non volatile compounds. 
Hyphenating HPLC with mass spectrometry (MS) permits the separation and 
characterization of a great number of compounds and it makes possible to collect 
information about molecular mass and structure of the species. Mass spectrometry 
detection increases the sensitivity and selectivity of the separation method. 
The greatest problem of HPLC-MS technique is the interfacing, because: 
                                                     
 
6 Hsieh Y, Korfmacher WA (June 2006). "Increasing speed and throughput when using HPLC-MS/MS systems for drug 
metabolism and pharmacokinetic screening". Current Drug Metabolism 7 (5): 479–89. 
7 Covey TR, Lee ED, Henion JD (October 1986). "High-speed liquid chromatography/tandem mass spectrometry for the 
determination of drugs in biological samples". Anal. Chem. 58 (12): 2453–60. 
8 Covey TR, JB Crowther, EA Dewey, JD Henion (February 1985). "Thermospray liquid chromatography/mass 
spectrometry determination of drugs and their metabolites in biological fluids". Anal. Chem. 57 (2): 474–81. 
9 Committee for Medicinal Products for Human Use (CHMP) (2004-06-23). "Position Paper on Non-Clinical Studies to 
Support Clinical Trials with a Single Microdose" (in en) (PDF). CPMP/SWP/2599/02 Rev 1. European Medicines Agency, 
Evaluation of Medicines for Human Use. 
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• in HPLC samples are liquids and soluble in the mobile phase, while in MS they 
are gases; 
• HPLC works at room temperature, while MS works at temperature between 
100° and 350° C; 
• in HPLC it is possible to use not volatile inorganic salt in the mobile phase, 
while in MS it is not possible. 
API (Atmospheric Pressure Ionization) permits to interface liquid chromatography and 
mass spectrometry. The most common ionization systems are: Electro Spray Ionization 
(ESI), Atmospheric Pressure Chemical Ionization (APCI) and Atmospheric Pressure 
Photochemical Ionization (APPI). 
4.4.2. ESI 
The electrospray ionization technique (ESI) (Figure 3) is a method to generate highly 
charged droplets from which ions are ejected by ion evaporation process. Ion Spray is an 
improved version of electrospray, in which droplets are created by both a high electric 
field and a pneumatic nebulisation which allows higher liquid flow rates to be employed 
and produces a more stable ion current. 
The mechanism by which ions can be emitted from a liquid into the gas phase was first 
proposed in 197610 and the term Ion Evaporation was applied to the process. Experimental 
evidence combined with a theoretical model suggested that, as a charged droplet 
evaporates; a critical point may be reached at which it is kinetically and energetically 
possible for ions at the surface of the liquid to “evaporate”. 
The details of the process are independent on how the droplets are originally formed or 
how they are originally charged. A charged droplet contains the solvent plus both positive 
and negative ions, with ions of one polarity being dominant, the difference being the net 
charge. 
The excess ions are those which were originally present in the liquid being sprayed. If 
there are enough excess ions, and the droplet evaporates far enough, a critical field is 
                                                     
 
10 Iribarne, J.V. and Thomson, B.A. (1976). On the Evaporation of Small Ions from Charged Droplets. J. Chem. Phys. 64, 
2287. 
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reached at which ions are emitted from the surface. The rate of ion emission depends on 
the solvation energies of the individual ions so that one type of ion may preferentially 
evaporate if it has lower solvation energy. 
In both electrospray and ionspray, an electric field is generated at the tip of the sprayer 
by applying a high voltage directly to the sprayer. The sprayer itself is isolated by fused 
silica tubing connected to the pump. Ions of one polarity are preferentially drawn into the 
drops by the electric field as they are separated from the bulk liquid.  
Electrospray and ionspray operate both with flow from 1 -5µl/min to 1 ml/min11. 
 
 
Figure 3 
4.4.3. APCI 
Atmospheric pressure chemical ionization (APCI) interface is mainly based on ion-
molecule reactions in gaseous phase which take place between analyte molecules and a 
                                                     
 
11 The API Book, Perkin-Elmer Sciex Instruments. 1994. 
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reagent gas, generated by a series of reactions ion-molecule which, in turn, arise from a 
“crown discharge”. 
This technique allows the source to be operated at atmospheric pressure. In negative ion 
mode, electrons created by the crown discharge undergo collisions with neutral species 
and are captured by species such as O2 to form O2- and O-. The superoxide anion (O2-), 
and its hydrates (O2-[H2O]n) and clusters (O2-[O2]n), are the major reactant negative ions 
in an APCI source directly sampling ambient air. The neutral species formed in the corona 
discharge (NO, NO2, CO, etc.) may react with O2- or O- to form a series of minor reactant 
ions as NO2-, NO3- and CO32. 
The ions may react in several ways: charge transfer, where the positive or negative 
charge on the reactant ion is transferred to the analyte; and proton transfer, where a proton 
is transferred from a positive ion to the analyte or a proton is transferred from the analyte 
to a negative reactant ion. These processes are summarized in the following equations. 
Charge transfer: 
• R+ + A —> A+ + R (1) 
• R- + A —> A- + R (2) 
Proton transfer: 
• RH+ + A —> AH+ + R (3) 
• R- + AH —> A- + RH (4) 
R represents the reactant and A the analyte. 
The sensitivity of the APCI system is approximately three orders of magnitude less for 
charge transfer than for proton transfer. For example, benzene is detected as the M+ ion 
with a detection limit in the 1µg L-1 range, whereas aniline is detected as the MH+ in the 
1ng l-1 range. To overcome this sensitivity problem in the charge transfer reactions, a 
suitable chemical ionization reagent may be added to the ambient air flow entering the 
source region12.  
Description in  
Figure 4. 
                                                     
 
12 The API Book, Perkin-Elmer Sciex Instruments. 1994. 
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Figure 4 
4.4.4. Mass analyzers 
4.4.4.1. Quadrupole and triple quadrupole 
The quadrupole is one type of mass analyzer. It is the component of the instrument 
responsible for filtering sample ions, based on their m/z ratio. A quadrupole mass analyzer 
is essentially a mass filter that is capable of transmitting only the ion of choice. The mass 
spectrum is obtained by scanning through the mass range of interest over time. The 
quadrupole consists of four parallel metal rods. Each opposing rod pair is connected 
electrically and a radio frequency (RF) voltage is applied between one pair of rods, and 
the other. A direct current (DC) voltage is then superimposed on the RF voltage. Ions 
travel down the quadrupole between the rods. Only ions of a certain m/z will reach the 
detector for a given ratio of voltages: other ions have unstable trajectories and will collide 
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with the rods. In liquid chromatography-mass spectrometry or gas chromatography-mass 
spectrometry they serve as exceptionally high specificity detectors. 
A linear series of three quadrupoles can be used; known as “triple quadrupole” mass 
spectrometer. The first (Q1) and third (Q3) quadrupoles act as mass filters, and the middle 
(Q2) quadrupole is employed as a collision cell.  
This collision cell is an RF only quadrupole (non-mass filtering) using Ar or N2 gas 
(~10-3torr) to induce collisional dissociation of selected precursor ions from Q1. 
Subsequent fragments are passed through to Q3 where they may be filtered or scanned. 
This process allows for the study of fragments (product ions) which are crucial in 
structural identification. For example, the Q1 may be set to "filter" for a drug ion of a 
known mass, which is fragmented in Q2. The third quadrupole (Q3) can then be set to 
scan the entire m/z range, giving information on the sizes of the fragments made. Thus, the 
structure of the original ion can be deduced13 from Figure 5. 
 
Figure 5 
                                                     
 
13 M.Vincenti. MS/MS Triple Quadrupole Analyzers MSn Ion Trap Analyzers, Acquisitions Methods, Scuola Nazionale di 
Spettrometria di Massa, Parma. 
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Quadrupole instruments typically have unit mass resolution throughout the mass range. 
In a triple quadrupole mass spectrometer, there are several types of experiment that can 
be performed. The figures show a schematic representation of four common types of 
MS/MS experiment: 
 
Figure 6: Product Ion Scan. 
Product ion scan.  
In this case, the precursor ion is focused in Q1 and transferred into Q2, the collision 
cell, where it interacts with a collision gas and fragments. The fragments are then 
measured by scanning Q3. This results in the typical MS/MS spectrum and is the method 
most commonly employed with ESI ionization and/or LC-MS, description in Figure 6. 
 
Figure 7: Precursor Ion Scan. 
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Precursor ion scan.  
In this case Q3 is held to measure the occurrence of a particular fragment ion and Q1 is 
scanned. This results is a spectrum of precursor ions that result in that particular product 
ion, this is especially useful when used with EI or CI ionization and/or GC-MS, 
description in Figure 7 
 
Figure 8: Neutral Loss Scan. 
Neutral loss scan.  
In this case Q1 is scanned as in precursor ion scan but this time Q3 is also scanned to 
produce a spectrum of precursor ions that undergo a particular neutral loss. Again this 
mode is especially useful for EI and CI ionization, description in Figure 8. 
 
Figure 9: Multiple Reaction Monitoring. 
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Multiple Reaction Monitoring.  
Also in this case, the precursor ion is focused in Q1 and transferred into Q2, the 
collision cell, where it interacts with a collision gas and fragments. Q3 is held to measure a 
particular fragment ion14, description in Figure 9. 
4.5. Population pharmacokinetics 
Population pharmacokinetics is the study of the sources and correlates of variability in 
drug concentrations among individuals who are the target patient population receiving 
clinically relevant doses of a drug of interest15,16. Certain patient demographic, 
pathophysiological, and therapeutical features, such as body weight, excretory and 
metabolic functions, and the presence of other therapies, can regularly alter dose-
concentration relationships. For example, steady-state concentrations of drugs eliminated 
mostly by the kidney are usually greater in patients suffering from renal failure than they 
are in patients with normal renal function receiving the same drug dosage. Population 
pharmacokinetics seeks to identify the measurable pathophysiologic factors that cause 
changes in the dose-concentration relationship and the extent of these changes so that, if 
such changes are associated with clinically significant shifts in the therapeutic index, 
dosage can be appropriately modified. 
4.6. Pharmacokinetics in practice 
The PK profile of a drug, in which the absorption, distribution, metabolism and 
excretion processes following in vivo administration are mathematically described, is 
derived from the plot of the systemic drug concentration versus time for that compound. 
Following either parenteral or oral administration, serial blood samples are collected as a 
                                                     
 
14 M.Vincenti. MS/MS Triple Quadrupole Analyzers MSn Ion Trap Analyzers, Acquisitions Methods, Scuola Nazionale di 
Spettrometria di Massa, Parma. 
15 Sheiner, L.B.; Rosenberg, B., Marathe, V.V. (1977). "Estimation of Population Characteristics of Pharmacokinetic 
Parameters from Routine Clinical Data". J. Pharmacokin. Biopharm. 5: 445–79.  
16 Sheiner, L.B.; Beal, S.L., Rosenberg, B. Marathe, V.V. (1979). "Forecasting Individual Pharmacokinetics". Clin. 
Pharmacol. Ther. 26 (3): 294–305.  
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function of time and then analyzed for drug content. The complete process is summarized 
in Figure 10and can be divided into five main areas: 
• the in vivo work, including the initial surgery required to prepare animals for 
dosing, actual dosing and collection of blood samples; 
• the calibration of an analytical method; 
• the preparation of samples prior to analysis; 
• the actual quantitative analysis; 
• data reduction and reporting. 
Consideration of the in vivo aspects yields little opportunity for throughput 
improvements for single-compound studies as, by definition, the experiment must be 
conducted in real time. However, alternate experimental designs such as multicomponent 
analysis might provide new options. Clearly, the calibration, sample preparation and 
analysis steps have represented the major bottlenecks and it is these that have appropriated 
the most attention for the development of higher throughput approaches. 
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Figure 10: Flow diagram representing the processes required to implement a typical pre-clinical 
pharmacokinetic study. The various components required are colour coated as follows: in vivo 
work (purple), calibration (orange), sample preparation (green), sample analysis (red) and data 
analysis (blue). 
4.7. Calibration 
To ensure that measured concentrations truly reflect the actual sample concentrations, 
analytical methods are calibrated by adding varying known concentrations of drug into 
control matrix (e.g. plasma). These are then prepared and analyzed following a protocol 
identical to that used for the actual samples. Preparation of appropriate dilutions is time-
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consuming and laborious, but must be performed to a high degree of accuracy as the 
integrity of the assay results depends on this. Similarly, quality controls are included to 
assess the performance of the assay over time as these are interspersed into the analytical 
run. These values are then compared with those obtained from the calibration standards. 
4.8. Sample preparation methodologies 
The aim of the sample preparation process is to provide a suitable specimen, usually for 
chromatographic analysis, which will not contaminate the instrumentation and where the 
concentration in the prepared sample is reflective of that found in the original. The 
selected method of sample preparation is generally dictated by the analytical techniques 
available and the physico-chemical characteristics of the analytes under investigation. The 
two main sample preparation methods are matrix cleanup or direct injection. In a matrix 
cleanup procedure, the aim is to remove as much endogenous material as possible from 
the drug sample, either by liquid- or solid-phase extraction (SPE) or by precipitation of the 
plasma proteins. In the direct injection, which is usually only amenable to relatively 
lipophilic compounds, the compound of interest interacts with a stationary phase, which is 
then eluted and analyzed, leaving behind the endogenous material. 
Although it is imperative that all samples, standards and quality controls are treated 
identically, processing each sample sequentially is time-consuming and prone to error, 
even in the hands of a well-skilled analyst, as the operations are highly repetitive. This 
suggests that the introduction of new technologies and automation at the sample 
preparation stage should help improve throughput and reduce errors. 
4.9. Analysis 
In the early 1990s, there was a vast increase in the analysis of xenobiotics in biofluids 
with the introduction and widespread adoption of atmospheric pressure ionization (API)-
MS and, in particular, MS/MS coupled to HPLC17,18,19. With non-selective analyses such 
                                                     
 
17 Gilbert, J.D. et al. (1992) Determination of L-365260, a new cholecystokinin receptor (CCK-B) antagonist, in plasma by 
liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Biol. Mass Spectrom. 21, 63–68. 
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as HPLC–UV, which was the previous mainstay of bioanalysis, all sample components 
possessing a chromophore could be detected resulting in complex chromatograms in 
which the peak of interest was often difficult to distinguish from endogenous components. 
With API-LC–MS, however, detection is performed on the basis of the presence of 
protonated molecular ion of the parent compound such that only components with that 
mass (± 0.5Da) are detected. There is a further gain in specificity through using LC– 
MS/MS operating in a single-reaction monitoring (SRM) or multi-reaction monitoring 
(MRM) mode. Here, the transition from the mass-to-charge ratio of the precursor ion to a 
specific product ion produced within a collision cell in the mass spectrometer is 
determined by collisionally induced dissociation (CID). This essentially removes 
background interference, as it is likely that only the ‘parent’ ion will generate these 
precursor and product ions.  
Improvements in signal-to-noise ratio result in higher simplified chromatograms with 
greater sensitivity and selectivity for the compound of interest. Additionally, the ability to 
rapidly scan different transitions enables the simultaneous analysis of several components 
without the requirement for chromatographic resolution, thereby reducing run times. 
Furthermore, this enables rapid generic gradients to be applied to all samples, therefore 
eliminating chromatographic method development time. 
                                                                                                                                                               
 
18 Gilbert, J.D. et al. (1992) Determination of L-654066, a new 5areductase inhibitor in plasma by liquid 
chromatography/atmospheric pressure chemical ionization mass spectrometry. Biol. Mass Spectrom. 21, 341–346. 
19 Gilbert, J.D. et al. (1996) High-performance liquid chromatography with atmospheric pressure ionization tandem mass 
spectrometry as a tool in quantitative bioanalytical chemistry. ACS Symp. Ser. 619,330–350. 
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5. High-throughput 
The development of new therapeutic drugs is a long and costly process. With the 
introduction of combinatorial chemistry, high throughput screening, and other 
technologies, the speed of lead generation has increased20. However, prioritization of leads 
with regard to drug metabolism and pharmacokinetics (DMPK) in animals appears crucial 
in the selection of viable targets from millions of compounds. 
With pressure on pharmaceutical companies to reduce time-to-market and improve the 
success rate of new drug candidates, higher-throughput pharmacokinetic support has 
become an integral part of many drug discovery programmers. 
To deliver the promise of HTPK are fundamental the amalgamation of robotics, new 
sample preparation technologies and highly sensitive and selective mass spectrometric 
detection systems. 
Discovery pharmacokinetics (PK) has traditionally been regarded as a low-throughput 
activity, a finding that is directly opposed to the need to address the high attrition rate of 
compounds in drug development caused by poor PK profiles21.  
Historically, the drug discovery cascade has been established as a sequential process 
with many drug candidates, which originate from a variety of sources, being initially 
screened for potency against a biological target. At best, limited PK and metabolism 
studies would be conducted prior to acceptance of a compound for safety evaluation with, 
as it transpires, the said high attrition rate. 
A new paradigm in drug discovery has emerged in which the entire sample collection is 
rapidly screened using robotized high-throughput assays at the outset of a programme22,23, 
often together with some selectivity testing against other targets. This frequently provides 
                                                     
 
20 High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and 
LC/MS/MS analysis. Takaho Watanabe, Daniela Schulz, Christophe Morisseau and Bruce D. Hammock. 
21 Broach, J.R. and Thorner, J. (1996). High-throughput screening for drug discovery. Nature 384, 14–16. 
22 Burbaum, J.J. and Sigal, N.H. (1997). New technologies for highthroughput screening. Curr. Opin. Chem. Biol. 1, 72–78. 
23 Gallop, M.A. et al. (1994). Applications of combinatorial technologies to drug discovery: Background and peptide 
combinatorial libraries. J. Med. Chem. 37, 1233–1251. 
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higher quality leads for optimization by the medicinal chemistry department, often 
employing new combinatorial synthetic technologies24, 25. 
Higher-throughput PK (HTPK) is being achieved through the introduction of new 
techniques, including automation for sample preparation and new experimental 
approaches for the evaluation of many substances in parallel. 
Application of these technologies can now support multiple projects at a pace 
appropriate to the output of a synthetic chemistry team, thus providing timely and relevant 
information that will impact directly on drug design. 
In this chapter, the PK process, the historical context of newer developments, current 
HTPK approaches (including upstream and downstream activities), and future prospects 
for further improvements are discussed. 
5.1. Automation perspective 
From the inception of modern chromatographic science, automation technologies have 
continuously developed, beginning with the introduction of autosamplers and 
microprocessor-controlled instrumentation in the late 1970s to early 1980s. This enabled 
the sequencing of samples, often requiring different analytical instrument characteristics, 
and this increased the number of samples that could be processed in a batch by enabling 
unattended, overnight operation.  
In the mid-1980s, early adopters of robotic technologies were using the newly 
introduced Zymark Zymate II26 to try to further improve throughput by programming a 
robot to reproduce manual operations from the sample preparation steps27, 28, 29.  
                                                     
 
24 Gallop, M.A. et al. (1994) Applications of combinatorial technologies to drug discovery: 1. Background and peptide 
combinatorial libraries. J. Med. Chem. 37, 1233–1251. 
25 Gordon, E.M. et al. (1994) Applications of combinatorial technologies to drug discovery: 2. Combinatorial organic 
synthesis, library screening strategies, and future directions. J. Med. Chem. 37, 1385–1401. 
26 Zymark Ltd, Runcorn, Cheshire, UK. 
27 Fouda, H.G. and Schneider, R.P. (1987) Robotics for the bioanalytical laboratory: A flexible system for the analysis of 
drug in biological fluids. Trends Anal. Chem. 6, 139–147. 
28 Fouda, H.G. and Schneider, R.P. (1988) Robotics for the bioanalytical laboratory: Analysis of antipyrine in human 
serum. Am. Clin. Prod. Rev. 7, 12–15. 
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Whilst some gains in productivity using this approach were evident, there were several 
problems with such systems: 
• the use of robotics to purely reproduce a manual method is usually not the most 
efficient or cost-effective way of proceeding; 
• many methods suffered from poor reliability and required frequent maintenance 
or recalibration; 
• at best, most methods were semi-automated, often requiring substantial manual 
input, and therefore negating the advantages of employing the system; 
• the timing of implementation, which was prior to the adoption of LC–MS/MS, 
was wrong as sample analysis was still the rate-determining step. Hence, 
automation of sample preparation did not bring substantial gains in productivity. 
In fact, the initial slow adoption of systems such as the linear track robots in the late 
1980s demonstrates the lack of commitment to automation at the time, as other areas of 
the infrastructure were not in place to allow this to be fully exploited nor justified from a 
cost perspective. 
The traditional sample containers or collection devices used in bioanalysis have been 
individual test tubes and vials, available in many different dimensions and made from 
glass or plastic. Individual pipettors have been used with this tubes or vial to transfer 
sample, solvent and any other liquids as part of the overall sample preparation procedure. 
Techniques such as protein precipitation (PPT) and liquid-liquid extraction (LLE) have 
also traditionally used single tubes for the extraction step; solid-phase extraction (SPE) has 
used individual cartridges. 
Individual tubes or vials held a stronghold as the preferred sample container until the 
late 1990s. At this time, several advances occurred in parallel that brought about a change 
from tubes to microplates as the preferred sample and collection format30. 
With the introduction of the microtiter plate format as the standard platform on which to 
perform a multitude of assays, it was inevitable that the time gains seen in areas such as 
                                                                                                                                                               
 
29 Fouda, H.G. et al. (1988) Liquid chromatographic analysis of doxazosin in human serum with manual and robotic 
sample preparation. J. Chromatogr. Sci. 26, 570–573. 
30 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. 3, 1, ( 
2003 ), 75-76. 
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biochemical screens through parallel sample processing would be adopted for 
bioanalytical assays.  
Furthermore, the shift in formats from vials and tubes to microtiter plates has made it 
much more viable to apply robotic technologies. While 96-well microplates had been in 
use in other areas of pharmaceutical research they become more commonly available in 
larger well volumes. They also were molded in polypropylene, a plastic that has the 
required solvent resistance for use with common organic solvents. Filtration and solid-
phase extraction were introduced in the 96-well plate format in flow-through process. 
The microplate presents many efficiencies of operation such as easier labeling, sealing 
and manipulation. 
When this format is combined with multiple probe workstations, dramatically faster 
pipetting throughput is achieved via parallel sample processing. The microplate 
architecture clearly offered the increased proficiency and productivity in sample 
preparation processes and analysis that were sought. 
5.2. Current technologies 
The current options available to increase the throughput of a PK assay can be divided 
into the two main areas of sample preparation and experimental design, although 
consideration should also be given to data handling and utilization, which will also be 
discussed. 
5.2.1. Sample preparation 
Simply grouping together the cartridges on one analysis plate, increases throughput, as 
it is easier to manually treat several samples simultaneously31. However, many groups are 
using this as the basis for more fully automated analysis32,33,34 with typical sample 
                                                     
 
31 Cheng, Y-F. et al. (1998) Straightforward solid-phase extraction method for the determination of verapamil and its 
metabolite in plasma in a 96-well extraction plate. J. Chromatogr. A 828, 273–281. 
32 Allanson, J.P. et al. (1996) The use of automated solid phase extraction in the ‘96 well’ format for high throughput 
bioanalysis using liquid chromatography coupled to tandem mass spectrometry. Rapid Commun. Mass Spectrom. 10, 811-
816. 
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preparation times of under two hours for 96 samples. A further extension of this approach 
is the use of SPE disk technologies35,36. Here, the thickness of the adsorbent bed is 
dramatically reduced, enabling elution in volumes approximating those used for 
chromatographic analysis.  
Hence, the eluent from the SPE disk can be analyzed directly, therefore eliminating 
steps such as evaporation and reconstitution. Liquid–liquid extraction can also reliably 
work in a 96-well plate format37. Other techniques, such as trace enrichment38 or online 
column switching39, can improve throughput but are usually application specific. 
5.3. Microtiter plate 
A microtiter plate or microplate (Figure 11) is a flat plate with multiple "wells" used as 
small test tubes.  
The microplate has become a standard tool in analytical research and clinical diagnostic 
testing laboratories. A very common usage is in the enzyme-linked immunosorbent assay 
(ELISA), the basis of most modern medical diagnostic testing in humans and animals. 
 
                                                                                                                                                               
 
33 Harrison, A.C. and Walker, D.K. (1998) Automated 96-well solidphase extraction for the determination of doramectin in 
cattle plasma. J. Pharm. Biomed. Anal. 16, 777-783. 
34 Pleasance, S. and Biddlecombe, R.A. (1998) Automating ‘96-well’ format solid phase extraction for LC-MS-MS. 
Methodol. Surv. Bioanal. Drugs 25, 205-212. 
35 Plumb, R.S. et al. (1997) Use of reduced sorbent bed and disk membrane solid-phase extraction for the analysis of 
pharmaceutical compounds in biological fluids, with applications in the 96-well format. J. Chromatogr. B Biomed. Sci. Appl. 
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36 Simpson, H. et al. (1998) High throughput liquid chromatography/mass spectrometry bioanalysis using 96-well disk 
solid phase extraction plate for the sample preparation. Rapid Commun. Mass Spectrom. 12, 75-82. 
37 Steinborner, S. and Henion, J. (1999) Liquid–liquid extraction in the 96 well plate format with SRM LC/MS quantitative 
determination of methotrexate and its major metabolite in human plasma. Anal. Chem. 71, 2340-2345. 
38 Kronkvist, K. et al. (1998) Automated sample preparation for the determination of budesonide in plasma samples by 
liquid chromatography and tandem mass spectrometry. J. Chromatogr. A 823, 401-409. 
39 Gao, V.C.X. et al. (1998) Column switching in high-performance liquid chromatography with tandem mass spectrometric 
detection for highthroughput preclinical pharmacokinetic studies. J. Chromatogr. A 828, 141-148. 
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Figure 11: An example of 96-well microtiter plate. 
High throughput applications are based on samples being reformatted from racks of test 
tubes or vials into 8-rows by 12-columns format. Once in this configuration, the samples 
are contained in a compact space and each well is uniquely identified by column number 
and row letter, e.g., A1, A2, A3, C5, F8 or H12. The tedious and time consuming task of 
individually labeling tubes or vials is now eliminated. 
Other kinds of microplate could have 6, 24, 384 or even 1536 sample wells arranged in 
a 2/3 rectangular matrix. Some microplates have even been manufactured with 3456 or 
even 9600 wells, and an "array tape" product has been developed that provides a 
continuous strip of microplates embossed on a flexible plastic tape40. 
Each well of a microplate typically holds somewhere between tens of nanoliters to 
several milliliters of liquid. They can also be used to store dry powder or as racks to 
support glass tube inserts. Wells can be either circular or square, example in 
Figure 12. 
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Figure 12: Different wells. Four well bottom geometries are commonly available in microplates: flat 
bottom (F-bottom), rounded bottom (U-bottom), conical (V-bottom) and rounded corners leading to 
flat bottom (C-bottom). 
For compound storage applications, square wells with close fitting silicone cap-mats are 
preferred. Microplates can be stored at low temperatures for long periods, may be heated 
to increase the rate of solvent evaporation from their wells and can even be heat-sealed 
with foil or clear film. Microplates with an embedded layer of filter material were 
developed in the early 1990s by several companies, and in 1992, the world's first Solid 
Phase Extraction (SPE) microplate was launched by Porvair Sciences. This allowed simple 
column chromatography to be carried out in a microplate footprint for the first time. 
Today there are microplates for just about every application in life Science research which 
involves filtration, separation, optical detection, storage and reaction mixing or cell 
culture. 
The enormous growth in studies of whole live cells has led to an entirely new range of 
microplate products which are "tissue culture treated" especially for this work. The surface 
of these products is modified, using a plasma discharge, to make it easier for adherent 
cells to grow on. 
A number of companies have developed robots to specifically handle SBS microplates. 
These robots may be liquid handlers which aspirate or dispense liquid samples from and to 
these plates, or "plate movers" which transport them between instruments, plate stackers 
which store microplates during these processes, plate hotels for longer term storage or 
microplate incubators to ensure constant temperature during testing. 
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Instrument companies have designed plate readers which can detect specific biological, 
chemical or physical events in samples stored in these plates. 
5.3.1. Manufacture and composition 
Microplates are manufactured in a variety of materials. The most common is 
polystyrene, used for most optical detection microplates. It can be colored white by the 
addition of titanium dioxide for optical absorbance or luminescence detection or black by 
the addition of carbon for fluorescent biological assays. Polypropylene is used for the 
construction of plates subject to wide changes in temperature, such as storage at -80°C and 
thermal cycling. It has excellent properties for the long-term storage of novel chemical 
compounds. Polycarbonate is cheap and easy to mould and has been used for disposable 
microplates for the polymerase chain reaction (PCR) method of DNA amplification. 
Cyclo-olefins are now being used to provide microplates which transmit ultraviolet light 
for use in newly developed assays. 
The most common manufacturing process is injection moulding, used for polystyrene, 
polypropylene and cyclo-olefin. Vacuum forming can be used with softer plastics such as 
polycarbonate. Composite microplates, such as filter plates and SPE plates and even some 
advanced PCR plate designs use multiple components which are moulded separately and 
later assembled into a finished product. ELISA plates may now be assembled from twelve 
separate strips of eight wells, making it easier to only partially use a plate. This saves cost 
for the scientist. 
5.3.2. History 
The earliest microplate was created in 1951 by a Hungarian, Dr. G. Takatsky, who 
machined 6 rows of 12 "wells" in Lucite. However, common usage of the microplate 
began in the late 1950s when John Liner in USA had introduced a molded version. By 
1990 there were more than 15 companies producing a wide range of microplates with 
different features. It was estimated that 125 million microplates were used in 2000 alone. 
The word "Microtiter" is a trademark registered by the Dynatech Company; it is now more 
usual to use the generic term "microplate". 
In 1996, the Society for Biomolecular Screening (SBS) began an initiative to create a 
standard definition of a microtiter plate. A series of standards was proposed in 2003 and 
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published by the American National Standards Institute (ANSI) on behalf of the SBS. The 
standards govern various characteristics of a microplate including well dimensions (e.g. 
diameter, spacing and depth) as well as plate properties (e.g. dimensions and rigidity). 
As early as the first meeting of the Society for Biomolecular Screening (SBS) in 1995, a 
need for clearly defined dimensional standards of a microplate was identified. At the time, 
the microplate was already becoming an essential tool used in drug discovery research. At 
the time, the concept of a microplate was similar among various manufacturers, but the 
dimensions of microplates produced by different vendors, and even within a single 
vendors catalog line varied. This often caused numerous problems when microplates were 
to be used in automated laboratory instrumentation. 
In late 1995, members of the SBS began working on defining dimensional standards for 
the standard 96 well microplate. The first written proposal was released in December 1995 
and presented at numerous scientific conferences and journals throughout 1996. This 
initial proposed standard was officially presented to the membership of SBS for approval 
at the annual meeting in October 1996 in Basel, Switzerland. Between then and late 1998, 
various versions of the proposed standards for 96 and 384 well microplates were 
circulated to the membership of the society. In early 1999, efforts to begin formalizing the 
proposed standards in preparation for submission to a recognized standards organization 
were begun. The email ListServ was started in March, and the first regular quarterly 
meeting of the working committee met in August of that year. To date, the ListServ 
contains members representing over 100 corporations, educational institutions, and 
government organizations from over 15 nations. 
This standard was processed and approved for submittal to ANSI by the Microplate 
Standards Development Committee of the Society for Biomolecular Screening. 
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5.3.3. Fundamental microplate specification as proposed by 
The Society for Biomolecular Screening (SBS)41 
• The wells in a 96-well microplate should be arranged as 8 rows by 12 columns. 
• Center-to-center well spacing should be 9.0 mm (0.3543 in). 
• The outside dimension of the base footprint, measured at any point along the 
side, shall be: Length 127.76 mm (5.0299 in), Width 85.48 mm (3.3654 in). 
• The footprint must be continuous and uninterrupted around the base of the plate. 
• The overall plate height (shallow well design) should be 14.35 mm (0.5650 in). 
• The maximum allowable projection above the top stacking surface is 0.76 mm 
(0.0299 in). 
• The four outside corners of the plate’s bottom flange shall have a corner radius 
to the outside of 3.18 mm (0.1252 in). 
                                                     
 
41 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. 3, 1, 
(2003), 81. 
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6. Automation 
Bioanalysis is used very early in the drug development process to provide support to 
drug discovery programs on the metabolic fate of chemicals in animals and living cells. Its 
use continues throughout the preclinical and clinical drug development phases. 
The detection techniques of choice, liquid chromatography interfaced with tandem mass 
spectrometry (LC-MS/MS), allows more samples to be analyzed per unit time than ever 
before. 
As a result of this capability for rapid analysis, and the greater number of compounds 
able to be synthesized by combinatorial chemistry techniques, faster turnaround became 
expected for both Pharmacological and Bioanalytical evaluations. 
The industry demanded faster sample analysis as the race to market became more 
aggressive. 
Sample preparation was targeted as a rate limiting step in the overall procedure for 
bioanalysis. 
The automation in sample preparation is an important goal for laboratories to meet the 
high throughput demands required in pharmaceutical research and development. The 
choices for automation differ in complexity according to the required tasks. 
Processes can be introduced to make a manual procedure less tedious, to replace most or 
all steps in a manual procedure, to perform a specific application comprised of multiple 
linked steps or to perform a procedure around the clock. 
The size of automated instruments can vary as well, from a small benchtop instrument 
to a large instrument placed on a tabletop to a room-sized throughput ultra high 
configuration composed of individual modules linked together. 
Faster off-line approaches were developed, more productive formats (96-well plate) and 
more efficient automation solutions for the off-line sample preparation methods. The term 
“off-line” refers to performing the sample preparation procedure independently of the LC-
MS/MS analysis. 
The throughput of sample preparation techniques for drug bioanalysis has increased 
dramatically in many approaches to keep peace with the speed of detection. 
Improving overall throughput and laboratory productivity are important goals for 
introducing automated processes into bioanalytical sample preparation methodologies, but 
there are other motivating factors. 
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Automation can reduce the hands-on time required by an analyst and allows the scientist 
to perform other tasks in the laboratory. Unattended operation of a process may permit 
multiple or overnight runs, further increasing throughput. Removing an individual from 
hazardous or mundane tasks can maintain worker health and safety. 
The automation of most processes has been shown to bring a degree of reproducibility 
and quality to the results that cannot be realized among different workers each performing 
the method manually. In addition, compliance with GLP is considerably improved as a 
result of the remarkable process consistency that automation provides. 
Automation can often facilitate troubleshooting by removing the manual component 
processes. It can introduce process documentation into a method and also allow for less 
skilled workers to perform a complex task. An important overall goal for implementing 
automation into a laboratory workflow is greater employee job satisfaction42. 
6.1. Strategies for Selecting Automation 
6.2. Defining how Automation will be used and supported 
A laboratory must properly assess its needs for automation and define how it will be 
used and supported in the workspace. 
The focus of my PhD project is on the off-line processes for sample preparation. 
How: it will be used for performing the off-line techniques for protein precipitation, 
liquid-liquid extraction, solid phase extraction and other techniques in microplates. 
Which: the flexibility of the system is the main objective and it could be reach with the 
adaptability of the instrument to perform multiple tasks which is an important criterion in 
the decision making process. Also upgradeability is very important, one configuration can 
be purchased and over time its capabilities can be upgraded. 
Where: multiple instruments can be scattered among individual laboratories or one 
instrument can be located in a common area and shared by a large user group. 
                                                     
 
42 D.A.Wells and T.L.Lloyd, In.: J.Pawliszyn, Ed., Sampling and Sample preparation for Field and laboratory: fundamentals 
and New Directions in Sample Preparation, Elsevier, Amsterdam (2002). 
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What type of access: when a dry down step is required off-line the automation should 
remain available. When the sample has been dry down the user returns to the instrument 
and performs the reconstitution step. 
How flexible should be the software: it can be a decision factor in selecting among 
automation choices. Software with great flexibility and many options can be daunting to 
some analyst taking weeks to master. Only experienced users or custodians are able to 
program them. 
How much support: Standard Operation Procedure (SOP) must be developed and 
followed to ensure accuracy and precision of pipetting with proper attention to 
maintenance and service issues. 
How much space: if the dimensions permit the best way to accomplish vapor removal is 
to place the unit inside a custom built enclosure. 
6.3. General considerations 
Aspects to be considered are the number of samples processed per hour in the 
automation productivity and the hands-on time required by the analyst. For example a 
semi-automated method that requires 15 min hands-on time may be preferable to a fully 
automated system that might cost more but perform at similar productivity. 
Usually the available founds strongly influence the capability that automation can 
provide and the rate at which it can be implemented. Having a 8-tip and a 96-tip sample 
preparation workstation is ideal one for reformation and one for extraction. When it is not 
possible the necessity to find other solutions grows. 
Continuous training and education in automation has a big priority even if training in 
the principles and operation of mass spectrometers is supported. Only individuals that 
have been properly trained can use a validated system, therefore training is an important 
requirement. 
Conferences in automation are a great source of continuing education. Vendor courses 
are also available at their site or in house for in-depth training on specific automation 
platforms. 
As described before in Merck Serono Ivrea Automation Laboratory the main instrument 
is a Microlab Starlet Hamilton Robotics, a flexible pipetting workstation with 8 probes 
that display variable spacing. 
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Unique to the STAR is a patented CO-RE technology (Compressed induced O-Ring 
Expansion). CO-RE represents advancement in tip coupling that allows positive grasping, 
sealing and releasing between the channel and the tip. Compatibility is demonstrated with 
both disposable tips and steel probes. 
Dual mode (capacitive and pressure based) liquid level detection provides sensing for 
both conductive and non-conductive liquids. An optional internal gripper called iSWAP is 
available to manipulate plates on the instrument deck or transfer the to adjacent microplate 
compatible instrument.  
A vacuum system can be placed to the deck of the STAR. A requirement of the vacuum 
manifold is that it must be self-sealing when a plate is placed on top, so the gasket material 
must perform every time the vacuum is applied. Also, in order to provide flexibility, a 
manifold has to be able to accommodate varieties in heights of flow-through microplates 
and collection plates. Another useful option is a temperature controlled microplate carrier 
that can maintain temperatures on the instrument deck from -22°C to +60°C43. 
Automation is a crucial resource in today's bioanalytical pre clinical and clinical 
laboratory environment, helping to offset a number of healthcare industry trends—
specifically, laboratory errors caused by manual mishandling of samples, a worsening 
labor shortage in laboratories.  
An automated solution provides faster, more-efficient, and more-accurate results. 
 
                                                     
 
43 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. 5, (2003). 
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7. Hamilton Robotics 
The aim of this PhD project in Pharmaceutical, Biopharmaceutical and Toxicological 
Analysis is to automate assays successfully and within budget such as the manual sample 
preparation processes for LC/MS analysis.  
Hamilton’s workstations and software serve as a high precision and flexible base upon 
which to provide automated solutions with air displacement pipetting and monitoring 
technology as well as the software controlling systems. 
 
7.1. Liquid Handling Workstations 
 
STARSTARlet
STARplus
 
Figure 13: Hamilton robotic workstation STAR Line. 
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Figure 14: Automation Lab. 
In  
Figure 13 and Figure 14 are shown the three MicroLab Star lines. The STAR line 
workstations are based on superior air displacement pipetting technology. This increases 
accuracy and repeatability while providing chain of custody with pipette condition 
monitoring and recording. Each workstation can be configured with multiple arms and 
each arm can be configured with multiple pipetting and labware gripping devices. 
Pipetting channels and labware grippers move independently of each other, supporting the 
use of a wide range of labware. The autoload option provides barcode tracking of samples, 
labware, racks and carriers. All workstation functions and integrated third-party devices 
are controlled by the Vector 4.1.1. Software. 
There are four different levels of authorization for the Vector Software 
• “Lab Operator”, routine user: operators may run any method. 
• “Lab Operato 2”, routine user: operators 2 may run any method and move 
elements on deck. 
• “Lab Method Programmer”, method programmer laboratory manager: method 
programmers may modify method and labware definitions. 
• “Lab Service”, service technician laboratory manager: service technician for 
Hamilton’s laboratory software, 
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This software offers an intuitive, flexible and powerful programming control and all the 
tools to allow simple to complex programming, without limiting imagination or 
compromising requirements. 
Data can be tracked and processed within the application as well as interfaces to internal 
and external databases, including LIMS. The STAR can serve as a simple pipettor for 
serial dilutions or act as the center of a large system with multiple workstations and third 
party devices such incubators, cell counters, centrifuges, etc. 
7.1.1. CORE-Technology: Compressed O-Ring Expansion 
Bioanalytical applications require precision tip attachment and positioning. To meet this 
demand, the workstation uses quality engineered components and the CO-RE tip 
attachment technology. The CO-RE system (Figure 15) attaches disposable tips or 
washable steel tips to the pipetting channels with a stable lock-and-key fit and a precision 
of ±0.1 mm in all axes. The Hamilton STAR is therefore ideal for tasks where the highest 
precision is required such as MALDI target spotting, 1536 well pipetting and, in my case, 
low volume dispensing.  
The Hamilton STAR requires no vertical force for tip attachment or tip ejection, thus 
eliminating mechanical stress and improving the overall system reliability along with 
pipetting speed and dexterity. Added benefits of CO-RE technology include:  
• Use of both disposable and washable tips within the same run.  
• Ability to pick up CO-RE grippers and other tools, Figure 15.  
• Elimination of aerosol production upon tip ejection. 
 
Figure 15: CORE Technology. 
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7.1.2. Total Aspirate and Dispense Monitoring: TADM 
During crucial sample transfers, the STAR can monitor aspiration and dispense steps in 
real time. TADM verifies with a traceable digital audit trail that a sample has been 
transferred.  
High and low pressure limit bands are first predetermined from multiple test sample 
runs. During routine pipetting, errors are time reported in real-time when the measured 
pressure exceeds these bands. The system can then simply record the errors or react to 
them, Figure 16. 
 
Figure 16: TADM 
7.1.2.1. Error event handling 
Pressure data is continuously recorded during pipetting for Chain of Custody. 
When the pressure goes outside the pressure limits prescribed for different times during 
the aspiration or dispense cycles, an error event is registered and communicated to the 
script. 
Vector scripts can be written in a variety of ways to handle these events. It can ignore 
them, stop the method, ask for user intervention or intelligently attempt to deal with the 
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error without user intervention. For example, in the event of a clog or too low pressure 
during aspiration, the script could evacuate the tip or needle and try to aspirate again. 
It could even move the tip slightly to avoid a swab in a tube and perhaps be 
programmed to make several aspiration attempts before requesting user intervention or 
flag the sample as an error and automatically move on to the next sample. 
Profile is described in  
Figure 17. 
Figure 17: typical curves. 
7.1.2.2. Aspiration Error Detection 
Tip blockage (2) is detected when the pressure drops below the minimum set values. 
The minimum set values vary with aspiration/dispense time and are predetermined by 
the results of test runs. Limits can be widened or tightened to minimize false errors. 
Insufficient sample (3) or incorrect aspiration is detected when the pressure rises above 
the maximum limit during aspiration. 
7.1.2.3. Dispense Error Detection 
Blocked tip (1) is detected when dispense pressure rises above the maximum pressure 
limit during dispense.  
Leaking seals (2) are detected when the pressure declines below the minimum pressure 
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limit during dispense. 
Figure 18: Typical curves - 50 successful runs 
TADM curves (mbar vs. msec) from aspirating 50 samples (Figure 18) of the same 
volume with no errors. Maximum and minimum error bands are set just outside this range 
of data to allow for variation within observed successful dispenses. Band settings are 
stored in the software by liquid class. A unique liquid class can be created for each liquid 
type and pipetting volume range. 
Figure 19: Typical curves - Insufficient samples 
Insufficient sample aspiration detected in three samples when the pressure abruptly 
increased above the maximum TADM error band. Figure 19. 
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Figure 20: TADM - clots 
Clots detected and aspiration aborted in two samples when the pressure gradually 
decreased below the minimum TADM error band. Figure 20. 
 
Figure 21: TADM - foam 
Foam detected and aspiration aborted in two samples when the pressure abruptly 
dropped below the minimum. Figure 21. 
7.1.3. Flexible and Precise tip Positioning 
The STAR’s Dynamic Positioning System allows each pipetting channel to move 
independently in both the Y and Z axes. Each channel uses its own high-precision motors 
and electronics to reach any position on the deck. In applications such as hit-picking, 
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where samples need to be transferred in an irregular pattern, this flexibility improves 
throughput. Since it is possible to have up to 16 channels on the same arm, multiple 
microplates may be processed simultaneously, drastically increasing throughput, Figure 
22. 
 
Figure 22 
7.2. General liquid handling 
7.2.1. Serial Dilution 
Hamilton Microlab STAR automated liquid handling workstations are ideal for carrying 
out the laborious task of serial dilutions. Sample liquid can be transferred to and from 
tubes, vials, and microtiter plates. 
Using the program DDM (Dynamic Dilution Module) included in ML_STAR Software 
System. It includes tip sequence (tip size and tip re-use), tip ejection after each dilution 
step, sample liquid pick-up sequence (1 to 8 wells), dilution liquid pick-up sequence, 
dispense sequence, dilution level, and sample volume. The template automatically 
calculates the transfer volumes, liquid volumes, pre- and post volumes and mix volumes. 
The serial dilution method is then run by simply clicking the play button. 
7.2.2. Plate Replication 
Super Simple Method allows the user to rapidly copy plates. After selecting this pipette 
method, the user is asked to select one of the variations of the method from a list. The user 
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then enters the number of plates to process, pipetting volume(s) and range. Pictorial views 
are then sequentially displayed to show which carrier and labware to load on the deck. The 
user then clicks the okay button. A pipetting script is automatically generated and run to 
completion. 
7.2.3. Reagent Addition 
Super Simple Method allows the user to quickly add reagents to plates. After selecting 
this pipetting method, the user is asked to select one of the variations of the method from a 
list. The user then enters the number of plates to process, pipetting volume(s) and range. 
Pictorial views are then sequentially displayed to show which carrier and labware to load 
on the deck. The user then clicks the okay button. A pipetting script is automatically 
generated and run to completion. 
7.2.4. Combining or Merging Plates 
Super Simple Method allows the user to conveniently merge plates. After selecting this 
pipetting method, the user is asked to select one of the variations of the method from a list. 
The user then enters the desired pipetting volume(s) and range. Pictorial views are then 
sequentially displayed to show which carrier and labware to load on the deck. The user 
then clicks the okay button. A pipetting script is automatically generated and run to 
completion. 
7.3. Chain of Custody 
The STAR liquid handling workstation supports the chain of custody in every aspect of 
pipetting, labware handling and sample tracking. 
7.3.1. Barcode Tracking 
When the Autoload option is used, the barcodes of all tips, labware, and carriers can be 
read as they are loaded. This confirms the correct items are loaded in the correct spot.  A 
record of all loaded items can be stored and used to control the pipetting process. Barcode 
data sets can be compared to worklists from LIMS, exported as data files, or printed. 
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7.3.2. Total Aspiration and Dispense Monitoring (TADM) 
Each channel has its own pressure sensor to monitor pressure in the pipette.  This data is 
monitored and stored in real-time. This provides independent evidence that the pipetting 
operated within standard conditions or not. Under pressure or over pressure conditions 
experienced during specific times of the pipetting cycle can reveal if a clog, foam, 
insufficient sample or improper dispense occurred. 
7.3.3. Tip Sensing 
Each tip size is physically different at the tip connection site so that the tip channel can 
sense which tips is attached. The workstation automatically checks type with the tip size 
called out in the application script. A record of this data can be stored. 
7.3.4. Labware Grip Sensing 
Hysteresis in both the CO-RE grippers and iSWAP articulating labware gripper motors 
are monitored and recorded during their use. This data is used to confirm if a labware was 
pick-up or not during labware transfers. 
7.3.5. Labware Sensing 
The STAR can monitor and record the hysteresis on the z-drive (up/down) of the 
pipetting channels. This information can be used to determine if labware is present or not 
prior to pipetting further confirming that the method executed correctly. 
7.3.6. Liquid Level Sensing 
The STAR pipetting channels are equipment with capacitive and pressure level sensing 
and recording functions. These techniques can be used to check or confirm the liquid level 
in an individual cell prior to or after pipetting. 
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7.3.7. Liquid Level Detection 
Hamilton offers both the traditional capacitive liquid level detection as well as pressure 
liquid level detection. The software can use these functions to drive the pipette tip to just 
above the surface to do a jet dispense, or touch the surface for a wet dispense, or dive 
below sufficiently to aspirate liquid without drawing in any air. 
7.3.7.1. Capacitive Liquid Level Detection  
A weak electrical potential is created between the pipetting channel and the labware 
carrier. When using conductive tips (black) and an ionic liquid the capacitance of the 
circuit is measured. From this data the software can determine the height of the liquid 
surface and take appropriate action. 
7.3.7.2. Pressure Liquid Level Detection 
 A pressure transducer inside the air displacement channel measures the pressure inside 
the barrel during pipetting. The data from this sensor changes as the tip approaches the 
liquid surface, touches the surface and drives below,  
 
Figure 23. This data can be used to control pipetting in real-time. Pressure level sensing 
is the only way to determine the level of non-ionic liquids. 
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Figure 23: pressure Liquid Level Detection, capacitive Liquid Level Detection. 
 
7.3.8. Monitored Air Displacement: MAD 
Monitoring air displacement allows for real time detection of pipetting errors during 
pipetting steps. This includes detecting: 
• if an insufficient amount of liquid has been aspirated for a single, multiple or 
partial dispense; 
• aspiration of air, because the level of the liquid in a reservoir/tube was too low; 
• blocked tips due to clotting. 
Errors can then be corrected by user-defined, software-guided error handling. The 
STAR’s Monitored Air Displacement eliminates uncertainty in automated assays by 
providing reliable, consistent, walk away automation. 
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7.3.9. Anti Droplet Control (ADC) 
The combination of air-tight tip seals and air displacement pipetting with pressure 
monitoring allows Hamilton to offer anti droplet control (ADC). It can be pipetted liquids 
with extremely low viscosity and high vapor pressure like Acetone and Methanol with 
ease and confidence knowing that there will be no loss of liquid and no contamination of 
other samples because of dripping tips.  
• Enables pipetting of highly volatile liquids; 
• Increases process safety; 
• Allows safe automation of Assays that require pipetting of substances like 
Acetone and Methanol. 
ADC,  
Figure 24, works by continuously monitoring the pressure in the channel. 
The STAR channels sense the minute increase in the vapor pressure inside the barrel. 
When the pressure reaches a point where a drip is likely to occur, the plunger is withdrawn 
a step or two to keep the liquid inside the tip and prevent dripping. Volatile liquids such as 
Ether and Acetonitrile can now be safely pipetted from one side of the deck to the other. 
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Figure 24: Anti Droplet Control. A: schematic drawing showing a pipetting channel with its 
pressure sensor. The volatile liquid contained in the tip evaporates into the air space. B: without 
ADC, as the pressure in the tip increases, a droplet forms at the end of the tip, reducing the 
pressure in the tip when it falls off. C: with ADC, pressure differences are detected by the pressure 
sensor and compensated for in real time by piston movements: droplet formation is prevented. 
7.3.10. Action Editor 
The Action Editor offers you a very intuitive user interface which includes access to all 
possible actions (pipetting, transport, incubation, etc.) in a toolbox for simple drag & drop 
programming. With the Action Editor you can quickly carry out throughput calculations 
and easily customize the actions by inserting action details like pipetting volume, pipetting 
source and target. 
The new 3D deck and the rich graphics make deck creation easy: 
• select carriers by category or just type some keywords; 
• drag the photo of the carrier on the deck;  
• add labware - find your plates by name, keyword and photo;  
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• switch to the Action Editor and drag a pipetting step into the method;  
• choose from simple pipetting steps, aliquoting or pooling;  
• answer a few steps about source, target, volume and start pipetting;  
• the Action Editor supports drag and drop of target and source plates. 
7.4. Pipetting Options 
7.4.1. 1000µl Channels 
The 1000µl Independent Channels are based on air displacement pipetting technology 
similar to the best hand-held pipettes. The pipette volumes range from 0.5 to 1000µl. The 
channels support pipetting with disposable tips. Disposable tips are available in four 
different sizes: 10, 50, 300, 1000µL CO-RE tips, Table 1. 
Movements in the Y (spreading) and Z (up and down) directions are independent. This 
provides the greatest flexibility to adapt to asymmetric labware positions and pipetting 
sequences. 
Pressure and Capacitive Liquid Level Sensing Each channel is equipped with its own 
pressure transducer and capacitance measuring circuitry. This allows it to measure liquid 
level either by pressure or capacitance or both. Pressure sensing is vital for measuring the 
liquid level of non-ionic liquids, supporting TADM and chain of custody. 
Tip Type Sensing Each channel senses which tip type is being attached.  If the tip type 
does not support the pipetting conditions set in the software script, the user is alerted. This 
ensures that liquid never accidentally enters the channel. 
Straight Alignment Each channel uses Hamilton's CO-RE technology for tip 
attachment. An internal o-ring is expanded to assure a tight seal and straight alignment. 
Hamilton tips also are individually imaged during manufacturing for straightness. 
Together with the CO-RE tip attachment design; this makes sure the tip of each tip on 
channel is in the right position even for 1536 plate pipetting. 
The Hamilton MICROLAB® STAR expands the high throughput of multichannel 
liquid handling with a96 channel pipetting head. 
The highly configurable and flexible Hamilton MICROLAB® STAR supports multiple 
arms, each with a multichannel pipetting head. The throughput and flexibility can be 
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achieved with both the 384 and 96 channel head on a single workstation with the highest 
on-deck plate density in the industry. 
Table 1: Pipetting specifications for disposable tips 
Tip size Volume Precision Trueness
10µl 0,5µl 6,0% 10,0%
10µl 10µl 1,0% 1,5%
50µl 1µl 4,0% 5,0%
50µl 50µl 0,75% 2,0%
300µl 300µl 0,75% 1,0%
1000µl 1000 µl 0,75% 1,0%
 
7.4.2. Disposable Tips 
The Hamilton Company designed the CO-RE tips for its MICROLAB pipetting 
workstations in order to solve the problem of sealing and alignment plagued by press-fit 
tip attachment techniques. Each CO-RE disposable tip has a circular groove inside the 
attachment orifice. An o-ring on the pipetting channel is expanded to fit this groove 
precisely providing an air-tight seal and straight alignment between tip and pipetting 
channel. 
Tip Type Signature Each CO-RE tip type has a unique set of ridges molded into it so 
that the pipette channel can detect the tip type and the software can compare tip type with 
pipetting settings to make sure they are compatible. 
Tip Quality Hamilton goes beyond on relying just on statistical analysis of tip quality 
to assure the highest product quality. Instead it has invested in an automated computer-
based visualization system to inspect every tip before it is packed in its rack.  Each tip is 
checked for straightness, concentricity of its orifice, and absence of flash from the 
molding process. This way you can be assured that Hamilton is shipping 100% performing 
product for accurate pipetting with each tip. 
Optimal Tip Design Hamilton tips are designed for optimal liquid handling. Each 
dimension of the tip has been analyze and optimized using numerical grid simulations and 
empirical testing to produce accurate and repeatable results in the widest range of 
pipetting modes. 
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7.4.3. Tip Types 
• Conductive (black) / Non-conductive (clear)  
• Filtered / non-filtered  
• Individual racks (blue frame) / stacked (black frame) 
Stacked Tips In order increase tip capacity on the workstation deck for longer walk-
away times and to increase tip packaging density, Hamilton designed a new stackable tip 
frame for the CO-RE 10µl, 50µl and 300µl unfiltered tips, Figure 25. These tips come in a 
package containing a disposable frame, five stacks with 4 tip racks, each rack with 96 tips. 
With these packs a user can load 1,920 tips on the deck in one step. And, all these tips take 
up only 6 tracks on the deck. The frames are able to be manipulated by the iSWAP, CO-
RE grippers and SWAP. Tips can be picked up by the independent channels or 96 channel 
mulitprobe head directly from the stack eliminating the need to move the frames to a tip 
pick-up position. This saves not only processing time but also frees up an extra position on 
the deck. Used tips and frames can be ejected into the standard waste bag or front/side 
mounted tip waste chute. 
Stacked tip racks can be loaded in bulk on the deck using a single low profile standard 
carrier, or individual frames or single stack of frames can be loaded on multiflex modules. 
 
Figure 25: CO-RE Disposable Tips and Washable Needles 
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7.5. Labware Manipulation Tools 
7.5.1. Microplate Gripping: CO-RE Grip 
Thanks to the CO-RE tip attachment technology, the STAR features an innovative plate 
transfer option. In addition to tips, the pipetting channels can pick up the compact CO-RE 
gripping tool during a run. With this gripping tool the pipetting channels act as a gripper, 
picking plates from a stack, moving plates around the deck, removing lids or placing a 
filter plate vacuum manifold. The CO-RE gripper is an inexpensive option than moves 
labware without time consuming positional teaching. 
 
Advantages: 
• Small budget plate handler; 
• Gripper paddles picked up by two channels; 
• Default position for labware; 
• Reaches all deck space; 
• Landscape and portrait plate gripping; 
• Facilitates stacking. 
7.5.2. Plate Gripping Tools / Plate handling 
Two different types of plate gripping tools are available on the STAR line of liquid 
handling robots, and an external robotic arm provides a third option for plate handling 
when building integrated systems that require labware handling away from the STAR 
deck. 
Two pipetting channels can pick up the CO-RE Gripper tool, providing a flexible, low-
cost solution for moving labware on the STAR deck, Figure 26. 
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Figure 26: CO-RE Gripper 
A robotic gripper with a full range of motion, the iSWAP can also reach off the STAR 
deck to access 3rd party equipment or custom labware positions, Figure 27. 
 
Figure 27: iSWAP 
The MICROLAB eSWAP is designed for seamless and simple integration of 3rd party 
peripheral devices with Hamilton liquid handling robots to create completely automated 
workstations, Figure 28. 
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Figure 28: eSWAP External Gripper 
 
7.6. Carriers & Accessories 
7.6.1. STAR Multiflex Modules 
The latest addition to the STAR accessories line is based on a modular concept. On a 
base plate, a variety of different modules can be mounted. There are modules available for 
plate or tip rack stacking, cooling, heating, tilting, shaking and many more. Compared to 
standard carriers, Multiflex allows the free combination of various modules on one base 
plate according to your needs. It’s customization based on standard parts. The number of 
modules is steadily increasing, so check back for new products frequently. 
7.6.2. Volume Verification Kit 
The MICROLAB STAR verifies pipetting volumes via gravimetric testing.  This is 
much more reliable than traditional verification testing using dyes and plate absorbance 
readers. 
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7.6.3. Autoload and Barcode Reading 
The Autoload option on the MICROLAB STAR automatically loads carriers as well as 
reads barcodes. With this option a loading shelf is supplied which attaches to the front of 
the workstation. This acts as a staging area for carriers to be inserted or removed from the 
workstation for either loading/unloading labware or changing carriers for another 
application. The track numbers are imprinted on deck to help the user position the carriers 
in the correct position.  In addition backlit track numbers are mounted on the front safety 
panel and can light up green to indicate the correct tracks to insert a particular carrier at a 
particular time. Plastic torpedoes guide the carriers into position. Then the workstation 
grabs the carrier and pulls it in front of the barcode reader.  
The barcode reader can read the barcodes on carriers to make sure the correct carrier is 
inserted in the correct track. It can read the barcodes on tip racks and plates to make sure 
the correct items are loaded on the correct carrier. This information can be compared to a 
work list either created by the user or downloaded from a LIMS. The barcode reader can 
also read the barcodes on tubes as well. These functions are paramount for IVD and chain 
of custody compliance. Also, with this design barcodes are read as the carrier is being 
loaded. If the barcode check fails, the user is alerted immediately before the carrier is 
pulled all the way on the deck thus saving the user time to get the correct carrier in the 
right position with the correct labware and consumables. 
7.6.4. Basic Vacuum System 
The MICROLAB STAR Basic Vacuum System (BVS) (Figure 29) is designed to 
automate solid phase extraction assays using either commercially available kits or custom-
made assays. 
The option consists of a dedicated carrier, vacuum pump and controller. The vacuum is 
completely controlled by the Venus software. The carrier consists of a vacuum chamber 
for the destination plate, a manifold with seals to place the source elution filter, a park 
position for the manifold and two empty MTP positions. iSWAP or CO-RE grippers can 
manipulate the manifold and access the target plate. 
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Figure 29: Basic vacuum System. 
 
 
 
  
64 
8. Sample Preparation Techniques 
The importance of accurate sample preparation techniques cannot be overstated, 
meticulous sample preparation is essential. Often overlooked, it is the midway point where 
the analytes from the sample matrix are transformed so they are suitable for analysis. 
In pharmaceutical bioanalysis, researchers develop and run various assays to quantitate 
drugs, pharmaceutical candidates, and their metabolites in biological fluids such as serum 
and plasma. The data resulting from these assays are used to help determine the 
pharmacodynamic and pharmacokinetic properties as well as the toxic and therapeutic 
concentrations of existing and emerging pharmaceutical compounds in living cells, tissues, 
and animals. Although advances in Liquid Chromatography-Mass Spectrometry (LC-MS) 
technology have reaped overwhelming benefits in terms of increased throughput and 
sensitivity, good sample preparation continues to be a critical component of bioanalysis. 
A sample matrix for bioanalysis almost always contains some amount of protein, along 
with other endogenous macromolecules, small molecules, metabolic byproducts, salts and 
possibly co administered drugs. These components must be removed from the sample 
before analysis in order to attain a selective technique for the desired analyte. 
It is important to remove the protein from a biological sample because that protein, 
when injected into a chromatographic system, will precipitate upon contact with the 
organic solvents and buffer salts commonly used in mobile phases44. 
The three most common sample preparation techniques used in Bioanalytical Sample 
Preparation are Protein Precipitation (PPT), Liquid-Liquid Extraction (LLE), and Solid 
Phase Extraction (SPE). Each technique offers unique advantages and disadvantages that 
are considered during the method development process. For example, protein precipitation 
methods are simple (2-3 steps), fast, and often require minimal method development. 
However, the technique offers minimal selectivity as it only removes gross levels of 
protein from a sample prior to analysis. In contrast, SPE offers significant benefits in 
terms of selectivity/sample cleanup, but the technique often requires moderate to extensive 
levels of expertise and time for adequate method development. In addition, SPE often 
                                                     
 
44 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. 6, 199, 
(2003). 
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requires multiple steps (5-8), resulting in increased assay time. Modern analytical 
laboratories are full of significant technological investment. Many are surprised to learn 
that the highest cost in a laboratory is still not the equipment but the analyst, and more 
specifically, analyst time. With analysts spending as much as 60% of their time on sample 
preparation, it is no wonder companies are turning to automation to recapture their 
investment in human resources. Only through a careful analysis of what tests, or portions 
of tests, are automated will one be able to assess the return on investment from 
automation. In the worst cases, an analyst could be replaced with an equipment repair 
technician, or a step that is not a critical path in the laboratory could be automated. In the 
best case, significant additional testing capacity and reduced cycle times can be created.  
Both routine and intensive analyst tasks are being automated because of favorable 
financial return. However, for laboratories in regulated industries, using this automation is 
not as effortless as simply turning on the switch. A significant amount of planning, along 
with additional investment in validation and documentation, must be invested prior to 
relying upon automation to generate a return. 
8.1. IQ/OQ/PQ 
Details for a successful instrument qualification, operational qualification, and 
performance qualification, known collectively in the pharmaceutical industry as 
IQ/OQ/PQ, must be established under GxP, Table 2, lists the general definitions of the 
qualifications, with the added definitions for equipment qualification (EQ) and design 
qualification (DQ). (EQ and DQ are newer interpretations of equipment qualification and 
not as widespread in application.) Why all the fuss about instrument qualification? GxPs 
mandate that analysts establish and document procedures to indicate that the 
instrumentation has been fully controlled. The industry adage “if the scientist didn't write 
it down, you didn't do it” applies not only to data but to instrumentation documentation as 
well. For now, let it suffice to say that all measurement equipment in a GxP laboratory 
must be qualified. Automated equipment not only must be qualified to demonstrate its 
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utility, but also to address concerns from directing much of an analysis away from human 
intervention and control45. 
Table 2 
Qualification definitions 
Installation Qualification (IQ) 
IQ establishes that the instrument is received as designed
and specified. IQ also verifies that the instrument
environment is suitable for the operation and use of the
instrument and that the instrument is properly installed. 
Operational Qualification (OQ) OQ is the demonstration that an instrument will function
according to its specifications in the selected environment. 
Performance Qualification (PQ) PQ is the demonstration that the instrument performs
according to a specification appropriate for its routine use. 
 
8.1.1. Validation vs. Qualification 
8.1.1.1. Validation 
Validation is the process of evaluating the performance of a specific measuring 
procedure and checking that the performance meets certain preset criteria. Validation 
establishes and provides documented evidence that the measuring procedure is fit for a 
particular purpose. Qualification is the verification that an instrument is performing under 
predetermined specifications. It should also be noted that “calibration” is also unique; it is 
the verification that an instrument is standardized against a nationally accepted standard 
(or a secondary standard that has been calibrated against such a standard). The terms 
“validation” and “qualification” are often mistakenly interchanged. 
                                                     
 
45 Considerations When Implementing Automated Methods into GxP Laboratories  Authored by: Gregory K. Webster, Laila 
Kott, Todd D. Maloney 
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8.1.1.2. Qualification 
Regulated industries look for equipment to undergo a series of qualifications: 
Equipment Qualification (EQ), Design Qualification (DQ), Installation Qualification (IQ), 
Performance Qualification (PQ), and Operational Qualification (OQ). Specifications for 
these qualifications are often predefined by the manufacturer and negotiated within the 
company. 
Automated methods can be introduced to the GxP laboratory by validating the 
automated method directly or establishing a successful analytical method transfer from an 
existing method to the automated procedure46. 
8.1.2. Method Validation 
The level to which a method is validated for GxP is normally based on where the 
methodology is being applied. In early drug development, there is less information about 
the chemical characteristics of the drug and a high likelihood it will not succeed and 
become a marketed product. It is not economically prudent to allocate significant 
resources to the drug, and the level of method validation is to a level consistent with the 
state of knowledge regarding the manufacturing processes and the concern for safety of 
patients taking the drug in a clinical setting. Reference standards are seldom available at 
this stage, leaving the validation of the method focuses on precision and selectivity of the 
drug from its matrix. Linearity of response is needed for all stages of development; 
however, sensitivity only needs to be established to the reporting limit. If the GxP study 
involves human testing, the level of validation increases to a point where confidence in the 
designed indication going into the patient is established. Finally, as the drug progresses to 
market, full analytical characterization is established. 
                                                     
 
46 Considerations When Implementing Automated Methods into GxP Laboratories  Authored by: Gregory K. Webster, Laila 
Kott, Todd D. Maloney. 
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8.1.3. Analytical Validation Principles 
Validation is establishing documented evidence that the analytical test method performs 
to established specifications. These specifications are generally defined in a study 
protocol, in company standard operating procedure (SOP), or in a compendial reference. If 
the method is being used for stability investigations, the validation must establish its 
suitability as a stability-indicating method for the analysis of the intended analyte.  
To some degree, all analytical method validations under GxP will test for specificity, 
precision (repeatability and intermediate precision), linearity, range, accuracy, robustness, 
and quantitation limit of the intended analyte.  
Sample preparation has been and continues to be the critical step for fast, accurate, and 
reliable LC-MS/MS assays. 
Conventional biological matrix extraction methods such as solid phase extraction, 
liquid-liquid extraction, and protein precipitation (PPT) are both time-consuming and 
labor-intensive. Due to its simplicity and universality, protein precipitation continues to be 
the main methodology employed for biological sample preparation, especially in the drug 
discovery arena. However, all three major sample preparation methods remain tedious 
processes and, consequently, bottlenecks limiting the throughput of current fast LC-
MS/MS analysis. Current trends in sample preparation have focused on the use of 96-well 
technology as well as automated sample preparation via 96-well parallel processing.1While 
the introduction of 96-well liquid handlers, such as the Tomtec Quadra, has helped 
overcome some of these bottlenecks, a completely automated sample preparation solution 
remains elusive.Current 96-well automation is composed solely of the liquid-transfer steps 
of sample preparation, but not the preparation of standards and quality control samples or 
sample dilutions. In addition, current automation is incapable of interfacing with either 
laboratory information management systems (LIMS) such as Watson or mass 
spectrometric data acquisition software. This report demonstrates the utility of a 
commercially available advanced robotic workstation, the Hamilton MicroLab Star, and 
the resultant fully automated 96-well sample preparation methodology for biological 
sample preparation. 
To achieve the automated Hamilton programming, we then considered whether 
bioanalytical sample preparation procedures could be standardized. Bioanalytical sample 
preparation basically consists of two main liquid transfer steps. The first step is sample 
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transfer, which includes transferring different types of samples, i.e., standards (STD), 
quality controls (QC), double blanks (BLKs) (blank matrix without internal standard [IS]), 
control blanks (blank matrix with IS), and study samples, from different source vials or 
containers to their destination wells on a 96-well sample collection plate. Then, IS is 
added to all wells except for the BLK. The second step is extraction and reconstitution. 
The most commonly used extraction methods are SPE, protein precipitation (PPT), and 
liquid-liquid extraction (LLE). The general procedures are shown below in Table 3. 
Table 3 
PPT LLE SPE 
Addition of precipitant solution Addition of organic solvent to the sample
plate
SPE 96-well plate conditioning
Supernatant transferring Organic layer transferring Loading sample to SPE 96-well plate
Dilution of supernatant, or
evaporation and reconstitution Evaporation and reconstitution Interference washing
Analyte eluting
Evaporation and reconstitution
 
The first step is quite complicated and prone to error if the manual programming is used 
because: 
1. Different types of samples are in different types of vials or containers, and thus they are 
on different carriers. Although it is possible to put all types of samples on the same carrier 
by manually transferring different types of samples into the same type of vials before 
sample transfer, the advantage of using a liquid handler is minimized. 
2. For high-dose study samples, dilution with a dilution factor (DF) up to 1,000-fold is 
sometimes needed to bring the concentration of those samples to the standard curve range. 
3. IS is only added to the part of wells on the 96-well sample collection plate, i.e., no IS 
will be added to blank samples. 
8.1.4. Liquid Classes 
The concept of Liquid Class is important. A liquid class is a set of parameters 
determining the most appropriate aspiration and dispense performances  of the pipette for 
any given liquid, tip type and dispense mode. For all aspiration and dispense steps I must 
select the most appropriate liquid class. 
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The accurate transfer of liquids depends on their specific properties and other physical 
parameters. For example, the volume of liquids is affected by the temperature and the 
ambient pressure, and organic solvents frequently tend to evaporate due to their often high 
vapor pressure. Density, viscosity and the surface tension of liquids and solutions are 
additional characteristics which strongly influence the precision and accuracy of liquid 
handling. The capillary action of a liquid will be significantly determined by its surface 
tension. The dimensions, shape and material of tips, needles and wells affect formation of 
drops, meniscus and bubbles. 
Liquids which are used in life science research include pure water, media, buffer 
solutions, DMSO, other organic solvents, protein and nucleic acid solutions, and many 
other liquids. All must be transferred with high accuracy and precision for satisfactory 
automation of applications. 
Allowing the liquid handling automation to accomplish all pipetting tasks can eliminate 
the introductions of human pipetting errors. The accuracy of pipetting is much higher 
when performed by a liquid handler compared with manual operation, especially when 
small volumes are aliquotted. 
The accuracy and precision of the automation with regard to pipetting performance are 
determined at regular intervals. When maintained and used properly automation 
performance is reliable. Many varieties of automation allow the user to adjust default 
settings for pipetting in order to allow for individual variation in the liquid type. A specific 
set of pipetting defaults can be used for plasma samples, organic solvents, aqueous 
solutions and 50/50 mixtures of organic/aqueous solutions. These settings can usually be 
overridden for individual steps when necessary. 
The highly flexible Hamilton robotics system is capable of handling multiple liquid 
class types within a given method. This feature allows accurate pipetting of a variety of 
solvents or matrixes by assigning a specific liquid class to an individual solvent 
throughout the method. However, in order to ensure accurate pipetting, each liquid class 
must be independently calibrated, typically on a quarterly basis. This is accomplished 
using the eight-channel head and a balance. Several liquid classes required calibration and 
validation, including a plasma liquid class for analysis of biological matrix, an organic 
liquid class for transfer of stock solutions. The validation process for each liquid class was 
conducted by measuring the weight of eight replicates, one replicate per channel on the 
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unit across a pipetting range of 5- 300µl. Volumes were calculated using the density of 
each liquid class. 
For quantitative bioanalysis, a variety of solvents, including methanol, water, mixed 
solvents, and plasma, are typically used to prepare standards and unknown samples. 
Density information is usually unknown for the mixed solvents, and the density of plasma 
can vary from species to species. For volumes of 5, 100, and 300 µl, the volume 
measurements were calculated from the weight values divided by the density of the given 
liquid class47. 
I could find several standard liquid classes in the software, but they are not enough to 
fulfill all the needs present in my methods, since sometimes there were particular liquids 
or liquid mixtures not covered by any ready-made liquid classes. 
In the section “Liquid Details” I can set the parameters I need such as the flow rate that 
correspond to plunger speed for aspirating, dispensing and mixing, the air transport 
volume, the over-aspirate volume which is a kind of pre-wetting volume, etc. 
In the section “Correction Curve” I can introduce the corrected values calculated with 
gravimetric tests. The “corrected volume” is the volume that actually needs to be moved 
by the plunger for this purpose. In aspiration or dispense steps, the “target volume” which 
will be actually dispensed into the vessel must be entered. For example a corrected volume 
of 107.2 µl for a target volume of 100µl does not mean that 107.2µl of liquid will be 
dispensed. The high flexibility of the liquid classes allows to pipette any liquid with high 
accuracy. The liquid classes I have calculated for the methods I utilized since now 
(MeOH-ACN 50-50; MeOH-H2O 50-50; ACN-MeOH 75-20; ACN-Formic Ac. 15-85; 
etc.) have good characteristics of accuracy and precision in dispensation more than the one 
requested48.  
 In Table 4 are described the main liquid classes created in Automation Laboratory. 
                                                     
 
47 Flexible Automated Approach for Quantitative Liquid Handling of Complex Biological Samples Joe Palandra, David 
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Bioanalytical Research, Department of Pharmacokinetics, Dynamics. 
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Table 4 
Liquid Classes
Tips 50ul and tips 300ul %
CH3CN 100
CH3CN 90
CH3CN-H2O 50-50
CH3CN-MeOH 75-25
H2O 0.1%HCOOH-CH3OH 0.1% HCOOH 95-5
H2O-CH3OH 50-50
CH3OH 100
CH3CN-HCOOH 75-15
Rat Plasma 100
Human Plasma 100
Dog Plasma 100
Urine 100
 
Statistical calculations are performed to determine values for the mean, standard 
deviation and CV% (coefficient of variation). Repeated failure signifies a mechanical 
adjustment issue or other problem; perhaps a correction needs to be made in the default 
settings for pipetting and system variables, Figure 30. 
Accuracy in solvent delivery is a function of the reagent type (biological matrix, 
aqueous, organic or aqueous/organic mixture) the speed of pipetting, and the physical 
dimensions of the delivery hardware (tips or probes). A gravimetric determination using 
specific gravity calculations is an accepted way to generate accuracy data. 
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Figure 30: Mechanical adjustments and parameters to evaluate in the creation of a liquid class. 
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9. Protein Precipitation Technique (PPT) 
9.1. Introduction 
PPT is a technique used to remove proteins from a biological sample matrix prior to 
analysis. It is not selective as other sample preparation methods but the simplicity and 
universality of this approach have broad appeal for many applications, particularly in 
support of drug discovery.  
High-throughput procedures for removing proteins from the matrix are important in fact 
these matrixes for bioanalysis always contain some amount of protein, other endogenous 
macromolecules, small molecules, metabolic byproducts, salt and possibly 
coadministrated drugs. These components must be removed from the sample before 
analysis in order to attain a selective technique for the desired analyte.  
Proteins play an important role in the transport and storage of drug substances. Most 
biological matrices contain protein to varying extents. Protein binding phenomena are 
known to influence drug-drug interactions in the clinical setting. Among the various 
plasma proteins serum albumin is the most widely studied and is regarded as the most 
important carrier for drugs. The presence of these materials for bioanalysis, however, is 
problematic. 
It is important to remove the protein from a biological sample because that protein, 
when injected into a chromatographic system, will precipitate upon contact with the 
organic solvents and buffer salts commonly used in mobile phases. The precipitated mass 
of protein builds up within the column inlet. The result is reduction of column lifetime and 
an increase in system backpressure. When protein is carried through the analytical system 
it may reach the mass spectrometer and foul the interface, requiring cleaning. 
A common approach for removing protein from the injected sample, amenable to high-
throughput applications in microplates, is precipitation using organic solvents, ionic salt 
and/or inorganic acids. The precipitated mass can be separated by either centrifugation or 
filtration; analysis of the supernatant or filtrate, respectively, is then performed. 
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9.1.1. Precipitating agents 
9.1.1.1. Acids 
Proteins are known to precipitate from solutions when subjected to strong acids, organic 
solvents and certain salts of heavy metal cations. 
TCA 10% w/v, perchloric acid 6% w/v and metaphosphoric acid. 5% w/v, for example, 
protonate basic sites on the protein to change its conformation, subsequently forming 
insoluble salts at pH below their isoelectric point. 
The isoelectric point is the pH at which a protein molecule has a neutral charge, at a pH 
higher than its isoelectric point, the protein will acts as a base, and at pH lower it will acts 
as an acid. A protein has its minimum solubility at its isoelectric point and can be 
coagulated more easily at this value. 
These acids are very effective protein precipitants but they are generally regarded as too 
harsh for many labile analytes when injected directly into LC-MS/MS system. 
9.1.1.2. Organic solvents 
Organic solvents are known to lower the dielectric constant of protein solutions and 
increase the protein-protein interactions. Solvents such as methanol, ethanol, acetonitrile 
(ACN) and acetone are reported to be slightly less effective than acids for their degree of 
protein precipitation but are preferred in bioanalysis because the conditions are very mild 
and analyte degradation is avoided. These organic solvents are also more compatible with 
the LC mobile phases commonly used and sometimes can be injected directly. 
Among choice for organic solvents used as precipitating agents, acetonitrile and 
methanol are most often utilized for bioanalytical sample preparation, each has its 
advantages and drawbacks in certain situations. For example, using ACN can result in 
poor recovery and also late eluting peaks. Methanol is not as efficient as ACN when used 
in the same ratio but it does tend to produce precipitate that facilitates mixing; the 
supernatant appears clear rather than the dark one produced by ACN. 
The ratio of precipitating agent to sample matrix is important for efficient removal of 
proteins. Acids achieve efficient removal of proteins at very low ratios (>98%). However 
the commonly used organic solvents require greater volumes relative to plasma. 
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The best results for precipitating proteins from plasma are obtained using a ratio of 1 
part plasma to 3 parts ACN or 1 part plasma to 4 parts methanol. 
9.1.2. Advantages 
PPT is one of the four main drug sample preparation methodologies for several reasons: 
• It is a simple and universal procedure for small drug molecules in plasma. 
• There is usually no pH modifications involved as with other techniques so the 
exact nature of the analyte (ionized or unionized) is not as important to success 
of the method. 
• The low speed of the procedure. 
• Little method development time invested before proceeding to method 
validation. 
• High recovery of analyte (>95%) can be obtained even when the extent of 
protein binding exceed 99%. 
• Very small sample volumes (e.g., 20-50µl plasma) can be efficiently eliminated 
of proteins using small volume microplate wells since this precipitation 
technique has minimal sample transfer and isolation steps. 
9.1.3. Disadvantages 
Satisfactory analyses have been demonstrated with this rapid sample preparation 
approach, but it has several disadvantages: 
• PPT typically dilutes the sample by a factor of three or more, so it is a useful 
technique only when analyte concentrations are relatively high (1-10ng/ml) and 
the detection limits allows an adequate quantitation. However the supernatant 
can be evaporated using nitrogen and heat to reverse this dilution effect. 
• The evaporation step requires an additional transfer step (with possible transfer 
loss) and time for the dry-down and reconstitution procedures. 
• The analyte volatility for newly synthesized compounds is often unknown, and 
lower recovery may result by introducing a dry-down and reconstitution 
procedures. 
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• A lower recovery upon dry-down may also be due to the potential contributions 
of analyte absorption to the sample container and inefficiency in resolubilizing 
the dried extract. 
• Gradual accumulation of small amount of protein or particulate may occur and 
be noticeable after injection of a large number of samples. 
• The use of an additional wash step in this manner adds time to the overall 
procedure and dilutes the sample further. 
• Lipid components are also undesirable. Various types of lipids can potentially 
accumulate in the LC column and elute slowly upon each injection, 
deteriorating column efficiency over time 
The case of variable ionization suppression, discussed in the next chapter, is even more 
of a problem than the accumulation of matrix components and the percentage of organic in 
the injected sample. 
9.1.3.1. Matrix effects 
The major precaution when using protein precipitation as a sample preparation 
technique is that matrix components are not efficiently removed and will be contained in 
the isolated supernatant or filtrate.  
In MS/MS detection systems, matrix contaminants have been shown to reduce the 
efficiency of the ionization process using API techniques and in ESI ion suppression is 
more severe. The observation seen is a loss in response and this phenomenon is referred to 
as ionization suppression.  
This effect can lead to decreased reproducibility and accuracy for an assay and failure to 
reach the desired limit of quantitation. 
Attempts have been made to minimize matrix effects from protein precipitation 
extractions. The best approach is a more selective extraction technique. 
When the technique is decided a recommended approach is to use a stable isotope of 
analyte as internal standard (IS) so that both compounds coelute and are affected in the 
same manner by ESI suppression. 
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9.1.4. High-throughput PPT techniques using collection 
microplates 
The first approach to automation was the development of a fully automated protein 
precipitation technique for biological sample preparation and it has been developed for the 
quantitation of drugs in various biological matrixes. 
All liquid handling during sample preparation was automated using a Hamilton 
MicroLab Star Robotic workstation, which included the preparation of standards and 
controls, shaking of 96-well plates, vacuum application and an interface with a Watson 
7.X LIMS to manage a work list. 
An overview of the process workflow is discussed, including the software development. 
Validation data are also provided, including specific liquid class data as well as 
comparative data of automated vs. manual preparation using both quality controls and 
actual sample data. The efficiencies gained from this automated approach are described. 
PPT traditionally has been performed in test tubes, but this approach is labor intensive 
with its required tube labeling and frequent manipulations.  
The manual approach does not meet the high-throughput needs required by the 
emphasis on rapid pharmaceutical drug development. Since the microplate format is 
commonly used in autosamplers for injection into the chromatographic system, it is 
desirable to retain that format and perform the sample preparation procedure in a 
microplate. 
Two general approaches are common for performing protein precipitation in the high-
throughput microplate format: 
 
• Use a collection plate or microtube rack, pellet the precipitated protein at the 
bottom of wells by centrifugation and collect the supernatant for analysis. 
 
• Use a filtration microplate to trap the precipitated protein on top of the filter and 
collect the filtrate for analysis. 
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9.1.5. Filter Plates 
 
Figure 31: Sirocco filter plate 
Sirocco filter plate Sirocco (Figure 31) 
The Sirocco 96-well filtration plate is an update in the automation and throughput of 
protein precipitation in drug metabolism/ADME/toxicology labs by providing a simplified 
means of sample preparation.  
The plate combines 96-well plate tip design features with proprietary membranes that 
result in rapid "in-well" sample preparation methods. This plate contains a unique filter 
system, a sealing cap mat and a patented valve technology designed specifically to allow 
“in-well” processing which prevents clogged wells, cross-talk or leaking during use. 
Is possible applying a vented cap mat, using a cap roller to ensure secure and uniform 
sealing. This will prevent leakage and cross talk during mixing. With Sirocco filter plates 
there is no need to remove the vented cup mats or valve tips from the plate before 
filtration because the valves and vented cap mat are designed to open under vacuum to 
allow controlled flow during filtration. 
Mix time 0.5-1 min at medium setting, filtration 3 min, 10” Hg. 
Excessive mixing could cause cross talk and under mixing this will cause clogging or a 
cloudy filtrate. 
 
 
Whatman Fast Flow 
The plate is made with 2ml, 96-well, rigid glass filled polypropylene which make the 
plate both robust and chemically resistant. The plate contains specially formulated dual 
membranes with two distinct layers. The top layer acts as a prefilter to remove coarse 
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particulates. The bottom layer is oleophobic for retaining the well contents without 
dripping. This provides a final filter for removing fine particulate matter when vacuum is 
applied. 
9.1.6. Automation of PPT in filter plates using a robotic 
workstation 
The use of filtration plates offers the advantage of eliminating the manual off-line steps 
of mixing and centrifuging, as used with a collection microplate. 
The precipitation occurs immediately and protein is trapped on the surface of the filter 
in each well. Vacuum is used to process liquid through the filter plate. 
The deck layout we created for PPT is shown in and Figure 33. 
• Position 1 is the location for the filter plate and at the same time is the mixing 
position. 
• Position 2 is the vacuum manifold containing the collection plate, in the same 
position will be located the filter plate after mixing. 
• Position 3 contains the precipitant solution, white plasma for the calibration 
curve. 
• Position 4 contains the standard solutions, the QCs and the IS. 
• Position 5 contains the sample plate which was prepared off line by mixing and, 
if occurs, sonication. 
• Position 6 contains different size tips as better shown in Figure 33. 
• Position 7 is the waste position. 
The liquid handling workstation first aspirate an aliquot of precipitation solvent, 
followed by an air gap, and than aspirates plasma from the sample plate. The plasma and 
solvent are forcibly dispensed into wells of the filtration plates, thus avoiding any manual 
intervention. The plate is mixed in the same position and than transferred by co-re gripper 
in vacuum manifold position. Vacuum is applied to collect the filtrate. Proteins remain on 
the top of the filter and are discarded with the plate. The underlying collection microplate 
containing filtrate is removed, dried and reconstituted by the liquid handler for injection. 
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Figure 32: deck layout 
 
Figure 33: deck layout 
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9.2. Experimental 
Then I translated the protocol method in several steps to be performed by the robotic 
workstation. 
I had to choose the best parameters to reach the best performance.  
One of the most important parameters is the way to dispense. At the beginning I used a 
“jet” dispensation but in this way I could not obtain the expected results. So, step by step, 
changing every time all the parameters that gave me the wrong results, I reached the right 
configuration on labware and layout, enabling to perform for (the) first (time) correct 
calibration curves. 
Each method remaining constant in his performance could be different in solvents and 
volumes. 
9.2.1. Instrumentation 
9.2.1.1. Reagents and chemicals 
Analysis is performed with the following reagents and chemicals: 
Acetonitrile:     HPLC grade 
Deionized water:    Milli-Q quality  
Methanol:     HPLC grade 
Dimetil Sulfoxide (DMSO):  Analytical reagent grade 
Diluent Solvent: Methanol/Water : 50/50 
Reconstitution Solvent (RS):  Acetonitrile/Water : 50/50 
9.2.1.2. Equipment 
Analytical balance:    Sartorius Research R200D or equivalent 
Centrifuge:     ALC 4239R 
Vacuum system:    Speed-Vac plus SC210A System, Savant 
Ultrapure waters system:   MilliQ Plus Millipore 
Protein precipitation system:  Waters Sirocco filter plates,  
     Whatman Fast Flow filter plates 
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Hamilton Workstation:   MICROLAB STARLet 
9.2.1.2.1. HPLC/MS System 
Autosampler:     CTC HTS PAL or Gerstel MP3 
HPLC pump:     Agilent HP 1100 binary pump 
Guard column:     Frit 2.1 mm for narrow bore column 
Column:     Waters SunFire, 3,5 µm 50 x 2.1 mm 
Switching valve:    Valco 2 position 
Mass spectrometer: PE-SCIEX API 4000 triple quadrupole 
equipped with a turbo ion spray source (TIS) 
Data system:     Analyst ver. 1.4.1 
9.3. Preliminary tests 
A well programmed test method is first performed with water, then with the final liquid 
classes accurately tested and prepared. 
The software is a Windows based, menu driven interface allowing the user to define 
deck layouts and methods. 
In the method tasks there is the possibility to introduce all the information required 
about positions (by the creation of the deck layout), liquid classes, way of dispensation, 
error detections etc. 
First the goal was to obtain an automated calibration curve. 
The first calibration curves obtained did not reach the linearity required. 
Optimization tests for the right settings were performed on rpm settings, dispensation 
settings, antidroplet activation etc. 
A screen view of a method is presented in Figure 34 
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Figure 34: Hamilton method editor 
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One of the first correlations between manual and automated results is described in Table 
5 and Figure 35. 
Table 5 
Conc, ng/ml Analyte 1 Peak Area
Analyte 1 -
blank Peak 
Area
IS, Peak 
Area Area Ratio
Area Ratio 
Blank  
Subtracted
STD.1 0.2 8173.9 6478.85 218634.2 0.03738619 0.029633287
STD.2 0.5 11301.2 9606.15 157178.7 0.07190033 0.061116105
STD.3 1 19851.7 18156.65 164576.1 0.12062323 0.110323735
STD.4 5 95444.6 93749.55 164415 0.58051029 0.570200712
STD.5 10 160284 158588.95 147294 1.08819097 1.076683029
STD.6 25 432467.6 430772.55 163285.4 2.64853808 2.638157178
STD.7 50 919286.5 917591.45 158967.1 5.78287268 5.772209784
STD.8 100 1823729.8 1822034.75 160665.5 11.3510978 11.3405476
QCL.p1.1 0.75 14376.8 12681.75 162686.9 0.08837098 0.077951882
QCL.p1.2 0.75 13914 12218.95 164018.4 0.08483195 0.074497434
QCL.p2.1 0.75 13499.8 11804.75 169830.8 0.0794897 0.069508888
QCL.p2.2 0.75 13013.8 11318.75 167334.3 0.07777126 0.067641542
QCM.p1.1 7.5 114149 112453.95 160212.9 0.7124832 0.701903218
QCM.p1.2 7.5 108063.5 106368.45 159996.8 0.67541038 0.664816109
QCM.p2.1 7.5 115849.1 114154.05 168143 0.68899151 0.678910511
QCM.p2.2 7.5 113474.1 111779.05 163498.3 0.69403841 0.683671023
QCH.p1.1 75 1035114.8 1033419.75 153332.8 6.75077218 6.739717464
QCH.p1.2 75 1079335.9 1077640.85 162036.1 6.66108293 6.650621991
QCH.p2.1 75 1177580.7 1175885.65 171239.3 6.87681332 6.866914604
QCH.p2.2 75 1060440.1 1058745.05 162998.8 6.50581538 6.495416224
 
 
Rec conc Acc% Rec conc-blank Acc% Rec conc Acc%
Rec conc-
blank Acc%
0.6616906 88.2254133 0.645262 86.03496 0.7405 98.7333333 0.9156337 122.084493 0.913 121.73328
0.6296289 83.95052 0.613686 81.82481333 0.7081509 94.42012 0.8845237 117.936493 0.882631 117.684147
0.5812309 77.4974533 0.568087 75.74497333 0.6593189 87.9091867 0.8375623 111.674973 0.838776 111.836827
0.5656627 75.4216933 0.551018 73.46912 0.6436112 85.8148267 0.8224562 109.660827 0.82236 109.648027
6.315822 84.21096 6.348618 84.64824 6.445326 85.93768 6.401941 85.3592133 6.398231 85.3097467
5.979961 79.7328133 6.009615 80.1282 6.106454 81.4193867 6.07605 81.014 6.072194 80.9625867
6.102999 81.37332 6.138448 81.84597333 6.230595 83.0746 6.195436 82.6058133 6.196099 82.6146533
6.148721 81.9829467 6.181962 82.42616 6.276727 83.6896933 6.239801 83.1973467 6.237949 83.1726533
61.01957 81.3594267 61.5385 82.05133333 61.63954 82.1860533 59.48199 79.30932 59.47738 79.3031733
60.20703 80.27604 60.7241 80.96546667 60.81973 81.0929733 58.69357 78.2580933 58.69413 78.25884
62.16143 82.8819067 62.70118 83.60157333 62.79165 83.7222 60.58997 80.7866267 60.59559 80.79412
58.80039 78.40052 59.30541 79.07388 59.40047 79.2006267 57.32868 76.43824 57.3297 76.4396
Linear Reg w 1/X2 Linear Reg
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Figure 35 
9.4. Validation of the System: method description 
After the optimization of the calibration curve tests, the liquid classes creations, the 
Hamilton StarLet Validation making use of an internal validation protocol was performed.  
A parallel validation of the method using the two different filer plates (Sirocco and 
Whatman) described above was made. 
The aim of the present study is to perform, at the RBM Preclinical Bioanalysis Lab., the 
validation of a LC-MS/MS method, for the quantitation of a new chemical active entity in 
Na-heparinized dog and rat plasma samples. The Full Validation will be performed to 
determine this new chemical active entity in Na-heparinized dog and rat plasma samples. 
Detailed description of LC-MS/MS procedure is described in the Test Method PBTM. 
Spiked plasma samples will be prepared and frozen at –20 ± 5°C before starting each 
validation program, in sufficient aliquots to complete the study. 
Spiked samples (Low, Medium and High SSs) will be prepared in the same way as QC 
samples as described in the test method and used for the following test. 
The validation was conducted by the use of two different kind of filter plates, Sirocco 
and Whatman. 
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9.4.1. Features and Benefits of automation in the method 
validation development 
The manual procedure is very difficult and time consuming; the manipulation of volatile 
solvent is not easy and has safety issues. Good and reproducible mixing of immiscible 
solvents is not easy to achieve. The manipulation of organic solvents, as told before, is 
very difficult to do manually. 
Using a workstation there are challenging aspects to consider. The non conductivity and 
the high volatile characteristics of the organic solvents can be overcome by the 
technological advantages that the workstation offers. A pressure transducer inside the air 
displacement channel measures the pressure inside the barrel during pipetting. 
Another aspect to observe is the dripping that may occur while pipetting organic 
solvents. In this case with the Anti Droplet Control technology pressure differences are 
detected by the pressure sensor and compensated for in real time by piston movements: 
droplet formation is so prevented. 
Other advantages are: 
• Automation friendly procedure improves productivity – no off-line steps 
required. 
• Efficient extraction process maximizes analyte recovery. 
• Only mechanical method development using the same solvent systems as LLE 
allowing direct transfer of methods. 
• Fixed well plate format is compatible with all common liquid handling systems. 
9.4.2. Method validation Key Performance characteristics49  
Validation is defined as “process of providing documented evidence that the method 
does what it is intended to do” it identifies the following parameters as important key 
performance parameter in method validation: accuracy, precision, selectivity, sensitivity, 
reproducibility, and stability. Measurements for each analyte in the biological matrix 
                                                     
 
49 2005 Test and Measurement Conference 
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should be validated. In addition, the stability of the analyte in spiked samples should be 
determined.  
Typical method development and establishment for a bioanalytical method include 
determination of (1) selectivity, (2) accuracy, precision, recovery, (3) calibration curve, 
and (4) stability of analyte in spiked samples. 
 
Selectivity is the ability of an analytical method to differentiate and quantify the analyte 
in the presence of other components in the sample. For selectivity, analyses of blank 
samples of the appropriate biological matrix (plasma, urine, or other matrix) should be 
obtained from at least six sources. Each blank sample should be tested for interference, 
and selectivity should be ensured at the lower limit of quantification (LLOQ). 
Potential interfering substances in a biological matrix include endogenous matrix 
components, metabolites, decomposition products, and in the actual study, concomitant 
medication and other exogenous xenobiotics.  
If the method is intended to quantify more than one analyte, each analyte should be 
tested to ensure that there is no interference. 
The accuracy of an analytical method describes the closeness of mean test results 
obtained by the method to the true value (concentration) of the analyte.  
Accuracy is determined by replicate analysis of samples containing known amounts of 
the analyte. Accuracy should be measured using a minimum of five determinations per 
concentration. A minimum of three concentrations in the range of expected concentrations 
is recommended. The mean value should be within 15% of the actual value except at 
LLOQ, where it should not deviate by more than 20%. The deviation of the mean from the 
true value serves as the measure of accuracy. 
 
The precision of an analytical method describes the closeness of individual measures of 
an analyte when the procedure is applied repeatedly to multiple aliquots of a single 
homogeneous volume of biological matrix. Precision should be measured using a 
minimum of five determinations per concentration. A minimum of three concentrations in 
the range of expected concentrations is recommended.  
The precision determined at each concentration level should not exceed 15% of the 
coefficient of variation (CV) except for the LLOQ, where it should not exceed 20% of the 
CV. Precision is further subdivided into within-run, intra-batch precision or repeatability, 
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which assesses precision during a single analytical run, and between-run, interbatch 
precision or repeatability, which measures precision with time, and may involve different 
analysts, equipment, reagents, and laboratories. 
 
The recovery of an analyte in an assay is the detector response obtained from an amount 
of the analyte added to and extracted from the biological matrix, compared to the detector 
response obtained for the true concentration of the pure authentic standard. Recovery 
pertains to the extraction efficiency of an analytical method within the limits of variability. 
Recovery of the analyte need not be 100%, but the extent of recovery of an analyte and of 
the internal standard should be consistent, precise, and reproducible. Recovery 
experiments should be performed by comparing the analytical results for extracted 
samples at three concentrations (low, medium, and high) with unextracted standards that 
represent 100% recovery. 
 
Calibration/Standard Curve 
A calibration (standard) curve is the relationship between instrument response and 
known concentrations of the analyte. A calibration curve should be generated for each 
analyte in the sample. A sufficient number of standards should be used to adequately 
define the relationship between concentration and response. A calibration curve should 
be prepared in the same biological matrix as the samples in the intended study by 
spiking the matrix with known concentrations of the analyte. The number of standards 
used in constructing a calibration curve will be a function of the anticipated range of 
analytical values and the nature of the analyte/response relationship. Concentrations of 
standards should be chosen on the basis of the concentration range expected in a 
particular study. A calibration curve should consist of a blank sample (matrix sample 
processed without internal standard), a zero sample (matrix sample processed with 
internal standard), and six to eight non-zero samples covering the expected range, 
including LLOQ 
 
1. Lower Limit of Quantification (LLOQ) 
The lowest standard on the calibration curve should be accepted as the limit of 
quantification.  
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• The analyte response at the LLOQ should be at least 5 times the response 
compared to blank response.  
• Analyte peak (response) should be identifiable, discrete, and reproducible with 
a precision of 20% and accuracy of 80-120%. 
2. Calibration Curve/Standard Curve/Concentration-Response 
The simplest regression model that adequately describes the concentration-response 
relationship should be used. Selection of weighting and use of a complex regression 
equation should be justified. The following conditions should be met in developing a 
calibration curve:  
• 20% deviation of the LLOQ from nominal concentration. 
• 15% deviation of standards other than LLOQ from nominal concentration.  
At least four out of six non-zero standards should meet the above criteria, including the 
LLOQ and the calibration standard at the highest concentration. Excluding the standards 
should not change the model used. 
 
Stability 
Drug stability in a biological fluid is a function of the storage conditions, the chemical 
properties of the drug, the matrix, and the container system. The stability of an analyte in a 
particular matrix and container system is relevant only to that matrix and container system 
and should not be extrapolated to other matrices and container systems. Stability 
procedures should evaluate the stability of the analytes during sample collection and 
handling, after long-term (frozen at the intended storage temperature) and short-term 
(bench top, room temperature) storage, and after going through freeze and thaw cycles and 
the analytical process. Conditions used in stability experiments should reflect situations 
likely to be encountered during actual sample handling and analysis. The procedure should 
also include an evaluation of analyte stability in stock solution. 
All stability determinations should use a set of samples prepared from a freshly made 
stock solution of the analyte in the appropriate analyte-free, interference-free biological 
matrix. Stock solutions of the analyte for stability evaluation should be prepared in an 
appropriate solvent at known concentrations. 
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1. Freeze and Thaw Stability 
Analyte stability should be determined after three freeze and thaw cycles. At least three 
aliquots at each of the low and high concentrations should be stored at the intended 
storage temperature for 24 hours and thawed unassisted at room temperature. When 
completely thawed, the samples should be refrozen for 12 to 24 hours under the same 
conditions. The freeze–thaw cycle should be repeated two more times, and then analyzed 
on the third cycle. If an analyte is unstable at the intended storage temperature, the 
stability sample should be frozen at -80°C during the three freeze and thaw cycles. 
 
2. Short-Term Temperature Stability 
Three aliquots of each of the low and high concentrations should be thawed at room 
temperature and kept at this temperature from 4 to 24 hours (based on the expected 
duration that samples will be maintained at room temperature in the intended study) and 
analyzed. 
 
3. Long-Term Stability 
The storage time in a long-term stability evaluation should exceed the time between the 
date of first sample collection and the date of last sample analysis. Long-term stability 
should be determined by storing at least three aliquots of each of the low and high QC 
concentrations under the same conditions as the study samples. The volume of samples 
should be sufficient for analysis on three separate occasions. The concentrations of all the 
stability samples should be compared to the mean of back-calculated values for the 
standards at the appropriate concentrations from the first day of long-term stability testing. 
4. Stock Solution Stability 
The stability of stock solutions of drug and the internal standard should be evaluated at 
room temperature for at least 6 hours. If the stock solutions are refrigerated or frozen for 
the relevant period, the stability should be documented. After completion of the desired 
storage time, the stability should be tested by comparing the instrument response with that 
of freshly prepared solutions. 
 
5. Post-Preparative Stability 
The stability of processed samples, including the resident time in the autosampler, 
should be determined. The stability of the drug and the internal standard should be 
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assessed over the anticipated run time for the batch size in validation samples by 
determining concentrations on the basis of original calibration standards. 
Although the traditional approach of comparing analytical results for stored samples 
with those for freshly prepared samples has been referred to in this guidance, other 
statistical approaches based on confidence limits for evaluation of analyte stability in a 
biological matrix can be used. SOPs should clearly describe the statistical method and 
rules used. Additional validation may include investigation of samples from dosed 
subjects. 
9.4.3. Application of validate method to routine drug analysis 
Assays of all samples of an analyte in a biological matrix should be completed within 
the time period for which stability data are available. In general, biological samples can be 
analyzed with a single determination without duplicate or replicate analysis if the assay 
method has acceptable variability as defined by validation data. This is true for procedures 
where precision and accuracy variabilities routinely fall within acceptable tolerance limits. 
For a difficult procedure with a labile analyte where high precision and accuracy 
specifications may be difficult to achieve, duplicate or even triplicate analyses can be 
performed for a better estimate of analyte. 
A calibration curve should be generated for each analyte to assay samples in each 
analytical run and should be used to calculate the concentration of the analyte in the 
unknown samples in the run. The spiked samples can contain more than one analyte. An 
analytical run can consist of QC samples, calibration standards, and either (1) all the 
processed samples to be analyzed as one batch or (2) a batch composed of processed 
unknown samples of one or more volunteers in a study. The calibration (standard) curve 
should cover the expected unknown sample concentration range in addition to a calibrator 
sample at LLOQ. Estimation of concentration in unknown samples by extrapolation of 
standard curves below LLOQ or above the highest standard is not recommended. Instead, 
the standard curve should be redefined or samples with higher concentration should be 
diluted and reassayed. It is preferable to analyze all study samples from a subject in a 
single run. 
Once the analytical method has been validated for routine use, its accuracy and 
precision should be monitored regularly to ensure that the method continues to perform 
satisfactorily. To achieve this objective, a number of QC samples prepared separately 
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should be analyzed with processed test samples at intervals based on the total number of 
samples. The QC samples in duplicate at three concentrations (one near the LLOQ (i.e., 
LLOQ), one in midrange, and one close to the high end of the range) should be 
incorporated in each assay run. The number of QC samples (in multiples of three) will 
depend on the total number of samples in the run. The results of the QC samples provide 
the basis of accepting or rejecting the run. At least four of every six QC samples should be 
within 15% of their respective nominal value. Two of the six QC samples may be outside 
the 15% of their respective nominal value, but not both at the same concentration. 
The following recommendations should be noted in applying a bioanalytical method to 
routine drug analysis: 
• A matrix-based standard curve should consist of a minimum of six standard 
points, excluding blanks (either single or replicate), covering the entire range. 
• Response Function: Typically, the same curve fitting, weighting, and goodness 
of fit determined during prestudy validation should be used for the standard 
curve within the study. Response function is determined by appropriate 
statistical tests based on the actual standard points during each run in the 
validation. Changes in the response function relationship between prestudy 
validation and routine run validation indicate potential problems. 
• The QC samples should be used to accept or reject the run. These QC samples 
are matrix spiked with analyte. 
• Any required sample dilutions should use like matrix (e.g., human to human) 
obviating the need to incorporate actual within-study dilution matrix QC 
samples. 
• Repeat Analysis: It is important to establish an SOP or guideline for repeat 
analysis and acceptance criteria. This SOP or guideline should explain the 
reasons for repeating sample analysis. Reasons for repeat analyses could include 
repeat analysis of clinical or preclinical samples for regulatory purposes, 
inconsistent replicate analysis, samples outside of the assay range, sample 
processing errors, equipment failure, poor chromatography, and inconsistent 
pharmacokinetic data. Reassays should be done in triplicate if sample volume 
allows. The rationale for the repeat analysis and the reporting of the repeat 
analysis should be clearly documented. 
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• Sample Data Reintegration: An SOP or guideline for sample data reintegration 
should be established. This SOP or guideline should explain the reasons for 
reintegration and how the reintegration is to be performed. The rationale for the 
reintegration should be clearly described and documented. Original and 
reintegration data should be reported. 
9.4.3.1. Acceptance Criteria for the Run 
The following acceptance criteria should be considered for accepting the analytical run: 
• Standards and QC samples can be prepared from the same spiking stock 
solution, provided the solution stability and accuracy have been verified. A 
single source of matrix may also be used, provided selectivity has been verified. 
• Standard curve samples, blanks, QCs, and study samples can be arranged as 
considered appropriate within the run. 
• Placement of standards and QC samples within a run should be designed to 
detect assay drift over the run. 
• Matrix-based standard calibration samples: 75%, or a minimum of six 
standards, when back-calculated (including ULOQ) should fall within ±15%, 
except for LLOQ, when it should be ±20% of the nominal value. Values falling 
outside these limits can be discarded, provided they do not change the 
established model. 
• Quality Control Samples: Quality control samples replicated (at least once) at a 
minimum of three concentrations (one within 3x of the LLOQ (low QC), one in 
the midrange (middle QC), and one approaching the high end of the range (high 
QC)) should be incorporated into each run. The results of the QC samples 
provide the basis of accepting or rejecting the run. At least 67% (four out of six) 
of the QC samples should be within 15% of their respective nominal 
(theoretical) values; 33% of the QC samples (not all replicates at the same 
concentration) can be outside the ±15% of the nominal value. A confidence 
interval approach yielding comparable accuracy and precision is an appropriate 
alternative. The minimum number of samples (in multiples of three) should be 
at least 5% of the number of unknown samples or six total QCs, whichever is 
greater. 
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• Samples involving multiple analytes should not be rejected based on the data 
from one analyte failing the acceptance criteria. 
• The data from rejected runs need not be documented, but the fact that a run was 
rejected and the reason for failure should be recorded. 
9.5. Sample Preparation and Automation 
9.5.1. Validation Results 
The results obtained during the validation of the assay fulfilled all requirements and 
recommendations regarding linearity, accuracy, and precision generally accepted for 
bioanalytical studies. 
A fully automated high-throughput Protein Precipitation Validation of an existing 
analytical method was developed to demonstrate the effectiveness of the Robotic System. 
9.5.1.1. Linearity 
The linearity of the method will be assessed by analyzing calibration samples at various 
concentrations between the lower (LLOQ) and upper limit of quantification (ULOQ). One 
set of calibration standards at 9 different non-zero concentration levels including the 
LLOQ and ULOQ will be analysed in one validation batch. 
Table 6:Linearity 
Slope Mean %Diff
Slope
± 25.0
Run02 0.0144 0.70
Run03 0.0138 0.0143 -3.50
Run04 0.0148 3.50
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Run02 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
1.00 2.50 5.00 10.00 25.00 50.00 100.00 250.00 500
      Back calculated 1.00 2.50 4.90 9.80 24.90 51.50 98.40 255.60 504.60
      Acc% 100.00 100.00 98.00 98.00 99.60 103.00 98.40 102.24 100.92
Run03 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
1.00 2.50 5.00 10.00 25.00 50.00 100.00 250.00 500
      Back calculated 1.00 2.50 4.60 9.80 20.80 48.80 102.70 254.90 527.70
      Acc% 100.00 100.00 92.00 98.00 83.2* 97.60 102.70 101.96 105.54
Run04 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
1.00 2.50 5.00 10.00 25.00 50.00 100.00 250.00 500
      Back calculated 1.00 2.30 4.70 9.90 25.40 49.80 106.70 246.50 512.40
      Acc% 100.00 92.00 94.00 99.00 101.60 99.60 106.70 98.60 102.48
 
9.5.1.2. Accuracy and Precision 
The concentration of low QC is 3.00ng/ml, near the lower limit of quantitation but no 
more than 3 times the LLOQ concentration; the medium QC concentration is 40.00ng/ml 
about in the middle of the calibration range it has to be near the geometric mean of the low 
and high QC concentrations; the high QC is 200.00ng/ml and is the upper end of the 
calibration curve, within the upper quartile of the calibration range. 
The analyses will be performed in 3 validation runs (on 3 different days) in order to 
assess the overall accuracy and precision. 
From the results is possible to notice that the mean intra-batch as well as the overall 
accuracy is within 85-115% at QC levels higher than LLOQ. 
The intra-batch and overall precision, expressed as CV%, do not exceed 15% at QC 
levels higher than LLOQ, as suggests from the guidance results validation lines. 
In both Table 7 and Table 8 are shown the results of intra and inter- run accuracy and 
precision.  
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Table 7: Intra run accuracy and precision 
Run02 True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml ng/ml each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 2.8 -6.67 93.33
3.00 2.8 -6.67 -8.89 93.33 4.23
2.6 -13.33 86.67
SS-Medium 41.2 3.00 103.00
40.00 38.4 -4.00 -4.33 96.00 7.85 -7.52 5.45
35.2 -12.00 88.00
SS-High 182.1 -8.95 91.05
200.00 175.5 -12.25 -9.35 87.75 3.00
186.3 -6.85 93.15
Run03 True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml ng/mL each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 3.2 6.67 106.67
3.00 2.7 -10.00 -1.67 90.00 11.99
N.A.
SS-Medium 39.50 -1.25 98.75
40.00 43.10 7.75 4.33 107.75 4.68 -0.39 9.21
42.60 6.50 106.50
SS-High 207 3.50 103.50
200.00 203.5 1.75 -4.27 101.75 12.50
163.9 -18.05 81.95
Run04 True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml ng/mL each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 2.80 -6.67 93.33
3.00 2.70 -10.00 -5.56 90.00 5.39
3.00 0.00 100.00
SS-Medium 36.00 -10.00 90.00
40.00 35.90 -10.25 -12.08 89.75 3.86 -11.36 7.34
33.60 -16.00 84.00
SS-High 159.00 -20.50 79.50
200.00 182.00 -9.00 -16.45 91.00 7.73
160.30 -19.85 80.15
 
Mean ACC% SD ACC% Mean ACC% SD ACC%
80.0%-120.0% each day each day
91.11 3.85
95.67 7.51 92.48 5.04
90.65 2.72
Mean ACC% SD ACC% Mean ACC% SD ACC%
each day each day
98.34 11.79
104.33 4.88 99.61 9.17
95.73 11.97
Mean ACC% SD ACC% Mean ACC% SD ACC%
each day each day
94.44 5.09
87.92 3.39 88.64 6.51
83.55 6.46
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Table 8: Inter run Accuracy and Precision 
Overall Overall  Overall SD ACC%
Mean Bias%  CV% ACC% Mean ACC%
≤ 10.0 ≤15.0
-7.08 8.68 93.58 8.12
 
9.5.1.3. Selectivity 
Selectivity of the method towards possible impurities or degradation products of the IS 
and of the analyte was so established by analyzing blank samples spiked with the 
molecules of interest, the good results obtained are shown in Table 9 
Table 9: Selectivity 
Run 01 Replicate Peak Matrix Peak LLOQ SELECT%
Area Area ≤20.0%
1.00 794.20 4771.80 16.64
2.00 843.10 5444.10 15.49
3.00 0.00 4176.80 0.00
4.00 596.30 5202.80 11.46
5.00 0.00 4375.40 0.00
6.00 0.00 4269.50 0.00
 
9.5.1.4. Carryover 
Table 10 
Run1 Peak Area Std 1 DBK after ULOQ Criteria: 270850.20
 ≤50.0% 300629.40
6503.70 1921.00 29.54 280800.60
280304.00
270467.10
276414.10
280515.90
Run1 Average Area IS DBK after ULOQ Criteria: 300312.70
 ≤20.0% 244440.40
278303.82 1888.10 0.68 Mean IS 278303.82
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9.5.1.5. Dilution Test 
Table 11 
Run03 True Conc. Estimated Conc. BIAS% Mean BIAS% CV% ACC% ACC% Mean ACC% S.D
ng/ml (ng/ml) ≤20.0% ≤15.0% 80.0%-120.0%
250.0 268.3 7.3 107.3
267.1 6.8 106.8
274.3 9.7 265.9 1.9 109.7 106.3 2.06
261.8 4.7 104.7
263.3 5.3 105.3
260.3 4.1 104.1
 
9.5.1.6. Autosampler Stability 
Table 12 
Run02 True Conc. Estimated Conc. Estimated Conc. STAB % Mean STAB%
(ng/ml)  t = 0 h  t = 24 h ≥ 80.0 - ≤ 120.0
ng/ml ng/ml
SS-Low 3.80 3.60 94.74
3.00 3.10 3.20 103.23 100.40
3.10 3.20 103.23
SS-High 404.40 416.80 103.07
400.00 409.90 434.00 105.88 104.13
405.30 419.30 103.45
 
9.5.1.7. Short Term Stability 
Table 13 
Run02 True Conc. Estimated Conc. Mean Estimated Conc. Mean STAB %
(ng/ml)  t = 0 h  t = 4 h ≥ 80.0 - ≤ 120.0
ng/ml ng/ml
SS-Low 3.80 3.60
3.00 3.10 3.33 3.80 3.53 106.01
3.10 3.20
SS-High 404.40 425.30
400.00 409.90 406.53 486.20 463.57 114.03
405.30 479.20
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9.5.1.8. Freeze&thaw stability 
Table 14 
Run02 True Conc. Estimated Conc. Mean Estimated Conc. Mean CYCLES %
(ng/ml)  t = 0 h 3 Cycles ≥ 80.0 - ≤ 120.0
ng/ml ng/ml
SS-Low 3.80 3.60
3.00 3.10 3.33 3.30 3.43 103.00
3.10 3.40
SS-High 404.40 413.00
400.00 409.90 406.53 446.70 437.67 107.66
405.30 453.30
 
 
9.5.1.9. Long Term Stability 
Table 15 
Run02 True Conc. Estimated Conc. Mean
(ng/ml) t = 0 h
(ng/ml)
SS-Low 3.80
3.0 3.10 3.33
3.10
SS-High 404.40
400.0 409.90 406.5
405.30
Run05 Estimated Conc. Mean STAB %
1 month ≥ 80.0 - ≤ 120.0
(ng/ml)
3.50
3.40 3.30 99.10
3.00
333.50
394.00 380.30 93.55
413.40
 
 
All the results were in accordance with the range required and all the tests passed. Even 
if the results in Run terms were in behalf of Whatman plates I decided to present and 
consider Sirocco’s results. For the future experiments of pharmacokinetic and 
toxicokinetic I’ll use Sirocco filter plates because in term of recovery demonstrated a 
better performance. 
  
101 
Even if  linearity of the calibration curve (over a concentration range of 1-250 ng/ml), as 
measured by r2, was comparable for both plates and precision of calibration curve 
parameters, filtration results, mixing results, inter-day precision etc were comparable for 
both the PPT filter plate, the relative recovery of analyte and Internal Standard using 
Whatman plates was lower of 16%.  
 
After having optimized and validate the system, I begun to perform the real samples’ 
extraction comparing them with manual extraction in real time.  
 
9.5.1.10. Real samples automated vs. manual extraction 
Table 16 
subj A 1 2 1 2 CV% CV% 1 2 3 4
manual manual robot robot manual robot ACC% ACC% ACC% ACC%
day 85 4h 111.30 109.50 109.90 107.00 1.15 1.89 98.74 100.37 96.14 97.72
day 85 6h 54.20 50.30 92.80
day 85 24h 1.00 1.10 0.80 0.90 6.73 8.32 80.00 72.73 90.00 81.82
day 89 4h 91.30 84.90 88.80 86.10 5.14 2.18 97.26 104.59 94.30 101.41
day 89 6h 59.70 56.30 55.50 1.01 94.30 92.96
day 89 24h 1.40 1.50 1.20 1.20 4.88 0.00 85.71 80.00 85.71 80.00
CV% CV% ACC% 1 ACC% 2 ACC% 3 ACC% 4 ACC%
mean mean mean mean mean mean total mean
4.48 2.68 91.47 89.42 91.82 90.24 90.74
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Table 17 
subj B 1 1 2 CV% 1 2
manual robot robot robot ACC% ACC%
day 1 4h 198.900 198.700 198.100 0.214 100.101 100.404
day 1 6h 89.400 85.300 85.400 0.083 104.807 104.684
day 1 24h 2.100 2.000 2.100 3.449 105.000 100.000
day 5 4h 212.200 205.600 206.200 0.206 103.210 102.910
day 5 6h 116.600 114.000 113.200 0.498 102.281 103.004
day 5 24h 7.400 8.200 8.200 0.000 90.244 90.244
day 50 4h 138.000 138.900 133.100 3.016 99.352 103.681
day 50 6h 56.700 56.700 59.600 3.526 100.000 95.134
day 50 24h 1.900 2.200 2.200 0.000 86.364 86.364
day 54 4h 76.400 76.400 78.500 1.917 100.000 97.325
day 54 6h 39.300 38.500 38.900 0.731 102.078 101.028
day 54 24h 1.000 1.200 1.100 6.149 83.333 90.909
 CV%  ACC%1  ACC%2  ACC%1 ACC%2
mean mean mean total mean
1.649 98.064 97.974 98.019
 
In Table 16 and Table 17 are presented the results obtained by a parallel extraction 
manual vs. automated of real plasma samples. The level of accuracy and CV% reached is 
high. 
9.5.1.11. Dilutions using Dynamic Dilution Module 
Table 18 
C 1 1 2 1 2
1 to 5 manual robot robot CV% ACC% ACC%
subj 72 5.300 5.100 5.300 2.720 96.226 100.000
subj 73 294.600 255.600 249.000 1.850 86.762 84.521
subj 74 1859.700 1719.200 1744.700 1.041 92.445 93.816
subj 75 229.7 221.100 224.300 1.016 96.256 97.649
CV% ACC% 1 ACC% 2 ACC% 
mean mean mean total mean
1.657 92.922 93.997 93.459
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Table 19 
D 1 1 2 1 2
1 to 10 manual robot robot CV% ACC% ACC%
subj 48 177.000 185.200 179.600 2.171 104.633 101.469
subj 49 223.300 220.200 243.600 7.135 98.612 109.091
subj 50 172.500 181.800 181.000 0.312 105.391 104.928
subj 51 156.200 145.800 147.300 0.724 93.342 94.302
CV% ACC% 1 ACC% 2 ACC% 
mean mean mean total mean
2.585 100.494 102.447 101.471
 
Table 20 
E 1 1 2 3 1 2 3
1 to 10 manual robot robot robot CV% ACC% ACC% ACC%
day 1 30min 474.000 428.000 414.000 434.000 2.413 90.295 87.342 91.561
day 5 30min 187.000 198.900 195.700 206.700 2.823 106.364 104.652 110.535
day 50 30min 746.000 840.800 835.800 823.700 1.055 112.708 112.038 110.416
day 54 30min 200.300 216.000 216.000 206.900 2.467 107.838 107.838 103.295
CV% ACC% 1 ACC% 2 ACC% 
mean mean mean total mean
2.189 104.301 102.967 103.952 103.740
 
Using DDM it is possible to interface directly the software to a macro containing the 
dilution factors indicated in the LIMS. The results obtained, described in Table 18, Table 
19 and Table 20, for both 1:5 and 1:10 dilution factor has accuracy high level. 
9.6. Conclusions 
Through use the Hamilton MicroLab Star liquid handling workstation, protein 
precipitation sample preparation has been successfully automated and implemented for 
several biological matrix samples. This in turn has greatly reduced the intensive labor as 
well as the possibilities of systematic error associated with the manual volumetric 
transfers. Significant advantages in terms of efficiency and throughput have now been 
realized by this automated process while maintaining the integrity of the precision and 
accuracy. 
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•Samples
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Figure 36 
Processing time is less than 30 s per sample or 25 min per 96-well plate (Figure 36), 
which is then immediately ready for injection onto an LC-MS/MS system or dried and 
reconstituted.. 
Over 12 studies and 5000 samples have been prepared in the Automation Laboratory 
since implementation in the first six months. The original goal to automate the sample 
workload using this approach was met.  
Table 21 
Project Study Quality Run Number of Samples
P964/P1074 QMS Validation Run 1 2 3  Whatman Run 1 2 3 4 5 Sirocco 274
P1016 RE5900 GLP Extraction Run on Parallel 231
P1016 RE6620 GLP Extraction Run on Parallel 58
P1417 RE5820 GLP Run 1 2 3 Reassay + QC Pool Preparation 1165
P1417 RE9030 WS QC IS Preparation
P1417 RE9680 QMS Run 1 2 6 482
P1417 RE9840 QMS Run 1 2 673
P1417 RF0150 GLP Run 1 2 3 4 5 + Incurred Samples 1032
0326-2008 GLP Run 1 2 3 4 7 1068
P1443 RE7730 GLP Extraction Run on Parallel 40
P1443 RE7930 GCLP Run 30 31 48
P1443 RE7930 Extraction Run on Parallel 54
P1443 RE8500 GLP Run 1 2 3 4 445
P1443 RE8510 QC Pool Preparation
P1443 RE8550 QMS Validation 40
P1492 WS QC IS Preparation
Tot 5610
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Furthermore, the open configurability of both the Hamilton hardware and software 
allows for the continual refinement, enhancements, or additions to our program, which in 
turn enables us to keep pace with the ever-changing landscape and external demands that 
drive and shape our future. 
  
106 
These findings were presented in poster sessions at the following meetings: 
“R&D Science Day”, Thursday, September 30th 2010 NCD Day, Merck Serono 
Headquarters. 9, Chemin des Mines CH-1202 Geneva. 
 
“Automation in Regulated Bioanalytics: High-throughput via Robotic Liquid 
Handling” 
Maria Chiara Zorzoli2, Luca Barbero2, Luigi Colombo1 
1 Global Bioanalytics, 2 Automation Laboratory. 
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10. Liquid-Liquid Extraction (LLE) 
10.1. Introduction 
Liquid-Liquid Extraction, also known as solvent extraction and partitioning, is a method 
to separate compounds based on their relative solubility in two different immiscible 
liquids, usually water and an organic solvent. It is an extraction of a substance from one 
liquid phase into another liquid phase. LLE can be labor-intensive and difficult to 
automate since it often requires off-line processing such as mixing or centrifuging.  
High-throughput LLE is performed when a collection microplate is used in place of 
multiple test tubes. An alternative approach to LLE is the use of solid support 
diatomaceous earth particles contained in tubes or cartridges. 
Due to advances in manufacturing, supported liquid extraction can now be done in high 
throughput 96-well plates compatible with most automated systems, requiring no off-line 
steps. 
10.1.1. Fundamental Principles 
LLE is a technique used to separate analytes from interferences in the sample matrix by 
partitioning the analytes between two immiscible liquids. 
A given volume of aqueous sample solution, as plasma or urine, containing analytes is 
mixed with an internal standard in solution. When necessary a volume of buffer at a 
known pH is then added to maintain the analytes in their unionized state. 
The resulting solution is then vigorously mixed with several ratio volumes of water 
immiscible organic solvent or mixture of two or more solvents such as hexane, diethyl 
ether, methyl tert-butyl ether (MTBE) or ethyl acetate (EA). 
Analytes distribute between the two liquid phases (aqueous and organic) and partition 
preferentially into the organic phase when the analytes are unionized and demonstrate 
solubility in that organic solvent. 
Agitation increases the available surface area for this interaction to occur and aids in the 
mass transfer process. 
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When LLE procedure is optimized, the hydrophilic compounds in the sample matrix 
will prefer to remain in the aqueous phase and the more hydrophobic compounds (ideally 
analytes to the exclusion of interfering substances) will migrate into the organic phase, 
description in Figure 37. 
Aqueous
phase
Organic
phase
Organic
phase
Aqueous
phase
mix
 
Figure 37 
The organic phase is isolate and, since it is typically not compatible with solvents used 
in liquid chromatography (LC), is concentrated by evaporation. Reconstitution in a mobile 
phase compatible solvent is then performer prior to analysis. 
10.1.1.1. Advantages 
A major benefit is that LLE is of wide general applicability for many drug compounds 
and this technique presents many advantages: 
Very clean extracts can be obtained with good selectivity for the target analyte 
using proper selection of organic solvent and adjustment of sample pH. 
Inorganic salts are insoluble in the solvents commonly used for LLE and remain 
behind in the aqueous phase along with proteins and water soluble endogenous 
components. 
Interferences are excluded are excluded from the chromatographic system and a 
cleaner sample and a cleaner sample is prepared for analysis. 
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The removal of these unwanted matrix materials provides potential benefits of 
extending LC column lifetime and minimizing the downtime of the mass 
spectrometer caused by interface fouling. 
10.1.1.2. Disadvantages 
Several disadvantages exist with the Liquid-Liquid Extraction: 
• It is a very labour intensive procedure because of multiple transfer steps and the 
need to frequently cap and uncap tubes. 
• It requires a large volume of organic solvents which can be expensive to 
purchase and presents added costs for disposal as hazardous waste. 
• Exposure of these solvents to personnel can present health hazards. 
• The procedure has been difficult to fully automate using traditional liquid 
handling instruments. 
• Evaporative losses may sometimes occur upon dry-down with volatile or 
oxygen labile reactive analyte. 
• Emulsion formation is a potential problem. 
10.2. Experimental 
A small molecule currently under clinical development for multiple sclerosis (MS) was 
used to develop a fully automated extraction method. 
The nucleoside analog 2-chlorodeoxyadenosine (Cladribine, CdA) is used in the 
treatment of patients with several hematological malignancies. After administration of 
CdA, the major catabolite measured in plasma and urine is 2-chloroadenine (CAde)50. 
Oral Cladribine is a proprietary oral tablet formulation of Cladribine that is being 
studied in an effort to demonstrate possible benefits as a treatment for patients with 
relapsing forms of MS. Cladribine is a purine nucleoside analogue that interferes with the 
behavior and the proliferation of certain white blood cells, particularly lymphocytes, 
                                                     
 
50 Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia Synno¨ve 
Lindemalm, Jan Liliemark, Gunnar Juliusson, Rolf Larssonc,Freidoun Albertioni, 8 March 2004 Cancer Letters 210 (2004) 
171–177. 
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which are involved in the pathological process of MS. Through its differentiated 
mechanism of action, Cladribine tablets may offer an effective new option to patients with 
MS. 
The aim of this part of the project was to find the correct way to automate a validation 
method for the LLE of the molecule. 
The use of a different extraction solvent from the more common end more manually 
manageable MTBE required the automation of the procedure. 
The solvent used was ethyl acetate. 
The advantage of MTBE in LLE is that it allows faster and cleaner recovery and is well 
suited for manual extraction because the aqueous solution free from the molecule of 
interest frozen in liquid nitrogen and it is easy to tip out from the tube in a new vial or in a 
96 well plate the solvent containing the molecule. In this case the best solvent to perform 
the extraction was ethyl acetate. It presents different chemical physical characteristics and 
it is impossible to separate the phases by freezing only one of them. 
The best mechanical way was evaluated in order to create the best full automated 
method. 
Hamilton offers both the traditional capacitive liquid level detection as well as pressure 
liquid level detection. By the use of organic solvents the capacitive level detection is not 
possible. Using the pressure liquid level detection it is permitted to drive the pipette tip to 
just above the surface to do a jet dispense, or touch the surface for a wet dispense, or dive 
below sufficiently to aspirate liquid without drawing in any air. 
The developed method was created for a pre study method validation. During pre-study 
validation, method precision and accuracy are determined through the analysis of QCs 
(validation samples) prepared in a biological matrix equivalent to that anticipated for study 
samples. Because of the endogenous nature of some biopharmaceuticals, it may be 
necessary to deplete the matrix of the analyte or employ a “surrogate” matrix to evaluate 
method accuracy and precision and molecule stability. 
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10.2.1. Instrumentation 
10.2.1.1. Reagents and chemicals 
The LLE extracts of the biological samples were analyzed by high-performance liquid 
chromatography with APCI (Atmospheric Pressure Chemical Ionization/Heated 
Nebulizer)) tandem mass spectrometry (LC-MS/MS). 
Analysis is performed with the following reagents and chemicals: 
Ammonia solution 2.5%:   Analytical reagent grade  
Deionized water:    Milli-Q quality  
Methanol:     HPLC grade  
Formic Acid 98%:    Analytical reagent grade  
Ethyl Acetate:     HPLC grade  
Dimetil Sulfoxide (DMSO):  Analytical reagent grade  
Dilution solvent:    Water/Methanol 95/5 with 0.1% Formic Acid  
Reconstitution Solvent (RS):  Water/Methanol 95/5 with 0.1% Formic Acid. 
10.2.1.2. Equipment 
Analytical balance:    Sartorius Research R200D. 
Centrifuge:     ALC 4239R. 
Vacuum system:    Speed-Vac plus SC210A System, Savant. 
Ultrapure waters system:   MilliQ Plus Millipore. 
Hamilton Workstation:   MICROLAB STARLet. 
10.2.1.2.1. UPLC/MS System (Figure 38) 
Autosampler:   Waters Acquity UPLC Sample Organizer/Sample 
Manager 
UPLC pump:    Waters Acquity UPLC Binary Solvent Manager 
Column:    Waters Acquity UPLC BEH C18 1.7µm 2,1x50 mm 
Mass spectrometer:   Applied Biosystems API4000 triple quadrupole e 
    quipped with APCI (Heated Nebulizer)  
Data system:    Analyst version. 1.4.2. 
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Figure 38: Ultra Performance Liquid Chromatography. 
Ultra Performance Liquid Chromatography (UPLC, Figure 38) is a relatively new 
technique giving new possibilities in liquid chromatography, especially concerning 
decrease of time and solvent consumption. UPLC advantages are clearly obvious. The 
separation mechanisms is still the same, chromatographic principles are maintained while 
speed, sensitivity and resolution is improved. 
10.2.2. Sample Preparation and Automation 
Automated LLE was carried out on the 8-channel Hamilton Robotic Workstation using 
EA as the extraction solvent. Each individual channel for every different kind of tips was 
calibrated during the creation of the relative liquid class for accuracy and precision. EA is 
a volatile organic solvent difficult to handle. 
The standard manual method indications suggest to thaw and centrifuge samples for 1 
min at 10000 rpm if necessary, than to transfer a small volume of each sample in a tube. 
Than is add a very small volume of working solution of internal standard and the 
solvent of choice to plasma. 
These operations have always been conducted manually in small tubes requiring a very 
labour and time consuming work. 
Method: 
• Thaw samples and centrifuge for 1 min at 10000 RPM; 
• Transfer 100µl into an Eppendorf tube (1.5 ml); 
• Add working solution of internal standards and 0.5 ml ethylacetate to plasma; 
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• Close tubes, vortex thoroughly, centrifuge (5 min/10000 RPM) and put samples 
into -80°C freezer for app. 15 min; 
• Transfer organic phase into a 96 deep well plate; 
• Evaporate to dryness under a stream of nitrogen at 50°C; 
• Add 100µl of methanol 10% in water; 
• Close 96 deep well plate and shake well (5 min at 1000 RPM); 
• Centrifuge 96 deep well plate for 2 min; 
• Put 96 deep well plate in autosampler and inject 25µl of each sample. 
In the automated extraction all the operations are conducted in 96-wellplates, not only 
the final transfer but also the extraction procedure. During the vortex robotic step care 
must be exercised to prevent potential contamination across the wells, the plate is cover 
with a dimpled sealing mat. 
Automated procedure: 
• Plasma samples aliquot are added with IS with 8 channel-Head; 
• Samples are vortex mixed to equilibrate IS with plasma; 
• EA is added with 8 channel-Head; 
• To avoid vortex mixing and increase the surface/volume ratio, an 
aspirate/dispense cycle is repeated about 15 times (Figure 39); 
• Plates can be centrifuged; 
• Organic layer is transferred using 8 channel-Head; 
• Aspiration height is 3mm above the plasma layer surface. 
Figure 39: An aspirate/dispense cycle. 
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Since during the extraction about 10% less out of the total of EA was transferred the 
extraction recovery could be therefore corrected for the volume change. 
10.2.3. Results 
A fully automated high throughput Liquid Liquid Extraction has been developed for 
preparation of biological samples for method validation using a 96-well plate and an 8-
channel robotic liquid handling workstation. 
The results obtained during the validation of the assay fulfilled all requirements and 
recommendations regarding linearity, accuracy and precision generally accepted for 
bioanalytical studies. 
The major time saving of using automation is at the sample aliquoting and extraction 
step. All the samples are vortex at the same time, manually instead each sample is 
singularly vortexed. To prevent the tip clogging a sample centrifugation step is needed for 
the automated sample aliquoting. The time saved of manual and automated process is 
described in Table 22. 
Table 22: manual and automated time comparison 
Manual Automated
Tube labeing 20 min None
Centrifugation None 20 min
Sample aliquoting 75 min 30 min
Extraction 100 min 20 min
Evaporation 15 min 15 min
Reconstitution and transfer 30 min 10 min
Total time 4 h 1 h 35 min 
Analyst time 3 h 45 min 50 min
The time with bold line indicates the presence of analyst is required.
 
10.2.3.1. Linearity 
The linearity of the method for Cladribine and 2-chloroadenine will be assessed by 
analyzing calibration samples at various concentrations between the lower (LLOQ) and 
upper limit of quantification (ULOQ). One set of calibration standards at 9 different non-
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zero concentration levels including the LLOQ and ULOQ will be analysed in one 
validation batch.  
The calibration curve for linearity assessment was established using 1/x2 weighted linear 
regression. 
Acceptance criteria: 
For calibration standards, the deviation of the back-calculated values from the nominal 
concentration must be within ±15% for all concentrations higher than the LLOQ and 
within ±20% at the LLOQ to be included in the regression line. 
75 % of the calibration standards will have to fulfill the above-mentioned acceptance 
criteria. At least 6 calibration levels have to remain in the calibration line. 
The correlation coefficient (r) for the calibration line must be ≥ 0.990. 
 
Table 23: Linearity urine, Linearity plasma dog 
Cladribine in urine 
 
2-chloroadenine in urine 
Run 01 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.50 1.00 2.50 5.00 10.00 25.00 50.00 100.00
      Back calculated 0.26 0.45 1.01 2.52 4.96 10.080 26.06 49.79 99.34
      Acc% 104.00 90.00 101.00 100.80 99.20 100.80 104.24 99.58 99.34
Run 03 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.50 1.00 2.50 5.00 10.00 25.00 50.00 100.00
      Back calculated 0.24 0.52 1.05 2.40 5.29 9.98 23.88 48.76 99.43
      Acc% 96.00 104.00 105.00 96.00 105.80 99.80 95.52 97.52 99.43
Run 04 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.50 1.00 2.50 5.00 10.00 25.00 50.00 100.00
      Back calculated 0.25 0.52 0.99 2.49 5.01 10.17 24.53 50.33 99.00
      Acc% 100.00 104.00 99.00 99.60 100.20 101.70 98.12 100.66 99.00
Slope Mean %Diff Slope (*)
≤ 25.0
Run 01 0.0563 8.157
Run 03 0.0584 0.0613 4.731
Run 04 0.0691 12.724
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Cladribine in plasma dog 
 
 
Slope Mean %Diff Slope (*)
≤ 25.0
Run 01 0.0408 1.449
Run 03 0.0439 0.0414 6.039
Run 04 0.0395 4.589
Run 01 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.25 0.5 0.98 2.27 5.12 10.3 26.65 50.69 97.06
      Acc% 100.00 100.00 98.00 90.80 102.40 103.00 106.60 101.38 97.06
Run 03 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.27 0.44 0.97 2.42 5.15 10.42 25.37 50.75 101.33
      Acc% 108.00 88.00 97.00 96.80 103.00 104.20 101.48 101.50 101.33
Run 04 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.28 0.43 0.86 2.43 5.14 10.42 25.17 53.86 104.91
      Acc% 112.00 86.00 86.00 97.20 102.80 104.20 100.68 107.72 104.91
Slope Mean %Diff Slope (*)
≤ 25.0
Run 07 0.0681 0.344
Run 08 0.0679 0.06787 0.049
Run 09 0.0676 0.393
Run 07 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.25 0.49 1.21 2.57 5.14 9.63 24.35 50.48 101.38
      Acc% 100.00 98.00 N.R. 102.80 102.80 96.30 97.40 100.96 101.38
N.R. = the std 3 not met the acceptance criteria
Run 08 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.25 0.38 1.13 2.27 4.45 10.45 24.02 47.81 113.06
      Acc% 100.00 N.R. 113.00 90.80 89.00 104.50 96.08 95.62 113.06
N.R. = the std 2 not met the acceptance criteria
Run 09 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.25 0.48 1.13 2.38 4.97 9.6 24.86 43.49 114.42
      Acc% 100.00 96.00 113.00 95.20 99.40 96.00 99.44 86.98 114.42
  
117 
2-chloroadenine in plasma dog 
 
10.2.3.2. Accuracy and Precision 
Intrabatch accuracy and precision of Cladribine and 2-chloroadenine in dog urine and 
plasma samples higher than LLOQ level will be determined by measuring 3 sets of quality 
control samples at three concentration levels (low, medium and high) representing the 
entire range of calibration curve, per validation run (intrabatch accuracy and precision). 
The concentration of low QC is 0.75ng/ml, near the lower limit of quantitation but no 
more than 3 times the LLOQ concentration; the medium QC concentration is 3ng/ml about 
in the middle of the calibration range it has to be near the geometric mean of the low and 
high QC concentrations; the high QC is 80ng/ml and is the upper end of the calibration 
curve, within the upper quartile of the calibration range. 
The analyses will be performed in 3 validation runs (on 3 different days) in order to 
assess the overall accuracy and precision. 
Any additional validation batches should contain at least duplicate QC samples 
(depending on batch size) at each of four concentrations higher than LLOQ. Intrabatch 
statistics will be calculated for these QC samples and they will be included in the overall 
statistics. 
 
Slope Mean %Diff Slope (*)
≤ 25.0
Run 07 0.124 4.202
Run 08 0.118 0.119 0.840
Run 09 0.115 3.361
Run 07 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.24 0.54 1.04 2.55 5.06 9.80 25.22 49.06 92.82
      Acc% 96.00 108.00 104.00 102.00 101.20 98.00 100.88 98.12 92.82
Run 08 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.25 0.36 1.02 2.35 5.12 10.28 24.26 49.45 102.81
      Acc% 100.00 N.R. 102.00 94.00 102.40 102.80 97.04 98.90 102.81
N.R. = the std 2 not met the acceptance criteria
Run 09 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
0.25 0.5 1 2.5 5 10 25 50 100
      Back calculated 0.26 0.45 1.05 2.39 4.98 10.01 25.84 46.89 107.84
      Acc% 104.00 90.00 105.00 95.60 99.60 100.10 103.36 93.78 107.84
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From the results (see Table 24) is possible to notice that the mean intra-batch as well as 
the overall accuracy is within 85-115% at QC levels higher than LLOQ. 
The intra-batch and overall precision, expressed as CV%, do not exceed 15% at QC 
levels higher than LLOQ, as suggests from the guidance results validation lines. 
For additional validation batches containing duplicate or triplicate QC samples, there 
are the following acceptance criteria to apply: at least 2/3 of the quality control samples 
must be within 85-115% of the nominal concentrations including at least 50% of the 
analyzed samples at each concentration level. 
 
Table 24: Intra run Accuracy and Precision 
Cladribine in urine 
Run 01 True Conc. Estimated Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml Conc. each level ≤15.0% each day each day
ng/ml ≤20.0 ≤15.0 ≤15.0
SS-Low 0.62 -17.3 82.7
0.75 0.70 -6.7 14.2 93.3 7.6
0.61 -18.7 81.3
SS-Medium 2.88 -4.0 96.0
3.00 2.72 -9.3 7.3 90.7 3.1 10.5 5.5
2.74 -8.7 91.3
SS-High 74.55 -6.8 93.2
80.00 70.22 -12.2 9.9 87.8 3.1
71.36 -10.8 89.2
Run 03 True Conc. Estimated Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml Conc. each level ≤15.0% each day each day
ng/ml ≤20.0 ≤15.0 ≤15.0
SS-Low 0.72 -4.0 96.0
0.75 0.74 -1.3 4.0 98.7 2.8
0.70 -6.7 93.3
SS-Medium 2.87 -4.3 95.7
3.00 2.88 -4.0 3.7 96.0 0.9 4.3 1.9
2.92 -2.7 97.3
SS-High 76.96 -3.8 96.2
80.00 74.25 -7.2 5.4 92.8
75.91 -5.1 94.9 1.8
Run 04 True Conc. Estimated Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml Conc. each level ≤15.0% each day each day
ng/ml ≤20.0 ≤15.0 ≤15.0
SS-Low 0.80 6.7 106.7
0.75 0.75 0.0 0.5 100.0 6.0
0.71 -5.3 94.7
SS-Medium 2.93 -2.3 97.7
3.00 2.90 -3.3 5.0 96.7 4.0 4.2 5.4
2.72 -9.3 90.7
SS-High 72.25 -9.7 90.3
80.00 75.01 -6.2 8.0 93.8 1.9
73.58 -8.0 92.0
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Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
85.80 6.56
92.67 2.90 89.51 4.89
90.07
2.80
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
96.00 2.70
96.33 0.85 95.65 1.83
94.63 1.72
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
100.5 6.01
95.0 3.79 95.8 5.21
92.0 1.75
 
Cladribine in plasma 
Run 07 True Conc. Estimated Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml Conc. each level ≤15.0% each day each day
ng/ml ≤20.0 ≤15.0 ≤15.0
SS-Low 0.82 9.3 109.3
0.75 0.84 12.0 10.2 112.0 1.4
0.82 9.3 109.3
SS-Medium 2.72 -9.3 90.7
3.00 2.75 -8.3 6.4 91.7 4.4 2.4 7.5
2.95 -1.7 98.3
SS-High 82.04 2.6 102.6
80.00 84.54 5.7 3.4 105.7 2.0
81.40 1.8 101.8
Run 08 True Conc. Estimated Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml Conc. each level ≤15.0% each day each day
ng/ml ≤20.0 ≤15.0 ≤15.0
SS-Low 0.70 -6.7 93.3
0.75 0.83 10.7 2.7 110.7 12.2
0.66 -12.0 88.0
SS-Medium 3.01 0.3 100.3
3.00 3.08 2.7 0.4 102.7 2.2 1.4 7.3
2.95 -1.7 98.3
SS-High 86.16 7.7 107.7
80.00 87.14 8.9 6.3 108.9 3.3
81.94 2.4 102.4
Run 09 True Conc. Estimated Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml Conc. each level ≤15.0% each day each day
ng/ml ≤20.0 ≤15.0 ≤15.0
SS-Low 0.80 6.7 106.7
0.75 0.78 4.0 4.5 104.0 2.0
0.77 2.7 102.7
SS-Medium 3.04 1.3 101.3
3.00 2.93 -2.3 0.1 97.7 1.9 3.7 3.6
3.02 0.7 100.7
SS-High 88.22 10.3 110.3
80.00 84.44 5.6 6.9 105.6 2.8
83.78 4.7 104.7
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Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
110.2 1.56
93.6 4.13 102.4 7.64
103.4 2.06
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
97.3 11.88
100.4 2.20 101.3 7.43
106.3 3.46
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
104.5 2.04
99.9 1.93 103.8 3.69
106.9 3.01
 
2 ChloroAdenine in urine 
Run 01 True Conc. Estimated Conc. Bias% Mean Bias% (*) ACC% CV% ACC% Mean Bias%  (*) CV% ACC%
ng/mL ng/mL each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 0.91 21.33 121.33
0.75 0.77 2.67 14.22 102.67 8.83
0.89 18.67 118.67
SS-Medium 3.53 17.67 117.67
3.00 3.04 1.33 8.56 101.33 7.67 8.22 7.90
3.20 6.67 106.67
SS-High 83.75 4.69 104.69
80.00 79.78 -0.27 1.87 99.73 2.50
80.95 1.19 101.19
Run 03 True Conc. Estimated Conc. Bias% Mean Bias% (*) ACC% CV% ACC% Mean Bias%  (*) CV% ACC%
ng/mL ng/mL each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 0.70 -6.67 93.33
0.75 0.78 4.00 0.00 104.00 5.81
0.77 2.67 102.67
SS-Medium 3.05 1.67 101.67
3.00 2.89 -3.67 0.22 96.33 3.00 0.65 3.52
3.04 1.33 101.33
SS-High 78.69 -1.64 98.36
80.00 77.09 -3.64 1.72 96.36 1.91
80.09 0.11 100.11
Run 04 True Conc. Estimated Conc. Bias% Mean Bias% (*) ACC% CV% ACC% Mean Bias%  (*) CV% ACC%
ng/mL ng/mL each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 0.78 4.00 104.00
0.75 0.79 5.33 4.00 105.33 1.28
0.77 2.67 102.67
SS-Medium 3.01 0.33 100.33
3.00 3.21 7.00 3.22 107.00 3.31 4.20 2.02
3.07 2.33 102.33
SS-High 83.84 4.80 104.80
80.00 84.95 6.19 5.38 106.19 0.68
84.11 5.14 105.14
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Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
114.22 10.09
108.56 8.33 108.22 8.55
101.87 2.55
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
100.00 5.81
99.78 2.99 99.35 3.50
98.28 1.88
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
104.00 1.33
103.22 3.42 104.20 2.10
105.38 0.72
 
2-chloroadenine in plasma dog 
Run 07 True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias%  CV% ACC%
ng/ml ng/ml each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 0.72 -4.0 96.0
0.75 0.80 6.7 0.0 106.7 5.8
0.73 -2.7 97.3
SS-Medium 2.74 -8.7 91.3
3.00 2.98 -0.7 4.7 99.3 4.2 2.4 4.2
2.86 -4.7 95.3
SS-High 78.00 -2.5 97.5
80.00 77.57 -3.0 2.6 97.0 0.3
78.05 -2.4 97.6
Run 08 True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias%  CV% ACC%
ng/ml ng/ml each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 0.71 -5.3 94.7
0.75 0.67 -10.7 7.1 89.3 3.4
0.71 -5.3 94.7
SS-Medium 2.92 -2.7 97.3
3.00 3.05 1.7 0.1 101.7 2.3 2.0 4.6
3.02 0.7 100.7
SS-High 81.16 1.5 101.5
80.00 82.60 3.2 103.3 2.2
79.13 -1.1 1.2 98.9
Run 09 True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias%  CV% ACC%
ng/ml ng/ml each level ≤15.0% each day each day
≤20.0 ≤15.0 ≤15.0
SS-Low 0.81 8.0 108.0
0.75 0.76 1.3 7.1 101.3 5.1
0.84 12.0 112.0
SS-Medium 2.94 -2.0 98.0
3.00 3.36 12.0 5.3 112.0 6.7 4.2 5.2
3.18 6.0 106.0
SS-High 79.86 -0.2 99.8
80.00 80.95 1.2 0.3 101.2 0.8
79.96 -0.1 100.0
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Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
100.0 5.84
95.3 4.00 97.6 4.09
97.4 0.32
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
92.9 3.12
99.9 2.31 98.0 4.47
101.2 2.21
Mean ACC% SD ACC% Mean ACC% SD ACC%
85.0%-115.0% each day each day
85.0%-115.0%
107.1 5.41
105.3 7.02 104.2 5.39
100.3 0.76
 
For both intra- and inter- run precision and accuracy, all QC samples, including those 
failed with no assignable cause, should be used for calculation, those that failed for an 
assignable cause (eg. Rejected chromatography or sample extraction problem) should be 
excluded from the calculation. 
 
Table 25: Inter run Accuracy and Precision 
Matrix urine 
 
Matrix plasma dog 
Overall Overall  Overall SD ACC%
Mean Bias% (*)  CV% ACC% Mean ACC%
≤ 10.0 ≤15.0
4.35 6.18 103.92 6.42
Overall Overall  Overall SD ACC%
Mean Bias% (*)  CV% ACC% Mean ACC%
≤ 10.0 ≤15.0
6.4 5.4 93.7 5.07
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10.2.3.3. Sensitivity (LLOQ) 
The target of the lower limit of quantification will be 0.1ng/ml for Cladribine and 2-
chloroadenine. Five samples spiked at this concentration were analyzed per batch together 
with the accuracy and precision levels. 
The analyte response has to be at least 5 times the response observed in blank samples. 
The mean intra-batch as well as the overall accuracy is within 80-120% at the LLOQ 
QC level. 
The intra-batch and overall precision, expressed as CV%, do not exceed 20% at the 
LLOQ QC level. 
Table 26 
Run 04 True Conc. Peak LLOQ Peak Matrix % Area Ratio Estimated Bias% Mean Bias% (*) CV% ACC% ACC% Mean ACC% SD ACC%
ng/ml Area Area ≤20.0% Conc ≤20.0% ≤15.0% 80.0%-120.0%
(ng/ml)
0,25 1128,0 0,0 0,0 0,24 -4,0 96,0
1130,9 0,0 0,0 0,24 -4,0 96,0
1086,4 0,0 0,0 0,22 -12,0 6,0 8,4 88,0 94,0 7,90
1023,2 0,0 0,0 0,22 -12,0 88,0
1041,0 0,0 0,0 0,22 -12,0 88,0
1264,9 0,0 0,0 0,27 8,0 108,0
N.R. Clean-up error
 
10.2.3.4. Selectivity 
The selectivity of the method towards endogenous compounds was established by 
analyzing blank plasma or urine samples. Selectivity of the method towards possible 
impurities or degradation products of the IS and of the analyte was so established by 
analyzing blank samples spiked with the molecules of interest, the good results obtained 
are shown in Table 27 
Overall Overall  Overall SD ACC%
Mean Bias% (*)  CV% ACC% Mean ACC%
≤ 10.0 ≤15.0
4.54 6.18 102.49 6.33
Overall Overall  Overall SD ACC%
Mean Bias% (*)  CV% ACC% Mean ACC%
≤ 10.0 ≤15.0
3.17 5.46 99.93 5.46
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Table 27: Test selectivity 
Run 04 Replicate Peak Matrix Peak LLOQ Average peak areas SELECTIVITY%
Area Area LLOQ samples ≤20.0%
1 0,0 1128,0 0,0
2 0,0 1130,9 0,0
3 0,0 1086,4 1112,41 0,0
4 0,0 1023,2 0,0
5 0,0 1041,0 0,0
6 0,0 1264,9 0,0
 
10.2.3.5. Carryover 
Carryover is calculated considering the area of the chromatographic peaks at AN, MET 
and IS retention time of the DBK sample placed after the ULOQ. 
The area of the chromatographic peaks at the AN and MET retention time in the sample 
DBK should be less than or equal to 50% of the area of the chromatographic peaks at AN 
and MET retention time of the LLOQ. 
The area of the chromatographic peak at the IS retention time in the sample DBK 
should be less than or equal to 20% of the area of the chromatographic peaks at IS 
retention time of the BK sample. 
If in a run the concentration of an unknown sample exceeds the ULOQ, the influence on 
the carryover of such a concentration will be evaluated. 
Peak areas of peaks eluted at the retention time of Cladribine and 2-chloroadenine 
following an ULOQ sample of Cladribine and 2-chloroadenine, resonse. will be expressed 
as percentage of the response at the LLOQ (obtained during linearity assessment). 
In Table 28 and Table 29 are reported carryover results. The response for the analyte in 
the solvent samples following the ULOQ sample is less than 50% of the mean response at 
the LLOQ. Also the parameter for IS carryover are respected. 
If carryover is observed exceeding the afore-mentioned levels, one or more blank 
samples have to be placed directly following a high concentration sample. 
Table 28: Carryover analyte 
Run 04 Average Area AN in LLOQ DBK after ULOQ Criteria: 
 ≤50.0%
1112,4 0,0 0,0
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Table 29: Carryover IS 
Run 04 Average Area IS in Calibration Curve DBK after ULOQ Criteria: 52622,3
 ≤20.0% 52318,8
53779,5 3382,1 6,3 53770,7
53155,9
53967,6
54943,5
56020,1
51858,8
55358,2
Mean 53779,5
 
10.2.3.6. Stability 
Long term stability 
After the validation steps I determined the long-term stability of the analytes in the 
matrix. At the beginning of the validation a sufficient number of QC samples at the 
required long-term storage temperature were stored. 
I analyzed 3 aliquots at low and high concentrations with fresh standard curves and I 
compared these against intended (nominal) concentrations. I will show in the tables the 
results of the 3, 6, 9 months long-term stability. 
Table 30 
Cladribine in urine 2-chloroadenine in urine
Run 06 True Conc. Estimated Conc. Mean Run 06 True Conc. Estimated Conc. Mean
(ng/ml) t = 0 h (ng/ml) t = 0 h
(ng/ml) (ng/ml)
SS-Low 0.69 SS-Low 0.70
0.75 0.76 0.74 0.75 0.72 0.73
0.76 0.78
SS-High 84.16 SS-High 78.27
80.00 82.20 83.22 80.00 77.35 77.52
83.29 76.95
Run 06 Estimated Conc. Mean STAB % Run 06 Estimated Conc. Mean STAB %
3 months -20°C ≥ 85.0 - ≤ 115.0 3 months -20 °C ≥ 85.0 - ≤ 115.0
(ng/ml) (ng/ml)
0.85 0.68
0.77 0.79 106.76 0.69 0.71 97.26
0.75 0.77
84.83 79.34
82.72 84.05 101.00 78.43 79.69 102.80
84.59 81.29
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Cladribine in plasma 2-chloroadenine in plasma
Run 11 True Conc. Estimated Conc. Mean Run 11 True Conc. Estimated Conc. Mean
(ng/ml) t = 0 h (ng/mL) t = 0 h
(ng/ml) (ng/mL)
SS-Low 0.84 SS-Low 0.80
0.75 0.78 0.77 0.75 0.89 0.84
0.70 0.84
SS-High 75.77 SS-High 87.91
80.00 76.13 75.39 80.00 86.58 88.31
74.28 90.45
Run 11 Estimated Conc. Mean STAB % Run 11 Estimated Conc. Mean STAB %
6 months -20 °C ≥ 85.0 - ≤ 115.0 6 months -20 °C ≥ 85.0 - ≤ 115.0
(ng/ml) (ng/mL)
0.71 0.82
0.74 0.76 98.70 0.69 0.75 89.29
0.82 0.74
76.63 74.01
88.78 82.60 109.56 74.74 75.58 85.58
82.40 77.99
Run 12 True Conc. Estimated Conc. Mean Run 12 True Conc. Estimated Conc. Mean
(ng/ml) t = 0 h (ng/ml) t = 0 h
(ng/ml) (ng/ml)
SS-Low 0.72 SS-Low 0.84
0.75 0.63 0.67 0.75 0.84 0.82
0.67 0.79
SS-High 72.20 SS-High 83.33
80.00 71.99 71.85 80.00 84.71 83.28
71.35 81.81
Run 12 Estimated Conc. Mean STAB % Run 12 Estimated Conc. Mean STAB %
9 months -20 °C ≥ 85.0 - ≤ 115.0 9 months -20 °C ≥ 85.0 - ≤ 115.0
(ng/ml) (ng/ml)
0.67 0.79
0.69 0.68 101.49 0.76 0.79 96.34
0.68 0.83
72.84 82.06
71.09 71.43 99.42 84.29 83.58 100.36
70.35 84.40
 
10.2.4. Conclusions 
The results obtained during the validation of the assay fulfilled all requirements and 
recommendations regarding linearity, accuracy, and precision generally accepted for 
bioanalytical studies. 
The fully automated LLE methodology avoids several disjointed steps involved in 
manual or semiautomated LLE method, leading to significantly reduced sample 
preparation time (Figure 40), increased sample throughput, and clean sample extracts for 
improved detection.  
Moreover the use of Ultra Performance Liquid Chromatography (UPLC), a 
chromatographic system designed in a special way to withstand high system back-
pressures, gives new possibilities in liquid chromatography, especially concerning 
decrease of time and solvent consumption. 
UPLC advantages are clearly observed. The separation mechanisms is still the same, 
chromatographic principles are maintained while speed, sensitivity and resolution is 
improved. This all supports easier method transfer from HPLC to UPLC and its 
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revalidation. The main advantage was particularly a significant reduction of analysis time, 
which meant also reduction in solvent consumption. 
VS.
•5ml tube (96)
•Samples
•Solvent 1ml(TBME/EtOAc)
•Liquid Nitrogen or transfer
•DW 1ml 96wellplate (1)
Manual procedure Automatic procedure
Time require for the 
extraction of 96 samples 
20”x96=1920”=32’
•DW 2ml 96 well plate (1)
•Samples
•Solvent 1ml (TBME/EtOAc)
•Mix 1’
•DW 1ml 96 well plate (1)
Time required for the 
extraction of 96 samples 
=1’
 
Figure 40: time saved in vortexing 96 samples using robotic workstation 
The automated method produced considerable improvements over the manual method 
with respect to the recovery and repeatability values obtained with the different clean up 
techniques. Subsequent testing of the method with real samples demonstrated its 
applicability. 
General strategies for automating liquid-liquid extractions have been achieved using the 
96-well format. The resulting assays drastically reduce sample preparation time (at least 3-
fold faster when compared to manual extraction), decrease material and labor costs and 
increase throughput in clinical studies. 
• Faster - At least 3 - fold faster when compared to manual extraction  
• Analyst time used more effectively  
• Increased throughput of clinical samples  
• Traditionally liquid-liquid extractions associated with being cumbersome, 
automation reduces many repetitive activities  
• Decreased material and labor costs  
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11. Solid Phase Extraction (SPE) 
11.1. Introduction 
Solid Phase Extraction (SPE) is versatile and selective methods of sample preparation in 
which analytes are bound onto a solid support, interferences are washed off and analytes 
are selectively eluted for further workup and analysis. The many different choices for 
sorbent chemistry that make SPE a very powerful method for sample preparation also 
create many different ways in which sorbents can be used51. 
11.2. Fundamental Principles 
SPE is a specific type of sample preparation in which an analyte, contained in a liquid 
phase, comes in contact with a solid phase (solid particles usually in column or disk, in 
this case in the wells of a 96 well plate) and is selectively absorbed in into the surface of 
that solid phase. All other materials not absorbed by chemical attraction or affinity remain 
in the liquid phase and go to waste. 
Generally a wash solution is then passed through the sorbent bed to remove any 
adsorbed contaminants from the sample matrix, yet retain the analyte of interest on the 
solid phase. Finally, an eluting solvent (usually an organic solvent such as methanol or 
acetonitrile that may be modified with acid or base) is added to the sorbent bed. This 
solvent disrupts the attraction between analyte and solid phase causing desorption, or 
elution, from the sorbent. Liquid processing through the sorbent bed can be accomplished 
via vacuum or positive displacement52. 
In Figure 41are represented the basic steps for solid-phase extraction: 
• (a) conditioning the sorbent bed; 
                                                     
 
51 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. (2003), 
cap 11, page 361. 
52 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. (2003), 
cap 2, pages 49, 50. 
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• (b) loading analytes; 
• (c) washing away interferences; 
• (d) selective elution for further workup and analysis. 
The SPE product format shown is for a disk in a cartridge or column although the 
procedure is generally similar regardless of format53. 
 
Figure 41: the basic steps for solid-phase extraction. 
High-throughput solid phase extraction utilizes 96 well microplate formats. 
Although the samples can be processes manually liquid handling workstation is 
preferred; the use of the automatic workstation results in very high throughput. Many 
sorbent chemistries and formats are available in the plates to meet most needs54. 
11.3. Advantages 
This technique has numerous advantages: 
                                                     
 
53 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. (2003), 
cap 11, page 362. 
54 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. (2003), 
cap 2, pages 49, 50. 
a b c d 
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• It provides very selective extracts reducing the potential for ionization suppression 
from matrix materials. 
• A wide variety of sample matrices can be accepted. 
• It permits high recoveries with good reproducibilities. 
• Analytes can be concentrated. 
• High recoveries with good reproducibilities. 
• Low solvent volumes. 
• No emulsion formation as with LLE technique. 
The technology has been improved in recent years with the introduction of more 
selective but also more generic solid sorbent chemistries, improved disk based SPE 
devices, smaller bed mass sorbent loading, improved plate formats for using smaller 
volumes, and faster and more efficient automation hardware55. 
11.4. Disadvantages  
Many of the disadvantages for SPE are directed toward the perceived difficulty to 
master its usage. The great selectivity and the many choices for manipulating pH and 
solvent conditions make it difficult to grasp the chemistry of the technique. An important 
argument is related to slow or difficult flow of sample through the particle bed; 
precipitated fibrins, thrombins or other particles in the biological are often at fault. In 
order to avoid this potential problem, samples are usually centrifuged or filtered prior to 
extraction and this step is especially important with the use of automated method. 
Sometimes a larger particle size packing (e.g., 100µm instead of 40µm) is used to improve 
flow characteristics. 
Also the development process of the method takes too much time. 
The cost of performing a solid phase extraction procedure can be greater than that of 
other techniques such as PPT or LLE. However any estimate of cost should not include 
                                                     
 
55 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. (2003), 
cap 11, page 364. 
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only the consumable items needed to perform the extraction but also must factor in the 
time saving that the approach offers56. 
11.5. Sorbent Chemistries and Attraction Mechanisms 
11.5.1. Nature of the Sorbent Particle 
Two major types of sorbent particles are used for SPE: silica and polymer. 
A wide range of surface areas and pore diameters can be prepared surface area is a 
function of the average pore diameter: the smaller the pore diameter, the higher the surface 
area. 
Particle size used affects flow characteristics and performance. In the case of biological 
matrices that are viscous a larger particle size is required to provide better flow 
characteristics. 
11.5.2. Attraction Mechanisms 
Four primary modes of analyte attraction to solid sorbent particle are: 
• Reversed phase (also called non polar). 
• Ion exchange. 
• Mix mode (also called mixed phase). 
• Normal phase (also called polar). 
11.5.3. Packed Particles Beads 
The traditional format for SPE has been single disposable columns, also called 
cartridges, filled with solid sorbent particles (from 25 to 500mg) held between two 
polyethylene frits. 
                                                     
 
56 D.A. Wells, High Throughput Bioanalytical Sample Preparation, Methods and Automation Strategies, Elsevier. (2003), 
cap 11, page 365. 
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The pharmaceutical industry responded to a challenge of higher throughput sample 
preparation by utilizing solid-phase extraction in a 96-well format. This microplate format 
presents many efficiencies of operation such as ease of labeling, sealing and manipulation. 
I decided to combine this format with multiple tip Hamilton Workstation in order to 
dramatically faster pipetting throughput via parallel processing of samples. 
11.5.4. High-Throughput and new Applications  
This application will describe an automated solid phase extraction method coupled with 
HPLC analysis to determine a peptides mixture in order to achieve results more accurately 
with more speed and less efforts. 
Automation is an effective tool in achieving all three of these goals. 
When the sample preparation step became rate limiting automation could be seen as the 
more efficient and faster way to work with greater number of samples cleaned up in a 96-
well format by the use of a Robotic Workstation and the ability of the operator. 
The evaporation and reconstitution steps not only take time and effort, but can also lead 
to loss of valuable sample. Therefore, the ability to elute in very small volumes of solvent 
is desirable to minimize the amount of time required. 
Currently, there are two technologies Disc and. µElution. 
In the µElution design, a much smaller sorbent mass (e.g., 2 mg) is packed into an 
internally tapered well with an aspect ratio of 1.15. The µElution technology functions 
more like a chromatography column and enhances the capture of target analytes. It also 
helps to prevent breakthrough during the load and wash steps. The hold-up volume for the 
µElution technology was determined to be as little as 15µL. 
A small hold-up volume is important for achieving a low elution volume. Larger hold-
up volumes result in larger elution volumes. 
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11.6. Experimental 
11.6.1. Objective 
The aim of this project was the automation of the sample preparation in the study for the 
evaluation of the stability assessment of a mixture of four natural peptides in human blood 
(derived from Myelin Basic Protein) using the UPLC-MS/MS technique. 
The study was conducted according to MSR-QMS. 
 
Figure 42: In Multiple Sclerosis the myelin sheath which is a single cell whose membrane wraps 
around the axon, is destroyed with inflammatory and scarring. 
This mixture is designed to induce immunological tolerance of the body’s T-cells to key 
auto-antigens involved in the pathogenesis of Multiple Sclerosis (Figure 42). 
Oligodendrocytes form a protective sheath, known as myelin that insulates the fibrous 
cables, or axons, radiating from nerve cells. 
In multiple sclerosis, the immune system's T cells and B cells attack oligodendrocytes, 
ultimately damaging the myelin sheath to the point that the electrical signals transmitted 
by the axons beneath it are disrupted.  
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11.6.2. Instrumentation 
11.6.2.1. Reagents and chemicals 
Analyte is a mixture of four linear peptides: Myelin Basic 
The peptides were provided by Bachem AG – Bubendorf, Switzerland. Human blood 
was collected from healthy volunteers (AVIS Torino and Ivrea, Italy). Acetonitrile and 
Methanol were HPLC-grade and purchased from Merck kGaA (Darmstadt, Germany). 
Protease inhibitor cocktail tablets, Complete Mini (Roche Diagnostics, Mannheim, 
Germany) without ethylenediaminetetraacetic acid (EDTA), were used to prevent peptide 
degradation in biological matrixes. Formic acid (FA) and Phosphoric Acid were obtained 
from Sigma-Aldrich (St.Louis, MO, USA). Ultrapure water was produced by a Milli-Q 
Plus, Millipore system (Billerica, MA, USA). 
11.6.2.2. Equipment 
MICROLAB STARlet Liquid Handling Workstation Hamilton Robotics.  
Oasis HLB: Hydrophilic-Lipophilic Balance Sorbent reversed-phase sorbent for all 
compounds (e.g. parent drug and its polar metabolites). Water-wettable sorbent, no impact 
of sorbent drying. 
The SPE Strata-X (Reversed Phase polymeric sorbent) µElution 96-well plate were 
purchased from Phenomenex (Torrance, California, USA).  
The UPLC/MS system used for the assay comprised an Acquity UPLC system (Waters 
Corporation; Milford, MA, USA) coupled with a triple quadrupole mass spectrometer 
equipped with a turbo ion spray source (API 4000; Applied Biosystems, Toronto, Canada) 
and with an Acquity BEH C18 column (2.1x100 mm, dp=1.7 mm; Waters).  
Data were processed using Analyst software (version 1.4.2) from Applied Biosystems. 
11.6.3. MS/MS detection 
Peptides were infused into the triple quadrupole mass spectrometer equipped with an 
ESI source operated in the positive ion mode for identification. Mass spectra were 
obtained infusing the mixture of peptides at a concentration of 10µg/ml in water/ACN 
(50:50, v/v) with 0.1% FA using a syringe pump operated at a flow rate of 5µl/min and 
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setting the UPLC flow rate at 200µl/min. For each peptide, the most abundant ion 
produced in positive mode was [M+3H]3+. 
11.6.4. Automated SPE 
The most logical method was created on Vector. It allows changes and modifications 
during the set up of the method in order to evaluate and establish the best conditions. 
It is possible the complete control of rates for aspiration and dispensing of the 
solutions/samples onto the SPE plates including the time associated with the air push and 
the pressure equilibrium.  
The method set-up was thoroughly investigated in order to obtain the best SPE 
conditions. During this phase, different SPE plates and different solvent mixtures were 
tested to obtain the best results in term of recovery, robustness and reproducibility of the 
extraction method. 
On the whole, analysis sampling and sample preparation are the most important steps of 
analytical procedures. Due to its flexibility, SPE is a multivariate process whose 
optimization should be approached from a multivariate perspective. For the optimization 
of this SPE procedure we investigated the selection of the most appropriate sorbent, the 
design of the SPE bed, the determination of the volume of the sample to load and the 
determination of the nature and volumes of solvents first used to wash the column and 
then to elute the analyte. Microelution SPE was used in order to avoid solvent and sample 
spending.  
Strata™-X plates have been engineered to allow higher loading volumes than Oasis® 
HLB plates, which helps to avoid limits on loading volumes that can lead to problems with 
lower limit of quantification (LLOQ) and lower limit of detection (LLOD) of low 
concentration analytes. 
The choice of sorbent is the key point in SPE because it can control parameters such as 
selectivity, affinity and capacity. 
This choice depends strongly on the analytes of interest and the interactions of the 
chosen sorbent through the functional groups of the analytes. 
In designing the automation strategy for Solid Phase Extraction there are many 
parameters that the operator has to consider.  
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In first has to be found the most convenient SPE condition, than it is important to 
planning of the most appropriate deck layout which has to be different from the other 
before described because of the needs of this technique. 
 
Figure 43: Different types of 96-SPE-well plates tested. 
With the Oasis HLB plate, are possible robust SPE methods without having to endure 
irreproducible results and low recoveries caused by undesirable silanol activity, sorbent 
drying, pH limitations, and breakthrough of polar compounds/metabolites. The technology 
incorporate the first hydrophilic-lipophilic-balanced water-wettable copolymer optimal for 
any sample cleanup and are unique in their purity, reproducibility, stability, and retention 
characteristics. 
At this point the microplate can be placed onto the workstation deck for all subsequent 
pipetting tasks. 
Once the sample plate has been prepared and place onto the deck the first pipetting 
action by the instrument is to aspirate the solvents for conditioning the plate. These 
solvents are sequentially aspirated from a reagent reservoir and dispensed into all the wells 
of the plate. If needed a vacuum manifold step is performed between. 
It is important to evaluate the correct measure of the vacuum to apply. It has to be not 
too strong but not too low. 
Than a volume of sample matrix is next aspirated from the sample plate, a vacuum 
manifold step follows. 
A clean collection plate is placed inside the manifold. 
In first was used an Oasis HLB µElution plate, 1/pk [186001828BA]. Plates and theie 
characteristics are shown in Figure 43, Figure 44 and .Figure 45. 
This plate can be correctly placed in a good position for dispensation and vacuum 
without moving any plate. 
Oasis HLB µElution by Waters Strata X by Phenomenex 
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In fact this plate has a low high and the axes of the workstation were inside the settled 
parameters. 
But during the clean up was noticed that there were some percolation problems. 
For this reason we decided to use Strata X plate but the deck layout positions had to be 
changed for the plate dimension. It was used a different carrier to avoid the collision 
between the tips and the plate. 
 
Figure 44 
Strata X: Material Characteristics 
• Particle Size (µm) 33 
• Pore Size (Å) 85 
• Surface Area (m2/g) 800 
• pH Stability 1-14 
 
Figure 45 
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The final SPE conditions were the following: 
• sample pre-treatment: 100µl of sample + 400µl of 0.5% Phosphoric Acid solution, 
• conditioning with 200µl of methanol; 
• equilibrating with 200µl of water; 
• pre-treated sample loading; 
• washing with 200µl of 10% methanol solution, drying for one minute and eluting 
with 100µl methanol/acetonitrile (1:1, v/v). 
11.6.5. Peptide Stability Investigation 
The samples used to investigate peptide stability in human blood were prepared by 
adding the peptides working solution to blood in order to achieve final concentrations of 
50.0 and 100.0ng/ml. The spiked blood samples were stored at 37°C (in order to simulate 
the human physiological conditions) and at different time points (5-15-30-60-120 min) 
samples were centrifuged at 2500xg for 10min at 4°C. Subsequently samples were 
extracted via SPE procedure and analyzed by LC-MS/MS technique. 
11.6.6. Results 
Results obtained using the better SPE conditions for all peptides: recovery and choice of 
the better clean-up are described below in Table 31 and in Figure 46. 
In table 8 is shown the extraction efficiency, a ratio of the detector response from the 
extracted sample to the detector response from an unextracted containing the same amount 
of analyte. This represents 100% recovery during extraction. In this case we have 
extraction efficiency over 90% for three of the compounds; only for the compound C it is 
below 90%. However extraction efficiency need not always to be very high but it should 
be consistent, precise and reproducible. 
Table 31 
Compounds Average SPE Recovery Inter-day% RSD
Compound A 92.20% 0.01
Compound B 98.90% 1.45
Compound C 84.50% 1.45
Compound D 91.60% 2.71
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The clean up step has some relevance in determining the repeatability in routine 
analyses, where a quite large number of different samples are run within the same session. 
This point could be even more critical for those multi-residue approaches, where the 
elution of several compounds of interest could last several minutes, thus enhancing the 
risk of progressive dirtiness of the interfaces. 
In an SPE procedure, choosing right washing solvent composition is a difficult task. A 
good washing solvent should be able to eliminate the matrix interferences as much as 
possible without eluting the analytes. In this part of the work, different washing solvent 
compositions are studied as shown in Figure 46. 
As a preliminary study to choose solvent, different concentrations of methanol as 
washing solvent are studied with Oasis HLB plates. 
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Figure 46: Choice of the better clean-up. 
11.6.7. Linearity, Sensitivity and Recovery: comparison 
between Manual and Automated procedure 
The linearity of results for both automated and manual methods demonstrates that drug 
samples in plasma can be reliably prepared by the Hamilton Robotic Workstation.  
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The high degree of linearity indicates that the purified samples generated following this 
automated procedure allow accurate LC-MS/MS analysis across a wide concentration 
range. The comparison is shown in. Figure 47 and Figure 48. 
 
Figure 47 
 
Figure 48 
Linearity by Automated Extraction
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Comparable chromatographic performance to the manual were achieved using the 
robotic workstation. 
A quick automated SPE sample preparation has been developed. This method compared 
to the manual procedure brings the same good results but also eliminates the need for time 
consuming sample preparation procedures. 
Chromatograms are shown in Figure 49 and. Figure 50. 
XIC of +MRM (10 pairs): 580.6/693.5 amu from Sample 1 (Sample 0.5% Acid - 5%CH3OH-ACN/CH3OH 1) of Strata x Manual 280709.wiff (Turbo S... Max. 7.1e4 cps.
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Figure 49: Chromatograms of the four peptides by manual extraction. 
XIC of +MRM (10 pairs): 580.6/693.5 amu from Sample 1 (Sample 0.5% Acid - 5%CH3OH-ACN/CH3OH 1) of Strata x Robot.wiff (Turbo Spray) Max. 4.8e4 cps.
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Figure 50: Chromatograms of the four peptides by automated extraction. 
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Figure 51 shows the recoveries obtained in the manual and automated extraction 
procedures. 
The recoveries are equivalent for one of the peptides of the mixture, and better for two 
of them. However recoveries are quite always greater or near 90% in the automated way. 
 
Figure 51: Recovery comparison between Manual and Automated Extraction. 
11.6.8. Conclusions 
Although the results obtained during stability assessment showed a rapid enzymatic 
degradation of the four peptides in human blood the use of liquid handling to automate the 
extraction was successful. 
The recoveries obtained in the manual and automated extraction procedures and 
chromatograms are comparable. 
It shows that all liquid handling steps can be performed by the workstation proving to 
be quick and labor saving so the future SPE-LC-MS-MS procedure could eliminates the 
human factors of specimen handling, extraction, and derivatization, thereby reducing labor 
costs and rework resulting from human error or technique issues. 
In conclusion, the automated extraction of peptides from blood samples has been shown 
to be feasible using the Hamilton robotic workstation. 
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Compared with manual extraction methods reported previously the method has a shorter 
processing time while maintaining equivalent linearity, sensibility and recovery. 
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“UPLC-MS/MS strategy to quantify a mixture of four shirt myelin basic peptides 
in human plasma samples” 
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12. Dried Blood Spots (DBS) 
Plasma has been the mainstay matrix for measurement of systemic concentration of 
compounds used in the assessment and evaluation of pharmacokinetics (PK) and 
pharmacodynamics (PD), both efficacy and safety, in drug discovery and development. An 
alternative, dried blood spots (DBS), has recently gained increasing popularity, with some 
distinct practical advantages but also technical issues, although the method was employed 
in pediatrics as early as 196357. 
12.1. Introduction 
DBS sampling is an innovative technique that reduces sample volume requirements and 
offers significant ethical and economical benefits, Figure 52. 
 
Figure 52: Dried Blood Spot cards 
                                                     
 
57 Use of Dried Blood Spots in Drug Development: Pharmacokinetic Considerations Malcolm Rowland and Gary T. 
Emmons, 25 March 2010. The AAPS Journal. 
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12.2. History 
The concept that capillary blood, obtained from pricking the heel or finger and blotted 
onto filter paper, could be used to screen for metabolic diseases in large populations of 
neonates was introduced in Scotland by Robert Guthrie in 1963. Neonatal screening for 
phenylketonuria became nationwide in 1969-70. Since then, Guthrie card samples have 
been collected routinely from infants in over 20 countries to screen for phenylketonuria 
and more recently for congenital hypothyroidism, sickle cell disorders and HIV infection. 
The limitations of sensitivity and specificity when screening such small volumes of blood 
restricted the use of dried blood spots for many years. However, recent advances such as 
the production of monoclonal antibodies, expression of synthetic proteins, and the 
introduction of the polymerase chain reaction have overcome many of these problems58. 
DBS is an FDA listed class II medical device. 
A medical device is a product which is used for medical purposes in patients, in 
diagnosis, therapy or surgery. If applied to the body, the effect of the medical device is 
primarily physical, in contrast to pharmaceutical drugs, which exert a biochemical effect. 
Specific regional definitions of medical device vary slightly as detailed below. The 
medical devices are included in the category: Medical technology. 
Medical devices include a wide range of products varying in complexity and 
application. Examples include tongue depressors, medical thermometers, blood sugar 
meters, total artificial hearts, fibrin scaffolds, stents and X-ray machines. 
12.3. Bioanalytics 
12.3.1. Preclinical Study 
Although very few applications of DBS in preclinical study have been published on 
toxicokinetic or pharmacokinetic assessment of drug or drug candidates in small animals, 
the potential benefits of using this technique is too pronounced to be ignored by 
                                                     
 
58 Parker SP, Cubitt WD (September 1999). "The use of the dried blood spot sample in epidemiological studies". J. Clin. 
Pathol. 52 (9): 633–9. 
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pharmaceutical industry. The small blood volume (<100µl for multiple spots) used for 
DBS sampling makes its use possible for serial bleeding from small animals59. 
12.3.1.1. Animal use 
DBS technology brings opportunities for animal use reduction and refinement. 
In 1986 the European Council of Ministers adopted Directive 86/609/EEC on ‘the 
protection of animals used for experimental and other scientific purposes’. The Directive 
sought to improve the controls on the use of laboratory animals, set minimum standards 
for housing and for the training of those handling animals and supervising the 
experiments. 
The Directive also aimed to reduce the numbers of animals used for experiments by 
requiring that an animal experiment should not be performed when an alternative method 
exists, and by encouraging the development and validation of alternative methods to 
replace animal methods. 
This legislation is largely a framework, and laws governing animal experiments in the 
UK, for example, are very much stricter. 
A few years ago, it became clear that officials within the European Commission wished 
to revise the Directive to promote improvements in the welfare of laboratory animals and 
to further encourage the development of alternative methods. Since 1986 important 
progress has been made in science and new techniques have become available, such as use 
of transgenic animals, xenotransplantation, and cloning. According to the Commission, 
these require specific attention, which the old Directive does not provide. 
The process of revising the Directive has been going on for several years, and draft 
legislation was only available to the European Parliament and the public at the end of 
2008. The Parliamentary process can take at least two years, and implementation in the 
Member States a further two, so national legislation to implement the Directive may not 
be in place for some time. 
                                                     
 
59 Barfi eld et al., 2008; Beaudette and Bateman, 2004. 
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12.3.2. Clinical Study and Therapeutic Drug Monitoring 
DBS-LC-MS/MS has been increasingly employed in clinical study and therapeutic drug 
monitoring for the analysis of a wide spectrum of drug molecule. 
Because DBS samples could be collected by patients themselves or their guardians with 
minimum training, this opens up the possibilities of collecting clinical pharmacokinetic 
samples not only from various in-patients, but also from out-patients, especially those 
from remote areas. 
In all cases where serum or plasma, instead of DBS, has been used as the matrix for 
quantitative analysis of drugs during discovery and development, it would be necessary to 
determine the relationship between the analyte concentration in the two matrices 
(plasma/serum vs. DBS). Hematocrit is an important parameter that needs to be 
considered. 
Current analytical methods require relatively large volume of plasma. Typical blood 
sample volume is 250µl for rat and 200µl for mouse. 
Mouse sampling frequently has to be terminal. Profiles frequently are limited by 
allowable blood sample volume and large number of mice and juvenile rats are added to 
studies to generate TK data. 
Blood is centrifuged to produce plasma and practically it is very hard to centrifuge small 
volumes of blood to yield plasma. 
12.3.3. Fundamental Principles 
There are different types of cards that can be used in DBS technology. 
S&S 903, Whatman manufactured from 100% pure cotton linters with no wet-strength 
additives added. 
FTA and FTA Elute cards, and recently FTA DMPK-A, FTA DMPK-B, FTA 
DMPK-C also manufactured by Whatman (now part of GE Healthcare). These are 
designed for nucleic acid analysis. According to the manufacturer, some of these cards are 
chemically treated with proprietary reagents that upon contact, lyse cells, denature 
proteins and prevent the growth of bacteria and other microorganisms. 
All the cards have been employed in combination with LC-MS/MS for the quantitative 
analysis of small drug molecules and their metabolites in preclinical and clinical studies. 
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Card choice is dictated by a combination of handling and performance criteria. 
Handling requirements may be influenced by operational or safety factors, while 
performance depends on many factors such as the analyte chemical structure, extraction 
solvent, and analysis workflow, which are usually determined empirically. To identify 
appropriate cards, normally the analyte recovery from all types of cards is investigated 
using, in part, the “Instruction for Use” protocol provided with the cards. 
FTA DMPK-A 
• Blood spots dry within 2 h; 
• Blood spot area is ~20% smaller than DMPK-B or DMPK-C cards; 
• Protein denaturing activity will inactivate endogenous enzymes; 
• Cell lysis releases endogenous cellular materials onto card; 
• Stabilization of DNA allows resampling of blood spot for pharmacogenomics; 
• Impregnated chemicals may interfere with mass spectrometry detection e.g. ion 
suppression. 
FTA DMPK-B 
• Blood spots dry within 2 h; 
• Protein denaturing activity will inactivate endogenous enzymes; 
• Cell lyses releases endogenous cellular materials onto card; 
• Stabilization of DNA allows resampling of blood spot for pharmacogenomics; 
• Impregnated chemicals may interfere with mass spectrometry detection e.g. ion 
suppression. 
FTA DMPK-C 
• Blood spots dry within 2 h; 
• No impregnated chemicals to interfere with analysis; 
• Proteins are not denatured so cards may be better suited for protein based 
biomolecules. 
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12.3.4. Blood Collection  
 
Figure 53 
In preclinical studies, small animals (e.g. mouse, rat, etc.) can be tail bled. After the 
pricks, the blood drop is directly applied onto the sampling paper/card within a pre-
marked circle, ideally one drop per spot. Touching the circle area should be avoided, 
especially before the blood is applied and dries completely. The predefined circle must be 
homogenously and symmetrically filled and both sides of the card/paper must show the 
same red color. Samples indicating contamination or hemolysis or with insufficient 
volume collected are deemed not suitable  
The blood sample can also be applied with a calibrated pipette (Figure 53) onto the 
sampling paper/card, thus avoiding potential variability in blood samples due to 
hematocrit effect, blood volume influence, possible uneven distribution of blood on the 
card/paper and other sampling errors. The pipette tip should be a few millimeters above 
the card/paper. As the blood drop touches the card/paper, it should be swiftly expelled60. 
12.3.4.1. Examples of Invalid Spots and Invalid Collections of DBS 
Examples of invalid spots and invalid collections on card are shown. 
                                                     
 
60 Dried Blood Spot sampling in combination with LC-MS/MS. Biomed. Chromatogr.2010; 24, 50. 
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In Figure 54 the specimen is invalid because the specimen was not dry before mailing. 
DBS must dry a minimum of 4 hours (possibly overnight in area with high humidity) 
before packaging and shipping. 
 
Figure 54: Spot with insufficient quantity of blood. 
In Figure 55 is possible to see that the sample is not completely dried before the placement in the 
storage bag. 
 
Figure 55: Sample not allowed to air dry before placing in storage bags. 
In Figure 56 the specimen is invalid because the specimen appears clotted or layered. 
The volume of specimen will not be uniform between spots resulting in errors during the 
testing process. 
This may have been caused by: 
• touching the same circle on the filter paper to blood drop several times; 
• filling circle on both sides of filter paper. 
 
Figure 56: Sample where blood was clotted and did not soak into paper. 
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In Figure 57 and Figure 58the specimen is invalid because the specimen exhibits 
emolization and serum rings i.e. serum becomes separate from cells. 
This may have been caused by the following: 
• Not allowing alcohol to dry at puncture site before making skin puncture. 
• Allowing filter paper to come in contact with alcohol, hand motion, etc. 
• Squeezing area surrounding puncture site excessively. 
• Drying specimen improperly. 
• Applying blood to filter paper with a capillary tube. 
 
Figure 57: DBS with contamination or hemolyzed blood. 
 
Figure 58: DBS where serum separated from cells. 
 
12.3.5. Drying, Storage and Transportation 
It is very important to dry blood spots completely before storage or transportation. In 
general, a minimum of 2–3 h drying in an open space at room temperature (15–22°C) is 
recommended. However, the drying time depends on the type of paper/card and the blood 
volume applied.  
The samples should not be heated, stacked or allowed to touch other surfaces, and 
should be kept away from direct sunlight or daylight if needed. 
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Thus, after drying, the DBS samples should be protected against humidity and moisture 
by covering them with a paper overlay and packing them in low gas-permeable zip-closure 
bags with desiccant packages. Humidity indicator cards should be included in the storage 
package. DBS samples protected in this manner may be stored at room temperature for 
many weeks, months or years, depending on the analyte stability. However, samples that 
contain unstable compounds should be stored at a lower temperature in order to enhance 
stability. DBS samples that have been packed as described above can be transported 
through the mail in a high-quality bond envelope61. 
12.3.6. Punching out prior analysis 
After drying at room temperature a disc is punched out from the dried blood spot using 
a specific manual puncher as shown in Figure 59. It is also possible to automate this 
operation with the use of BSD 600/1000 robotic puncher. 
 
Figure 59 
12.3.7. Off -line extraction 
For quantitative analysis, one or more DBS disks are punched from DBS card/paper into 
assay tubes or the appropriate wells of 96-well microtiter plate for extraction. The 
                                                     
 
61 Dried Blood Spot sampling in combination with LC-MS/MS. Biomed. Chromatogr.2010; 24, 51. 
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extraction procedure is usually carried out by adding a certain amount of extraction 
solvent (methanol, acetonitrile or a mixture of water/organic) containing the internal 
standard(s). The extraction solvent must be strong enough to interrupt the binding of 
analyte to protein in the matrix or the paper material. The analyte of interest is then 
extracted with gentle shaking or vortexing. Sonication may be necessary for better 
extraction efficiency62. After centrifugation, the resulting extracts are transferred manually 
or by an automated liquid handler to new tubes or microtiter plates. The extracts can be 
directly injected onto the LC-MS/MS system for analysis, or dried for reconstitution using 
an MS-friendly solvent prior to analysis. 
12.3.8. Stability 
The DBS technique provides another dimension for the storage of biological samples, 
even in the absence of refrigeration in some cases. Several applications have demonstrated 
the advantages of DBS over other means in preserving some unstable analytes from 
degradation or delaying the degradation process63. Room temperature is the intended 
storage condition for most DBS samples. However, a lower temperature may be necessary 
for longer stability coverage for some analytes. 
12.3.8.1. Approaches for enhanced stability 
DBS is not a miraculous process for all unstable compounds. Necessary, approaches 
should be undertaken to extent the stability coverage of any unstable compound. Three 
main approaches are suggested: 
• Temperature adjustment: lowering the temperature is very common for 
stabilizing small molecules in DBS. The degradation reaction (reduction, 
oxidation or hydrolysis) is expected to be 10 times slower when the temperature 
is decreased from 22 to 0°C. 
                                                     
 
62 Damen et al., 2009; Wilhelm et al., 2009; van der Heijden et al., 2009 
63 Alfazil and Anderson, 2008; Garcia Boy et al., 2008 
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• Maintaining dryness: the water present in DBS samples plays a critical role in 
enzymatic and chemical hydrolysis. Minimizing water content by drying the 
DBS card completely, changing desiccant bag or applying vacuum to DBS 
sample containers during storage would be a good combination. 
However this effect is apparently compound dependent.  
12.3.9. Advantages 
Blood is directly spotted onto collection cards it is air dried and stored with desiccated 
at room temperature. 
The process is simplified and the possibility to obtain better quality is higher. 
It is possible to avoid: 
• Centrifugation 
• Sub-aliquoting 
• Freezing 
• Defrosting 
Samples volume passed from 300µl to 10-20µl, in consequence: 
• Reduction of the number of animals used. 
• Reduced costs 
• Shipping  
• Storage 
12.3.10. Disadvantages 
The use of DBS bears some apparent disadvantages. Because the collected blood 
volume is very small, assay sensitivity is always a challenge for the determination of some 
analyte at low circulating level. 
Unlike samples from aqueous matrix such as whole blood, plasma or serum, for which 
homogeneity could be easily ensured during collection and prior to analysis, the quality of 
DBS samples is often a concern for absolute quantification due to possible DBS 
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card/paper quality issue, possible no-compliance in sample collection, drying, storage and 
transportation. 
Manual punching is very time consuming and is definitely not suited for the current 
high throughput environment. A punch device could be a source of assay error and/or 
contamination. 
With a good quality control of blood sampling (procedure standardization and 
adherence to the established procedure), implementation of automation for DBS sample 
punching and extraction, improved chemistry of pretreated card/paper for enhance 
stability of unstable compounds, and an higher analysis throughput via DBS-BSD-
Hamilton Robotic Workstation-UPLC-MS/MS is expected to play an increasingly 
important role in the quantitative analysis of drugs and metabolites in blood64. 
BSD (Figure 60) is a fully automated walk away punch instrument designed specifically 
for high-throughput. It automatically punches without the need for the operator to insert 
the framed sample card. The instrument has been designed to accommodate internationally 
accepted and standardized framed cards. 
 
Figure 60: BSD throughput punch instrument 
                                                     
 
64 Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small moleculesWenkui Li and 
Francis L. S. Tse 
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12.3.10.1. Benefits in High-Throughput of automated DBS sampling 
• Very small sample volume per subject required (only 10-20 µl). This makes it 
far easier and faster to extract samples, and also allows multiple samples to be 
extracted from the same animal. 
• DBS is suitable for both preclinical (animal) samples and clinical (human) 
samples. 
• The minimal sample volume required makes it possible to do serial bleeds from 
one lab animal for a more accurate pharmacokinetic profile.  
• No centrifugation or other preparatory handling steps are needed as with 
traditional plasma samples. 
• Faster throughput at both the sample collection point and at the Bioanalytical 
lab. 
• Cards are stored and handled at room temperature in ambient atmospheric 
conditions. No refrigeration needed. 
• DBS cards containing samples ship using standard carriers. No expensive 
refrigerated shipment by courier or other special handling required.  
• Enthalpy can process DBS samples rapidly and with great precision using 
robotic systems specially developed for the purpose. Enthalpy has automated 
the process of generating DBS QC samples for calibration, which makes sample 
throughput faster while maintaining required levels of accuracy. 
• Analytical results obtained from DBS samples can be more meaningful than 
those from conventional liquid plasma samples because DBS uses whole blood. 
12.3.11. Experimental 
A new small chemical entity (NCE) was used to evaluate the possible application of the 
technique. 
An NCE is a molecule developed by the innovator company in the early drug discovery 
stage, which after undergoing clinical trials could translate into a drug that could be a cure 
for some disease. 
It was evaluated the possibility for DBS technique to bring advantages in Merck Serono 
PK processes. 
It was evaluated: 
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• the sample processing procedure in order to find the most suitable type card, the 
appropriate solvent and mixing extraction time. 
• the accuracy and precision, using QC samples at three different concentrations, 
the matrix effect and the recovery. 
• the reduction of the punched area diameter maintaining the same MS peak area 
ratio with the purpose to enable the automation of the extraction process. 
• finally it was investigated if the molecule of interest is equally distributed onto 
the blood spot. 
12.3.12. Materials 
• Analyte with IS available and analytical validated method; 
• Small organic molecule for cancer disease and Internal Standard; 
• FTA® DMPK-A Cards, Lot No. FE6847009 (1); 
• FTA® DMPK-B Cards, Lot No. FE6847069 (2); 
• FTA® DMPK-C Cards, Lot No FE6847509 (3); 
•  Extraction solvents. CH3OH - CH3OH/CH3CN - CH3OH/ACN/H2O - CH3CN; 
• Harris UNI-CORE 6.0-3.0mm W/Mat (5), Harris cutting Mat (8), 903® Dry 
Rak (9), Plastic Storage Bags; 
• Eppendorf tubes (4), 96 Deep Well Plate 1ml (6); 
• Microtiter Stirrer model 715+, cod 29970005, Tecnovetro (7); 
• Termomixer comfort, Eppendorf 1.5ml (10). 
All the instrumentation is shown in Figure 61. 
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Figure 61 
12.3.13. Sample Preparation and Automation 
We developed a DBS extraction method on the base of a LC-MS/MS method developed 
for the determination the molecule as free base in rat, dog, rabbit and monkey plasma 
using a deuterated  internal standard, in the concentration range of 1.0ng/ml to 500.0ng/ml 
further extended to 250,000.0ng/ml. 
In origin plasma samples were extracted using protein precipitation with precipitation 
reagent in Sirocco filter plates. 
12.3.14. Instrumentation, Chromatographic conditions and Mass 
Spectrometry conditions 
MICROLAB STARlet Liquid Handling Workstation Hamilton Robotics. 
The chromatography has been achieved using an Agilent 1100 Series pump equipped 
with a Waters Sunfire column, 50 x 2.1 mm, 5.0µm. 
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An Applied Biosystems API4000 triple quadrupole mass spectrometer equipped with 
turbo ion spray source (TIS) operating in positive ion mode has been used. 
HPLC/MS system: Autosampler: CTC HTS PAL, HPLC pump: Agilent HP 1100 
binary pump Guard column: Frit 2.1 mm for narrow bore column Column Waters Sunfire, 
5 µm 50 x 2.1 mm Switching valve: Valco 2 position. 
Mass spectrometer. SCIEX API 4000 triple quadrupole equipped with a turbo ion spray 
source (TIS). 
Data system: Analyst version. 1.4.2. 
12.4. Results 
12.4.1. Sample preparation  
We decided to prepare spiked samples with the molecule of interest, and then we 
directly applied the sample onto the sampling card with a calibrated Gilson 20µl pipette. 
We spotted 15µl of sample in the pre-marked circle of the spot. 
The pipette tip should have been a few millimeters above the card, as the blood drop 
touches the card it should have been swiftly expelled. 
Touching the circle area is avoided especially before the application of the blood and his 
completely drying. 
12.4.2. Choice of the optimal extraction conditions 
The extraction method is the solution containing the IS to be added on the punched spot. 
For quantitative analysis the DBS were punched from the cards using the Harris cutting 
Mat into Eppendorf tubes or wells of 96-well microtiter plates for extraction. The 
extraction procedure was carried out by adding a certain amount of different extraction 
solvents containing IS. 
The extraction solvent must be strong enough to interrupt the binding of the analyte to 
protein in the matrix or paper material. 
The different solvents we tested on FTA-DMPK-A and FTA-DMPK-B cards are: 
• CH3OH; 
• ACN/CH3OH 50/50; 
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• ACN/CH3OH/H2O 1/1/1; 
• ACN (after extraction an equivalent volume of H2O was added); 
• ACN/H2O 60/40; 
• ACN/H2O 70/30. 
The analyte was extracted with gentle shaking. Sonication may be necessary for better 
extraction. 
 
 
Figure 62 
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As we can see in Figure 62 the best extraction solvent is CH3OH and the most 
appropriate card is FTA-DMPK-A. Vortexing for 10 minutes improves the extraction, but 
is not a determinant parameter. 
12.4.3. Linearity 
 
Figure 63 
Calibration plots of the analyte peak area ratio to that of the internal standard versus the 
nominal concentration in blood were constructed and the results are shown in Figure 63 
and in Table 32. 
Linearity was tested by preparing and analyzing three calibration curves in the range of 
1.0 to 500ng/ml and the result was that linear responses were observed for DBS over the 
range. This is represented by the following linear regression equation for each day: y = 
0.0137x + 0.000587, r = 0.9988; y = 0.0143x + 0.000177, r = 0.9984; y = 0.0129x + 
0.0019, r = 0.9989 where y represents the peak area ratio of the molecule to that of IS and 
x represents the concentration of the molecule in ng/ml. 
  
163 
Table 32 
Run 01 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
1.0 2.5 5.0 10.0 25.0 50.0 100.0 250.0 500.0
1.0 2.6 5.4 9.2 24.7 54.2 94.7 239.0 499.0
100.0 104.0 108.0 92.0 98.8 108.4 94.7 95.6 100.0
Run 02 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
1.0 2.5 5.0 10.0 25.0 50.0 100.0 250.0 500.0
1.0 2.6 5.3 8.8 25.2 53.2 98.0 242.2 504.1
100.0 104.0 106.0 88.0 100.8 106.4 98.0 96.9 100.8
Run 03 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std 9
1.0 2.5 5.0 10.0 25.0 50.0 100.0 250.0 500.0
1.0 2.8 4.9 9.8 23.7 53.5 98.4 246.5 489.6
100.0 112.0 98.0 98.0 94.8 107.0 98.4 98.6 97.9
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12.4.4. Accuracy and Precision QC samples stored at RT for 1 
month (Stability) 
Table 33 
True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml ng/ml each level ≤15.0% each day each day
≤20.0% ≤15.0% ≤15.0%
SS-Low 3.3 10.0 110.0
3.0 2.8 -6.7 7.8 93.3 12.5
3.6 20.0 120.0
SS-Medium 40.4 1.0 101.0
40.0 40.7 1.8 0.5 101.8 1.5 1.6 8.5
39.5 -1.3 98.8
SS-High 373.8 -6.6 93.5
400 384.6 -3.8 3.6 96.2 3.2
398.4 -0.4 99.6
True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml ng/ml each level ≤15.0% each day each day
≤20.0% ≤15.0% ≤15.0%
SS-Low 3.1 3.3 103.3
3.0 3.4 13.3 2.2 113.3 11.4
2.7 -10 30.0
SS-Medium 40.5 1.3 101.3
40.0 40.3 0.7 1.5 100.8 0.9 0.1 6.6
41.0 2.5 102.5
SS-High 375.3 -6.2 93.8
400.0 384.6 -3.8 3.5 96.2 3.0
398.4 -0.4 99.6
True Conc. Estimated Conc. Bias% Mean Bias% ACC% CV% ACC% Mean Bias% CV% ACC%
ng/ml ng/ml each level ≤15.0% each day each day
≤20.0% ≤15.0% ≤15.0%
SS-Low 3.5 16.7 116.7
3.0 3.3 10.0 5.6 110.0 13.2
2.7 -10.0 90.0
SS-Medium 42.9 7.3 107.3
40.0 39.5 -1.3 2.3 98.8 4.3 4.2 7.4
40.4 1.0 101.0
SS-High 431 7.8 107.8
400.0 426.7 6.7 4.8 106.7 4.1
399.7 -0.1 99.9
 
The intra- and inter-day accuracy and precision of the method of DBS method were 
evaluated using QC samples at three different concentrations analyzed against calibration 
curve, which was constructed using calibration standards prepared from a separated stock 
solution.  
The accuracy, the percent deviation from theoretical concentration, was generally within 
10% for all QC samples. 
DBS technique provides with another dimension for storage of biological samples, even 
in absence of refrigeration. This application has demonstrated the advantages of DBS in 
preserving analytes from degradation or delaying the degradation process. 
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In this case samples have been stored at room temperature for 1 month. However, a 
lower temperature may be necessary for longer stability coverage for some analytes. 
12.4.5. Punch position and size comparison 
Although good accuracy and precision date were obtained from the DBS assay, 
important parameters that may potentially affect the assay performance, such as punch 
position, punch size, different extraction volume etc, were investigated. 
Spots of 10 and 50µl of LLOQ from two different donors were added to the center on 
the printed circle on FTA Elute cards and allowed to diffuse. These samples were allowed 
to dry for at least 3h at room temperature prior to analysis. Before analysis the DBS 
samples were sealed in a plastic bag with desiccant at room temperature. 
In this test was evaluated if a 10µl of blood sample was sufficient for making an area of 
3mm diameter. 
Moreover 50µl of sample blood volume was chosen to allow more than one punch for a 
3mm disk to be taken from the same blood spot; an example of the procedure is shown in 
Figure 64. 
The influence of the following parameters on the assay performance was then evaluated: 
• Different punch position; 
• Different punch size (for automation); 
• Different volume of extraction solvents; 
• LLOQ Comparison between: Different cards, Blood samples from different 
donors, Different punch size. 
  
166 
 
Figure 64 
In Table 34 are described the results of sampling location. Usually the 3mm or 6mm 
sample disks are punched out from the center area of the blood spots. 
But we wanted to test if the sample taken from the center area were different from those 
collected away from the center area. 
A drop of 50µl at LLOQ concentration was spotted on the card. 
We punched out five 3mm sample disks. One was punched out from the center area and 
four from the peripheral area. 
The one taken from the center area as three taken from the peripheral area were 
extracted with 100µl CH3OH plus IS. 
It was found that there is no significant difference between the center spots and 
peripheral spots for the tested molecule: all Areas ratio are comparable. 
Than the fifth 3mm disk was extracted with 50µl of CH3OH plus IS. This volume was 
tested in order to evaluate the possibility of an automated extraction. The results 
confirmed this possibility. 
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Table 34 
FTA DMPK-A punch diameter 6mm, extraction solvent 200µl
*Remaining peripheral area after the first punched step
Parameter Results in Area Ratio (AU) Recovery (LLOQ Area Ratio %)
Mean LLOQ Donaor A n=2 0.004 100
Mean LLOQ Donaor B n=2 0.004 100
Mean LLOQ Donaor A n=2* 0 0
Mean LLOQ Donaor B n=2* 0 0
FTA DMPK-C punch diameter 6mm, extraction solvent 200µl
*Remaining peripheral area after the first punched step
Parameter Results in Area Ratio (AU) Recovery (LLOQ Area Ratio %)
Mean LLOQ Donaor A n=2 0.004 100
Mean LLOQ Donaor B n=2 0.0036 90
Mean LLOQ Donaor A n=2* 0.001 25
Mean LLOQ Donaor B n=2* 0.001 28
Direct comparison results of LLOQ samples punched from the center area and non center area of the spot
Puncher 3mm, extraction solvent 100µl
Area Ratio Donor A FTA DMPK-A Donor B FTA DMPK-A
Center 0.003 0.002
No center n=3 0.002 0.0023
Punch diameter 3mm, extraction solvent 50µl in order to obtain automatic extraction in 96 DW plates
Area Ratio Donor A FTA DMPK-A Donor B FTA DMPK-A
No center 0.004 0.004
 
12.5. Conclusions 
A simple and rapid assay has been developed using whole blood dried onto filter paper 
cards. The collection of samples is easier, and sample preparation prior to analysis is less 
time-consuming and requires fewer resources, as it involves the simple extraction of 
compound from a disc punched from a dried blood spot into LC mobile phase solvent. 
The method is both precise and accurate, selective and linear over the investigated 
concentration range with acceptable inter and intra-assay variability. 
We selected the correct card type for our molecule, the best extraction solvent and the 
appropriate mixing time. We did not detect the influence of hematocrit (patient A and B) 
composition. The blood spots proved to be stable during a period of 1 month at ambient 
temperature. The intra- and inter-run accuracy and precision are within the method 
acceptance criteria. It has been found that sampling location and punching position on the 
spot do not significantly affect the precision and accuracy of the assay. We have been able 
to use 3mm punched spots with 50µl of extraction solvent in order to enable the 
automation of the extraction process in future. 
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In conclusion we developed a method suitable for analyzing our molecule and DBS 
technique can be considered as alternative technique for PK/TK Regulated Bioanalytical 
studies giving results comparable to the standard methods, but with significant savings in 
time and resources. 
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13. LIMS 
13.1. Definition 
A Laboratory Information Management System (LIMS) is a software system used in 
laboratories for the management of samples, laboratory users, instruments, standards and 
other laboratory functions such as invoicing, plate management, and workflow 
automation. 
Laboratory Information Management Systems, specifically designed for this field, are 
highly beneficial in speeding up all involved steps, from protocol design to the production 
of the final pharmacokinetic report. 
LIMS are database systems, designed to combine study and sample information with 
acquired data from laboratory instruments in order to reduce administration and speed the 
production of the final report”. 
Most commercial LIMS have been developed for quality control and clinical chemistry 
applications. Because of their sample oriented design, these systems do not meet in a 
straight forward way requirements important for protocol driven and highly organized 
kinetic studies. In contrast, kinetic LIMS are study oriented, in the sense that interest is 
focused on the study in total and not just on a single sample. These systems ‘fully 
understand’ the design of the study and, therefore, are able to take over various study 
activities from the user, like managing involved samples, coordinating the sample 
analyses, reducing acquired raw data to concentration-time profiles, reporting final data 
and exporting profiles to pharmacokinetic calculation modules. Once entered or acquired, 
information about the study, samples and analytes is available during all subsequent study 
phases, thus speeding up all involved steps, from protocol design to production of the final 
kinetic report.  
13.1.1. Data model 
All study and sample information is stored in the LIMS database according to a data 
model specifically designed for kinetic studies and reflecting all the complex relationships 
between study parameters and samples observed in practice. The simplified data model 
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contains all relevant study elements as entities, namely involved treatments, species, 
subjects, matrices, study days and sampling times, as well as the resulting study samples. 
The arrows between the entities describe the relationships between the different study 
elements. Matrices and species are selected from pre-defined dictionaries.  
13.1.2. Functionality and Traceability 
• When the sample arrived. 
• Who received it, who accepted it and under what kind of contract conditions. 
• Where the sample was conserved initially. 
• How the sample was distributed. 
• Where the sample was conserved until the moment of the analysis. 
• If someone split the sample or sampling procedure. 
• What analytic procedure was followed (with detail, for example, of the 
conditions of use of equipment). 
• Quality parameters of the analytic method used. 
• Technicians that carried out the analyses (training and qualifications). 
• What reagents were used (with detail, for example, of reception date and of 
opening date). 
• What standards / strains were used (with the supplier's certificate or all the 
relative information in its preparation was). 
• What equipment was used (maintenance, calibration and verification). 
• Who and how the specifications of the equipments, reagents, cultivation means 
and materials used were checked to their reception. 
• What mechanisms for the evaluation of the quality of the results were used. 
• What were the environmental conditions. 
• Who validated the results. 
13.1.3. Initialization 
During the initialization phase, a new kinetic study is defined, which means, that 
information concerning the study design, involved samples (including calibration 
standards and QC samples), and analytes to be measured are entered into the LIMS. First, 
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all involved study elements like treatments, subjects, collected matrices, nominal sampling 
times, etc. are entered and linked according to the study plan. Using this information, the 
system is able to calculate the total number of samples to be collected and to describe each 
sample by treatment, dose, study day, species, subject, matrix and sampling time. A 
flexible procedure then allows the automatic generation of sample identification codes for 
all kinds of coding conventions, which are in use in the different preclinical and clinical 
centers. 
After initialization all the samples expected are described in the LIMS by a combination 
of study parameters. Each combination is unique and is identified internally by a sample 
number. Generation of sample codes is initiated by providing the system with the desired 
syntax. 
The study undergoes a number of consecutive phases during LIMS treatment. During 
initialization, the study is completely open for any modification or extension. After 
approval, the study is ready for sample log-in and data acquisition and the study protocol 
is available as a printout. Completed studies are “frozen” to prevent any further handling 
on reported and already interpreted bioanalytical data and than archived for long-term data 
storage. In case of limited storage capacity, archived studies are removed from the on-line 
database leaving only some key data in the LIMS to allow management of archived 
studies. 
13.1.4. Sample management 
Study samples undergo a certain life cycle during LIMS treatment which can easily be 
monitored by providing each sample with a status. The status changes each time a certain 
study activity has been completed for a sample. Versatile management functions update 
the user at any time about the current sample situation, with regard to sample definition, 
receipt, availability, analyses, storage and disposal.  
During initialization the samples remain in the status ‘expected’ and various outputs, 
like sample lists, sample labels, etc. can be generated, thereby using information readily 
available from the study initialization. Labels contain a detailed description of the sample 
to be collected together with the sample identification code. Modem systems even provide 
bar-codes on the labels for quicker and more reliable sample identification. After receipt, 
the samples are logged into the LIMS, either manually or by means of a bar-code reader. 
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Even the manual procedure allows a quick sample log-in due to a simple three-step 
procedure: retrieving codes for all delivered samples from the database, changing the 
status from ‘expected’ to ‘received’ and again storing the updated status for each sample 
in the database. Log-in of samples which are ‘missing’ for various reasons is performed 
accordingly. During log-in, all relevant information about sample source, collection, 
storage and condition is registered and stored in the LIMS database as part of the sample 
description. Additionally, all effective time values documented during sample collection, 
as well as subject initials, urine volumes, effective dosing times, etc. will be entered into 
the LIMS during this phase. Input of sample information can be very time-consuming, in 
particular for large studies with manual data entry. For this reason, some companies store 
all patient related information in a special database which is connected to the kinetic LIMS 
for rapid data transfer. During sample analysis, the samples are in ‘progress’. When 
sample analysis has been ‘completed’, the samples are ‘archived’ for a certain time and, 
because of the limited lifetime, finally “disposed” of. 
 For management of calibration standards and QC samples a less sophisticated LIMS 
functionality is required. Usually, only details about preparation, biological matrix, 
storage, analyte lots, etc. are stored in the database to provide sample reports with 
appropriate header information.  
13.1.5. Worksheets, data capture 
Electronic generation of worksheets represents one of the central LIMS activities. 
Sample codes are transferred into an empty worksheet, supplemented with vial numbers, 
dilution factors, etc. and then downloaded via local network into the analytical instrument. 
During sample analysis, the worksheet file is filled with acquired data and finally 
uploaded to the LIMS, which closes the worksheet circle. Since no manual data transfer is 
involved during worksheet generation and data acquisition, considerable time is saved 
daily during sample analysis, reducing significantly the overall time required for a kinetic 
study.  
During sample analysis, acquired data are transferred to the worksheet file and linked to 
the corresponding sample codes. Usually, raw data such as chromatograms, spectra, etc. 
remain in the analytical instrument and are maintained and archived there, while processed 
data such as retention times, peak heights, areas, optical densities are imported by the 
LIMS for further data reduction. 
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13.1.6. Pharmacokinetic evaluation 
Approved concentration-time profiles are the input data for all pharmacokinetic 
evaluations. Graphical representations visualize the input data and help to understand 
derived kinetic interpretations. Pharmacokinetic parameters are released in the form of 
kinetic summary tables. 
Usually, kinetic evaluation starts when sample analysis is finished and all profiles are 
complete. However, in special circumstance, it might be helpful to obtain preliminary 
kinetic information during an ongoing sample analysis. In this case, the LIMS should 
release warnings that the profile is incomplete and that kinetic calculations have to be 
repeated after the sample analysis has been completed. 
The user should have access to the usual model-dependent and model-independent 
calculation routines. However, special packages, such as population kinetics, are rarely 
integrated into pharmacokinetic LIMS. For this reason, the LIMS should obtain an 
interface for exporting concentration-time profiles to external pharmacokinetic programs. 
Since the input routines of such commercial packages are not standardized, the LIMS must 
be able to export the concentration-time profiles in different output formats as Excel table. 
13.1.7. Good Automated Laboratory Practices 
All computerized systems which are involved in pivotal studies are subject to the 
principles of Good Automated Laboratory Practice (GALP). 
Treatment of non-GLP studies, now called QMS, follows the common scientific 
standard: a study can be directly used after initialization, data correction is possible 
without special restriction, corrective actions do not need to be documented and final data 
do not have to meet specific acceptance criteria. 
For GLP studies, additional effort is needed to restrict access to the study, to handle data 
according to agreed procedures, to maintain a constant quality of final concentrations and 
to assure that the history of study; sample and data treatment will be transparent during 
study audits to drug regulatory authorities. 
To meet these goals, access to the study should be carefully controlled, in such a way 
that only personnel responsible for the study, together with their deputies and seniors, are 
authorized to enter, edit or delete study elements, samples and data. 
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In conclusion the use of a LIMS Software, in my particular case the use of Watson 
LIMS by Thermo, is very useful in fact it allows better planning work, it facilitates the 
registration of primary data and its traceability in general; it is also able to save it. 
13.1.8. Creation of an Excel File containing macro 
In order to optimize and enhance an important existing manual application, a particular 
Excel File containing macros was created. 
This File (Figure 65) consists of 13 sheets.  
It can be used for a maximum of 1000 samples  
 
Figure 65 
It allows the creation of analytical sequences with the vial position number automatically 
assigned without manual intervention. It interfaces directly the LIMS with Analyst without 
the necessity of any further operation. 
In the previous situation, the process required the operator manually reformatted plates 
to produce the correct analytical sequence. 
This file provides a flexible way to import a variable number of samples into Analyst. It 
illustrates an innovative application and adaptation of existing concepts in response to a 
specific need. 
It is also used to interface the dilution factors selected into the LIMS with the Hamilton 
Vector Software. 
Although the file was developed for a particular application, we believe it can be easily 
applied to other circumstances. 
13.1.8.1. General Instruction 
• Creation of different folders (Figure 66). 
  
176 
 
Figure 66 
• Into LIMS “Study Storage Report Selection” select container and box of 
interest. 
• Copy as an Excel file the “Storage Report” in the first sheet of the Excel file. 
• The same operations have to be done also for “Samples Position” and “Samples 
Custom ID”. 
• After the compilation of the first four sheets on the fifth called “Transformed” 
the macro is activate as shown in Figure 67, Figure 68 and Figure 69. 
. 
Figure 67 
  
177 
 
Figure 68 
 
Figure 69 
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By the creation and the export from LIMS of a “Work list/ Sequence File” pasted in the 
sheet “Raw Sequence File”, the residual macro steps are activate. The final sheet is 
obtained and it will be imported into Analyst software. The analysis can start without the 
manual or automated effective reorganization of the plate. This operation allows the 
operator to save time. 
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14. Conclusions 
In this PhD project in Pharmaceutical Analysis the manual sample preparation processes 
for LC/MS analysis have been automated using highthroughput techniques, and the 
developed process has been enclosed in the frame of a pharmaceutical bioanalytical 
process managed by a LIMS system in Merck Serono S.A.  
Through use the Hamilton MicroLab Star liquid handling workstation, the most 
important sample preparation techniques were successfully automated and implemented 
for several biological matrix samples and analytes. This in turn has greatly reduced the 
intensive manual labor as well as the possibilities of systematic error associated with the 
manual volumetric transfers. Significant advantages in terms of efficiency and throughput 
have now been achieved by this new automated process while maintaining the integrity of 
the precision, accuracy and quality of the produced data. 
• Over 12 studies and 5000 samples have been prepared using Protein 
Precipitation Technique in the Automation Laboratory since implementation in 
the first six months. The original goal to automate the sample workload using 
this approach was met.  
• A fully automated high throughput Liquid Liquid Extraction method 
validation has been developed. The results obtained during the validation of the 
assay fulfilled all requirements and recommendations regarding linearity, 
accuracy and precision generally accepted for bioanalytical studies. 
• Solid Phase Extraction procedure can be performed by the workstation 
proving to be quick and labor saving so in the future it could eliminate the 
human factors of specimen handling, extraction, and derivatization, thereby 
reducing labor costs and rework resulting from human error or technique issues. 
The automated extraction of peptides from blood samples has been shown to be 
feasible using the Hamilton robotic workstation. Compared with manual 
extraction methods reported previously the method has a shorter processing time 
while maintaining equivalent linearity, sensibility and recovery. 
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• It has been demonstrated also that Dried Blood Spot technique is useful 
to eliminate critic processing aspects and could become of key importance in 
providing breakthrough in the time required to develop a drug by increasing the 
number/time of analyzed samples; avoiding blood centrifugation to produce 
plasma; simplifying collecting, shipping & storing blood samples; reducing the 
number of animals. The preliminary tests demonstrated the feasibility and 
applicability of this technique in Regulated Bioanalytics. It was found that with 
this innovative technique all the steps before the analysis were simplified and the 
capability to obtain better result quality was higher. 
 
Comparative evaluations between manual and automated sample preparation techniques 
for new chemical entities in different matrixes have been done. The results in terms of 
accuracy and precision are at a very high level. 
 
In addition, several advantages over conventional manual methods were confirmed, 
such as reducing “working hour” for analysts, eliminating “working-hour” restriction, and 
decreasing drastically lag time for each prepared sample toward HPLC analysis. 
 
Automation Laboratory can work as a bridge between the sample management system, 
New Chemical Entities Laboratory and the information management system (LIMS), and 
it will reduce drastically budgets and time frame for development of pharmaceutical 
product. 
 
We have developed a fully automated laboratory robotic system for sample preparation 
capable of conducting most of routine experiments. Main objectives for developing this 
novel robotic system are to streamline the analytical tasks by automating sample 
preparations and analytical procedures, and to ensure the safety of analysts by assigning 
risk-involving procedures, such as handling of highly dangerous substances. 
 
Final conclusions: 
• Automated PPT has been utilized for many studies in Merck Serono S. A.; 
• LLE for biological sample extraction has been validated for Clarity study; 
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• SPE, and DBS for biological sample extraction can be automated; 
• Automation saves time and increases the quality of data, extraction steps are 
more reproducible/reliable if computer controlled; 
• It is important to automate without loosing control of the process and keeping 
the possibility of method changes if necessary; 
• Risk of cross contamination due to human mistakes is avoided; 
• HTBSP can be used in GLP and GCLP environments. 
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Author in GxPDocs of the following documents: 
 
• WI: “Centrifuga Allegra 6 R Beckman Coulter, 5810 R Eppendorf, GR. 4.22 
Jouan”. 
• WI: “File Excel: Gestione dei campioni tra i sistemi Watson LIMS, Vector 
(Hamilton) e Analyst”. 
• SOP: “Sistema robotico Integrato Hamilton Microlab STARlet”. 
